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Abstract 
 
The hepatic adaptive response to repeat acetaminophen exposure 
 
The adaptive response to chemical stress arises when an injurious exposure to a drug 
initiates phenotypic changes in the liver.  These phenotypic changes limit hepatotoxicity 
upon subsequent exposures, and constitute an important evolutionary safeguard to the 
individual’s survival.  The factors governing hepatic adaptation to the popular analgesic and 
antipyretic acetaminophen (paracetamol) represent valuable research avenues, since 
acetaminophen toxicity is a leading cause of emergency hospital admissions through 
accidental and intentional overdose.  Knowledge of the broader mechanisms governing 
hepatic adaptation to chemical exposure are limited; and concerning acetaminophen 
specifically, the research focus to date has been on select proteins implicated in 
metabolism.   
The aim of this thesis was to investigate the molecular mechanisms of adaptation to 
chemical stress in two preclinical models using the classical hepatotoxin acetaminophen.  
These models have been characterised through clinically accepted toxicological and 
histopathological assessments, establishing acetaminophen-induced injury in high dose 
acetaminophen exposure groups in both rat and mouse models.  A global proteomic 
analysis of rat liver has given insight into the changes in abundance of a subset of proteins 
common to all rats throughout the duration of the repeat exposure study, demonstrating 
that the process of adaptation to repeat acetaminophen exposure is not mediated by a 
single enzyme or pathway, but rather by a dynamic shift in expression of a large number of 
hepatic proteins.  Key observations included widespread loss of phase I, II and III drug 
metabolising enzymes at the peak of toxicity, indicating a phenotypic shift away from drug 
metabolism.  Focusing on the role of cytochrome P450 2E1 (CYP2E1) as the major 
 v 
 
bioactivator of acetaminophen revealed changes in both expression and activity of this 
enzyme as the timecourse progressed. 
Whilst initial similarities were seen in terms of hepatocellular injury, comparison of key 
markers of the adaptive response in rat and mouse revealed that the regenerative 
response provoked in this model is incompletely conserved.  The rat showed induction of 
Nrf2-dependent proteins implicated in redox homeostasis, as well as extensive mitotic 
activity, restoring both mass and function to the liver despite continued dosing.  The mouse 
was still able to adapt despite an absence of Nrf2 activation and no significant mitosis, 
indicating that the mechanisms by which each organism survives is quite different.   
The findings of this work have implications for research into drug development and 
preclinical modelling of toxicity and adaptation, since the pharmaceutical industry typically 
employs rats and academia uses mice; however neither is a complete analogue of the 
human response.  Additionally, further characterisation of the influence which adaptation 
has on the metabolic fate of subsequent xenobiotic exposures will be of value to the drug 
development and clinical management pathways.  Further into the future, an improved 
understanding of the constituents of human adaptation, and the consequences of its 
failure, may permit more effective management of both acute and chronic liver injury. 
Rowena May Liddell Eakins 
February 2016 
 
 
 
  
 vi 
 
Acknowledgements 
No (wo)man is an island… 
Tremendous thanks are owed to my supervisors Chris Goldring, Neil Kitteringham and 
Kevin Park, for the time and energy they have put into supporting my project; a debt of 
thanks also to the Medical Research Council and the Safe-T Consortium for funding my 
studentship.  
Heartfelt gratitude to Neus Prats, Mariona Auli, Pepi Torres and colleagues at Almirall for 
their investment and ongoing interest in my humble efforts.  Thank you for making me 
welcome in Barcelona, and being so willing to assist with all my queries despite your own 
substantial workloads.   
Additional academic support has been provided by many, including Cliff Rowe, Roz Jenkins, 
Olga Vasieva, Phil Starkey Lewis, Mark Bayliss, Steve Webb, Geoff Edwards, Sophie Regan… 
I would have been stuck without any single one of you.  Thank you. 
Huge appreciation for everyone in the pharmacology labs that I’ve shared this journey with, 
and all my lovely office mates.  In particular, Nicola for being a trailblazer (and Laurence for 
bringing up the rear!), Phil and Karthik for making me welcome upstairs, Holly and Ali for 
being willing huggees, Max for pep talks and help with lists, Jon and Charles for the endless 
entertainment, Mo for always being pleased to see me. 
The marvellous Jo Walsh deserves public recognition for her relentless support and 
friendship, scientific guidance, patience under very trying circumstances, and spectacular 
baking skills.  WWJD.  Thanks for being an all-round good egg. 
Honourable mentions to Iain, and to Paul and Jens - my Farm Urban cheerleading team.  
Thanks for having my back through the toughest time, and for opening my horizons.  Your 
support means more than you know. 
Extra-special thanks go to my long-suffering husband and family.  Thank you for putting up 
with the moods, long hours, crazy workload, and general studentiness for so many years.  
I’ll do my best to be worth the investment.  Thank you for being so proud of me. 
  
 vii 
 
Publications 
Eakins R, Walsh J, Randle L, Jenkins R, Schuppe-Koistinen I, Rowe C, Starkey Lewis P, 
Vasieva O, Prats N, Brillant N, Auli M, Bayliss M, Webb S, Rees J, Goldring C, Kitteringham N, 
Park BK (2015).  Adaptation to acetaminophen exposure elicits major changes in 
expression and distribution of the hepatic proteome. Scientific reports, 5, 16423.  
(This paper forms the basis of chapters 2 and 3, and a copy is included at the end of the 
thesis.) 
Godoy P, Hewitt N, Albrecht U, Andersen M, Ansari N, Bhattacharya S, Bode J, Bolleyn J, 
Borner C, Böttger J, Braeuning A, Budinsky R, Burkhardt B, Cameron N, Camussi G, Cho C, 
Choi Y, Rowls JC, Dahmen U, Damm G, Dirsch O, Donato MT, Dong J, Dooley S, Drasdo D, 
Eakins R, Ferreira K, Fonsato V, Fraczek J, Gebhardt R,  Gibson A, Glanemann M, Goldring C, 
Gómez-Lechón M, Groothuis G, Gustavsson L, Guyot C, Hallifax D, Hammad S, Hayward A, 
Häussinger D, Hellerbrand C, Hewitt P,  Hoehme S, Holzhütter HG, Houston JB, Hrach J, Ito 
K, Jaeschke H, Keitel V, Kelm J,  Park BK, Kordes C, Kullak-Ublick G, LeCluyse E, Lu P, Luebke-
Wheeler J, Lutz A, Maltman D, Matz-Soja M, McMullen P, Merfort I, Messner S, Meyer C, 
Mwinyi J, Naisbitt D,  Nussler A,  Olinga P, Pampaloni F, Pi J, Pluta L, Przyborski S, 
Ramachandran A, Rogiers V, Rowe C, Schelcher C, Schmich K, Schwarz M, Singh B, Stelzer E, 
Stieger B, Stöber R, Sugiyama Y, Tetta C, Thasler W, Vanhaecke T, Vinken M, Weiss T, 
Widera A, Woods C, Xu J, Yarborough K, Hengstler J (2013).  Recent advances in 2D and 3D 
in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-
parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell 
signaling and ADME. Archives of toxicology, 87 (8), pp 1315-1530 
Goldring C, Duffy P, Benvenisty N, Andrews P, Ben-David U, Eakins R, French N, Hanley N, 
Kelly L, Kitteringham N, Kurth J, Ladenheim D, Laverty H, McBlane J, Narayanan G, Patel S, 
Reinhardt J, Rossi A, Sharpe M, Park BK (2011).  Assessing the safety of stem cell 
therapeutics. Cell Stem Cell 8 (6) pp 618-628 
Eakins R, Brillant N, Walsh J, Schuppe-Koistinen I, Prats N, Auli M, Goldring C, Kitteringham 
N, Park BK.  The regenerative response in rats and mice is incompletely conserved. 
(Manuscript in preparation) 
 
Abstract: 
Eakins R, Walsh J, Jenkins R, Rowe C, Sleckus A, Starkey Lewis P, Vasieva O, Prats N, Auli M, 
Schuppe-Koistinen I, Kitteringham N, Goldring C, Park BK. Analysis of the hepatoproteome 
during repeat acetaminophen exposure reveals novel processes associated with the 
adaptation of the liver to chemical insult. British Toxicology Society Annual Congress, 2014   
 viii 
 
Abbreviations 
 
(-/-) Homozygous null 
(+/+) Homozygous wild type 
µl Microlitre 
µm Micrometre 
µM Micromolar 
  
6’-OH CZX 6-hydroxy chlorzoxazone 
  
Å Angstrom 
ACN Acetonitrile 
ADR Adverse drug reaction 
ALR Augmenter of liver regeneration 
ALT Alanine aminotransferase (EC 2.6.1.2) 
amu Atomic mass units 
ANOVA Analysis of variance 
APAP Paracetamol, acetaminophen 
ARE Antioxidant response element 
AST Aspartate aminotransferase (EC 2.6.1.1) 
ATP Adenosine triphosphate 
  
BD Bile duct 
  
C Centigrade 
CCl4 Carbon tetrachloride 
CE Collision energy 
CL Centrilobular 
cm Centimetre 
CM Carboxymethyl 
CO Carbon monoxide 
CO2 Carbon dioxide 
CV Central vein 
CXP Collision cell exit potential 
CYP1A2 Cytochrome P450 1A2 isoform (EC 1.14.14.1) 
CYP2E1 Cytochrome P450 2E1 isoform (EC 1.14.13.n7) 
CYP450 Cytochrome P450 
CZX Chlorzoxazone 
  
  
D Diffuse 
DAB 3', 3’-diaminobenzidine 
dH2O Distilled water 
DILI Drug-induced liver injury 
DNA Deoxyribonucleic acid 
DP Declustering potential 
  
EDTA Ethylene diamine-tetracetic acid 
  
 ix 
 
FA Formic acid 
FDA Food and Drug Administration 
FDR False discovery rate 
FMO3 Flavin-containing monooxygenase 3 (EC 1.14.13.148) 
  
g Gram 
GCLC Glutamate-cysteine ligase, catalytic subunit (EC 6.3.2.2) 
GS Glutamine synthetase (EC 6.3.1.2) 
GSH Glutathione 
GSSG Oxidised glutathione 
GSTP1 Glutathione-s-transferase pi (EC 2.5.1.18) 
  
h Hour 
H&E Haematoxylin and eosin 
H2O2 Hydrogen peroxide 
HO-1 Haemoxygenase-1 (EC 1.14.14.18) 
HRP Horseradish peroxidase 
  
i.p. Intraperitoneal 
IAA Iodoacetamide 
ICH International Conference on Harmonization 
IHC Immunohistochemistry 
IS Internal standard 
iTRAQ Isobaric tags for relative and absolute quantification 
IU International units 
  
KCl Potassium chloride 
kDa kiloDalton 
Keap1 Kelch-like ECH associated protein 1 
kg Kilogram 
Km Rate constant 
  
L Litre 
LC Liquid chromatography 
LPC Liver progenitor cell 
  
M Molar 
mg Milligram 
min Minute 
miR-122 MicroRNA-122 
mL millilitre 
mm millimetre 
mM Millimolar 
MMTS Methylmethane thiosulphate 
MOPS 3-morpholinopropane-1-sulfonic acid 
MRM Multiple reaction monitoring 
mRNA Messenger RNA 
MRP3 Multidrug resistance-associated protein 3 
MRP4 Multidrug resistance-associated protein 4 
MS Mass spectrometer/spectrometry 
MS/MS Tandem mass spectrometry 
 x 
 
MW Molecular weight 
  
NADPH Nicotinamide adenine dinucleotide phosphate 
NAPQI n-acetyl-p-benzoquinoneimine 
nm Nanometre 
NQO1 NAD(P)H:quinine oxidoreductase 1 (EC 1.6.5.2) 
Nrf2 Nuclear factor erythroid 2 related factor 2 
  
OECD Organisation for Economic Co-operation and Development 
  
P periportal 
p Probability 
p.o. Per oralis 
PC Principal component 
PCA Principal component analysis 
PCNA Proliferating cell nuclear antigen 
PT Portal triad 
  
RNA Ribonucleic acid 
ROS Reactive oxygen species 
rpm Revolutions per minute 
RT Room temperature 
  
s Second 
SEM Standard error of mean 
  
TBS Tris-buffered saline 
TBS-T Tris-buffered saline containing 0.05% Tween 20  
TEAB Triethyl ammonium bicarbonate 
  
v/v Volume by volume 
Vmax Maximum rate of reaction 
  
w/v Weight by volume 
WT Wild type 
 
Designation of statistical significance: 
p < 0.05 = * 
p < 0.01 = ** 
p < 0.001 = *** 
p < 0.0001 = **** 
  
 
 
  
Chapter 1: General Introduction 
Chapter 1: General Introduction 
 
2 
 
 
Contents 
1.1. Drug-Induced Liver Injury ......................................................................................... 3 
1.1.1. DILI and drug development ............................................................................... 4 
1.2. Drug Metabolism ...................................................................................................... 5 
1.2.1. Phase I metabolism ........................................................................................... 6 
1.2.2. Phase II metabolism .......................................................................................... 7 
1.2.3. Phase III metabolism ......................................................................................... 8 
1.2.4. Reactive metabolite formation and oxidative stress ........................................ 8 
1.2.5. The oxidative stress response ........................................................................... 9 
1.3. APAP as a model hepatotoxin .................................................................................11 
1.3.1. Nrf2 mediated defence against APAP toxicity ................................................13 
1.4. Liver regeneration and adaptation to hepatotoxicants ..........................................15 
1.4.1. Proposed mechanisms for liver regeneration .................................................16 
1.5. Adaptation and APAP ..............................................................................................19 
1.6. Aim ..........................................................................................................................22 
1.6.1. Hypothesis .......................................................................................................22 
 
 
  
Chapter 1: General Introduction 
 
3 
 
1.1. Drug-Induced Liver Injury 
An adverse drug reaction (ADR) can be defined as any undesirable effect of a drug beyond 
its anticipated therapeutic action (Pirmohamed et al. 1998).  As a major site of drug 
metabolism, the liver can often be affected by ADRs.  The liver is considered a vital organ 
due to its diverse roles in maintaining homeostasis. Its functions include protein synthesis, 
digestion, lipid metabolism, glucose regulation, and detoxification of both endogenous and 
exogenous toxins.  Despite the range of detoxification pathways active in the liver, it 
remains especially vulnerable to injury from environmental toxins or xenobiotics. 
Liver injury due to prescription or non-prescription drugs is a worldwide problem.  Drug 
induced liver injury (DILI) can occur when either a parent drug or its metabolite perturbs 
liver cell biochemistry, or elicits an immune response.  DILI encompasses a diverse range of 
symptoms and may result from either acute or chronic exposure to a compound or 
compounds.  It can loosely be categorised into hepatocellular or cholestatic injury, 
although it is possible to identify hallmarks of both categories in an individual patient.  An 
individual’s susceptibility to DILI is influenced by both genetic and environmental risk 
factors, and as such, DILI can be challenging to predict, diagnose and treat.   
The main functional cell of the liver is the hepatocyte, and these cells comprise around 70% 
of the liver’s mass.  A severe toxic insult to the liver can result in widespread death of 
hepatocytes, and if this happens on an organ-wide scale, the outcome is fulminant hepatic 
failure, which necessitates urgent medical intervention.  Hepatic failure carries a 60 to 80 % 
mortality rate in patients who do not receive a transplant (Bjӧrnsson and Olsson 2005).   
When hepatocellular injury is less severe, and particularly when it is also chronic in nature, 
the liver can become fibrotic as scar tissue accumulates at the sites of injury.  A patient may 
present with symptoms of hepatitis, as liver function becomes compromised by fibrosis.  
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Hepatitis can in turn predispose an individual to liver cancer, and both of these conditions 
are associated with increased morbidity and mortality (Cardin et al. 2014).  Hepatocellular 
DILI and its potential sequelae therefore present a considerable clinical burden and public 
health concern.  
1.1.1. DILI and drug development 
DILI is a common cause of liver injury, representing around 50 % of all cases of acute liver 
failure (Ostapowicz et al. 2002).  It therefore presents a substantial concern to the 
pharmaceutical industry.  In excess of 600 drugs have been linked with liver toxicity (Park et 
al. 2005), and DILI is the most commonly cited reason for the withdrawal of drugs from the 
market after approval (Lee 2003).  Given that the cost of developing a single drug has risen 
to an estimated $2.6 billion (Tufts 2014) it is imperative that potential toxicity is identified 
as early in the development process as possible.  Similarly, robust preclinical screening will 
prevent the unnecessary attrition of compounds which may go on to have therapeutic 
value.  In order to improve preclinical screening of new chemical entities, an understanding 
of the mechanisms underlying liver injury and the ways in which the liver can defend itself 
from harm are vital. 
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1.2. Drug Metabolism 
Microanatomically, the liver is formed of hexagonal units termed lobules (Figure 1.1).  
These lobules are fed with blood from the digestive system via the hepatic portal vein, part 
of the portal triad which is located at each peripheral angle of the lobule.  Blood passes 
along plates of hepatocytes, converging on the centre of the lobule and draining through 
the central vein.  Hepatocytes along the portal to central axis are exposed to gradients of 
signalling molecules, making them phenotypically heterogeneous (Park et al. 2005; 
Hailfinger et al. 2006).  This gives rise to a spatial pattern of gene expression called zonation 
(Jungermann and Katz 1989).  Functional specialisation can therefore be observed across 
the zones. 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: The microanatomy of the liver 
Legend: The lobule is the structural unit of the liver, and is comprised primarily of 
hepatocytes.  Plates of hepatocytes process blood from the hepatic portal vein as it passes 
to the centre of the lobule and exits the liver.  Gradients of signalling molecules exist along 
the axis that runs between the portal and central veins giving rise to functional 
specialisation and zonation.  (Killpack 2016) 
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Hepatocytes are particularly rich in molecules which support drug metabolism, the process 
by which living organisms biochemically modify xenobiotics, usually in order to facilitate 
their excretion.  Drug metabolism is achieved through highly specialised enzymatic systems 
which are generally well conserved between model species.  These enzymatic systems 
convert non-polar, lipophilic compounds into polar hydrophilic ones, reducing tissue 
penetration and supporting renal elimination.  Effective drug metabolism therefore 
reduces an organism’s exposure to potentially toxic xenobiotics. 
Drug metabolism is categorised into distinct and usually sequential phases, which are 
briefly summarised below. 
1.2.1. Phase I metabolism 
Phase I metabolism involves the introduction into the compound of a polar or reactive 
group by way of oxidation, reduction or hydrolysis.  The reactivity of the compound is 
increased, and sometimes therefore the product may be more toxic than the parent 
compound.  Additionally, this is the means of activation of a prodrug.   
The majority of phase I reactions are catalysed by the cytochrome P450 monooxygenase 
system, predominantly expressed in centrilobular regions (Bühler et al. 1992; Oinonen and 
Lindros 1998).  The cytochrome P450 (CYP450) enzymes are a superfamily of related 
enzymes, denoted by CYP allele nomenclature (Sim and Ingelman-Sundberg 2006).  The 
enzymes differ in structure and therefore substrate specificity, though there is much 
functional overlap.  In the liver, CYP450 enzymes are resident in the lumen of the smooth 
endoplasmic reticulum, and although the pathway for CYP450-catalysed reactions can be 
complex, the net result is the formation of a hydroxyl group at the site of a hydrogen atom, 
with the by-product of a single molecule of water. 
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In addition to CYP450 enzymes, lesser phase I enzymes include NADPH quinone 
oxidoreductases, epoxide hydrolases, flavin-containing monooxygenases, cyclooxygenases, 
alcohol dehydrogenases, hydrolases and monoamineoxidases.  All catalyse the addition of 
functional groups required by phase II reactions. 
1.2.2. Phase II metabolism 
Phase II metabolism involves conjugation reactions, which often occur sequentially after 
phase I, at the site of phase I modification of the compound (Hodgson 2004), in order to 
increase the hydrophilicity of the compound.  Reactions include sulphation, 
glucuronidation, acetylation and glutathione conjugation. 
Phase II enzymes are generally therefore transferases, adding a polar group to the 
compound, usually glucuronyl, sulphate, methyl or acetyl (Jancova et al. 2010).  
Additionally, glutathione (GSH) can conjugate drugs via its sulphydryl group.  GSH 
conjugation is an important route of detoxification for a number of xenobiotics including 
epoxides, alkenes and aromatic nitro compounds (Timbrell 1999).  GSH is ubiquitously 
present in cells, and represents a significant buffer against redox perturbation.  GSH 
conjugation, which may occur either spontaneously or by a mechanism catalysed by 
glutathione s-transferase (Hodgson 2004), is a key cellular defence from electrophilic 
molecules. In the liver, GSH is zonally expressed, with the poorest areas found within 100 
µm of the central vein (Smith et al. 1979).  These perivenous hepatocytes have also been 
shown to be slowest to replenish GSH (Kera et al. 1988).  Perivenous cells preferentially 
express drug metabolising enzymes (Oinonen and Lindros 1998), and these factors combine 
to explain these cells’ peculiar susceptibility to injury. 
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1.2.3. Phase III metabolism 
Phase III metabolism describes further structural modification of metabolites, and 
subsequent excretion by transmembrane transporter channels.  Transporters may be ATP 
dependent, or independent of both ATP and sodium.  Examples include P-glycoprotein, 
multidrug resistance protein, and organic anion transporting polypeptide (Xu et al. 2005). 
1.2.4. Reactive metabolite formation and oxidative stress 
In the majority of instances, the drug metabolism processes occurring in the liver very 
effectively detoxify compounds and permit their safe excretion.  However, in some 
instances, these same processes result in a metabolite that is more reactive than the 
parent compound.  This has largely been demonstrated following phase I oxidative 
metabolism (Park et al. 1995; Antoine et al. 2008), but can to a lesser degree occur upon 
phase II conjugation reactions (Kretzrommel and Boelsterli 1993; Hargus et al. 1995).  The 
generation of reactive metabolites can result in covalent modification of cellular proteins as 
well as damage to nuclear and mitochondrial DNA (Hinson et al. 2010).  These processes 
are strongly linked to GSH depletion and oxidative stress, and are exemplified by the 
toxicity seen in acetaminophen overdose (Josephy 2005). 
Oxidative stress, therefore, arises from an imbalance between the abundance of pro-
oxidant species in the cell, and the antioxidant mechanisms (such as synthesis of GSH) that 
exist to protect the cell from oxidative injury.  Reactive oxygen species (ROS), such as free 
radicals, are constantly produced as a by-product of mitochondrial oxidative 
phosphorylation, as well as being formed by the activity of enzymes on xenobiotics (Li et al. 
2015).  ROS are highly unstable due to a single unpaired electron, and will remove a single 
electron from any molecule encountered in order to increase stability.  This in turn creates 
a new ROS, perpetuating a chain reaction and can causing oxidative damage to proteins, 
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lipids and DNA.  Oxidative stress has been associated with a number of disease processes 
including neurodegenerative conditions, cancer, and cardiovascular disease (Miller 1970; 
Amens 1983; Dhalla et al. 2000; Valko et al. 2007). 
1.2.5. The oxidative stress response 
The oxidative stress response allows an organism to manage constitutive oxidative stress 
on a cellular level, as well as responding swiftly to neutralise acute oxidative insult.  A range 
of cytoprotective proteins are important for mediating the oxidative stress response, and 
although these proteins are expressed constitutively, their expression can also be 
upregulated following oxidative insult (Primiano et al. 1997), thereby helping to restore 
homeostasis through mechanisms such as GSH repletion and the direct detoxification of 
electrophiles.  One of the most important mediators of this upregulation is the 
transcription factor nuclear factor-erythroid 2–related factor 2 (Nrf2).   
1.2.5.1. The Keap1/Nrf2 pathway 
The Keap1/Nrf2 pathway is a key redox sensitive cellular defence pathway (Copple et al. 
2010).  Keap1 (Kelch-like ECH associated protein 1) is a particularly cysteine-rich protein, 
and this relative overabundance of cysteine residues is thought to enable Keap1 to function 
as a thiol-based redox sensor (Dinkova-Kostova et al. 2002).    Keap1 exists in the cytoplasm 
as a homodimer, and under basal conditions it sequesters Nrf2 and targets it for 
proteasomal degradation (Cullinan et al. 2004).   
Under oxidative stress, key cysteine residues on the Keap1 homodimer become modified in 
specific patterns according to the structure of the reactive molecules which are disrupting 
redox status (Hong et al. 2005).  This conformational change prevents the targeting of 
bound Nrf2 for degradation, so Keap1 therefore becomes saturated by incompletely bound 
Nrf2, and newly synthesised Nrf2 begins to accumulate in the cytoplasm.  Free Nrf2 
Chapter 1: General Introduction 
 
10 
 
translocates into the nucleus where it interacts with the antioxidant response element 
(ARE), a motif within the DNA.  Through this complex, Nrf2 upregulates the transcription of 
cytoprotective genes which facilitate restoration of redox homeostasis (Surh et al. 2008).  
The complex response of the cell to oxidative stress protects macromolecules from injury, 
and also facilitates their repair where injury occurs.   
1.2.5.2. Consequences of Nrf2 activation 
The ‘graded Nrf2 activation’ model described by Liu et al. (2013) explores the role of Nrf2 in 
protection from hepatotoxicants.  This model used a number of different genetic systems 
(Figure 1.2) to demonstrate that Nrf2 plays a key role in defending the liver from several 
commonly encountered hepatotoxicants including acetaminophen, carbon tetrachloride 
and ethanol.  The consequences of Nrf2 activation in this model were shown to be dose-
responsive, reducing the expression of genes associated with inflammation, oxidative 
stress, endoplasmic reticulum stress and cell death.  The protection afforded by Nrf2 
activation was accompanied by induction of antioxidant genes, suppression of the 
inflammatory response and attenuation of oxidative stress.   
 
LOW                                                                                                                                              HIGH 
 
Nrf2 null 
mouse 
 
 
Wild type 
mouse 
Keap1 
knockdown 
mouse 
Keap1 
hepatocyte 
knockout 
mouse 
 
Figure 1.2: The graded Nrf2 activation model of protection from hepatotoxicants  
Legend:  The model presented by Liu et al. (2013) encompasses a range of possible Nrf2 
activation states.  Mice which do not express Nrf2 are at the lowest end of the scale and 
are most vulnerable to liver injury.  At the highest end of the scale is a hepatocyte-specific 
knockout of Nrf2’s repressor Keap1, mimicking maximal Nrf2 induction. 
  
Chapter 1: General Introduction 
 
11 
 
1.3. APAP as a model hepatotoxin 
Acetaminophen (paracetamol, APAP) is a model hepatotoxin widely used preclinically to 
study liver injury because of the predictable nature of its effect.  It is used clinically as an 
analgesic and antipyretic, and is a common cause of liver injury in man through both 
accidental and intentional overdose (Larson et al. 2005).  APAP poisoning is the commonest 
cause of acute liver failure in the USA (Larson et al. 2005) and the UK (Fagan and Wannan 
1996; Karvellas et al. 2010).  In the UK, the annual number of deaths by poisoning through 
APAP alone ranged from 90 to 155 over the years of 2000 to 2008 (Hawton et al. 2011).  In 
addition to this there are considerably more deaths involving APAP ingested alongside 
other toxicants (Hawton et al. 2011). 
At therapeutic doses, APAP is largely excreted via urine through the phase II conjugation 
reactions sulphation and glucuronidation.  At supratherapeutic doses (Figure 1.3), toxicity 
arises when APAP is extensively bioactivated by cytochrome P450 2E1 (CYP2E1), and to a 
lesser extent CYP1A2, CYP2A6, CYP2D6 and CYP3A4 (Patten et al. 1993; Chen et al. 1998; 
Dong et al. 2000).  Bioactivation of APAP results in the intracellular accumulation of the 
highly reactive metabolite N-acetyl-p-benzoquinone imine (NAPQI) (Dahlin et al. 1984).  
NAPQI is a strongly electrophilic metabolite which can conjugate and deplete the redox 
buffer GSH and bind covalently to cellular macromolecules (Albano et al. 1985).  When 
cellular defences are overwhelmed in this manner, the ensuing oxidative damage to 
proteins, lipids and DNA can ultimately result in cell death (Hinson et al. 2010).  The 
evolution of toxicity can be further exacerbated by the involvement of the immune system 
(For a review, see Liu and Kaplowitz (2006)).  Liver cell death is seen in a characteristic 
centrilobular distribution, reflecting the zones of the liver which are relatively rich in 
CYP450 and poor in GSH (Sastre et al. 1992), and therefore most vulnerable to NAPQI 
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accumulation.  Widespread loss of liver cells can result in severe liver injury, ultimately 
causing organ failure and death. 
 
Figure 1.3: APAP metabolism at supratherapeutic doses 
Legend: In APAP overdose, NAPQI is formed by direct 2 electron oxidation of APAP, which is 
catalysed mainly by CYP2E1.  NAPQI is conjugated with glutathione to form 3-glutathion-S-
yl-acetaminophen and excreted from the cell.  NAPQI can also be transformed by reduction 
back to acetaminophen – not shown (Dahlin and Nelson 1982; Hinson et al. 1982).  Both of 
these detoxification processes deplete glutathione by up to 80–90 % (Jollow et al. 1973; 
Mitchell et al. 1973a, 1973b).  Loss of glutathione perturbs redox homeostasis and 
stimulates an oxidative stress response which is in part mediated by the transcription 
factor Nrf2.  Nrf2 governs the expression of a large panel of cytoprotective genes, including 
enzymes responsible for glutathione synthesis.  If formation of NAPQI outpaces restitution 
of glutathione, accumulating NAPQI is able to covalently bind to any sulfhydryl groups, 
causing cellular injury.   
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Compared to other organs, the liver is particularly rich in GSH, with basal levels of up to 10 
mM (Lu 2009).  This acts as an effective defence system to sequester electrophilic 
molecules thereby preventing oxidative stress.  Additionally, various transcription factors 
including Nrf2 aid cell defence against chemical stressors by upregulating the transcription 
of cytoprotective genes such as haemoxygenase and glutamate-cysteine ligase (Randle et 
al. 2008).  This is believed to play an essential role in the defence against chemical stress 
elicited by APAP.  This response to toxicity is not unique to APAP; it is also seen with other 
model hepatotoxins including  carbon tetrachloride (Xu et al. 2008), ethanol (Lamlé et al. 
2008), bleomycin (Cho et al. 2004) and cisplatin (Liu et al. 2009).   However, depletion of 
GSH following APAP overdose has been associated with a reduction in many oxidative 
stress response enzymes, including glutathione reductase, glutathione transferase, 
glutathione peroxidase, γ-glutamylcysteinyl synthase, catalase and superoxide dismutase 
(O’Brien et al. 2000; Acharya and Lau-Cam 2010).   This effect may be indicative of a 
‘tipping point’ in the process of toxicity, and further complicates the clinical picture of APAP 
overdose. 
1.3.1. Nrf2 mediated defence against APAP toxicity 
Nrf2 has been directly implicated in the in vivo cellular response to APAP toxicity (Goldring 
et al. 2004), and its involvement in defending the liver against the reactive metabolite 
NAPQI has been explored in the literature.  NAPQI has been shown to directly activate Nrf2 
(Copple et al. 2008), both by direct modification of cysteine residues on Nrf2’s cytosolic 
repressor Keap1, and indirectly via depletion of intracellular GSH.  This activation results in 
the increased transcription of a panel of cytoprotective genes.  Within this panel, of 
particular pertinence to APAP toxicity are NAD(P)H quinone oxidoreductase 1 (NQO1) 
(Venugopal and Jaiswal 1996) , a scavenger of reactive metabolites which is also 
upregulated in human APAP-induced liver injury (Aleksunes et al. 2006); and the catalytic 
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subunit of glutamate cysteine ligase (GCLC) (Wild et al. 1999),  a key step in the GSH 
synthesis pathway, and instrumental to patient recovery when the antidote to APAP 
poisoning n-acetyl cysteine is administered.   
Studies using techniques such as genetic knockouts or RNA silencing have shown increased 
susceptibility to APAP toxicity as a consequence of inactivation or absence of Nrf2 (Itoh et 
al. 1997; Reisman et al. 2009b).  Conversely, methods which activate Nrf2, using genetic or 
pharmaceutical mediators, result in protection (Okawa et al. 2006; Reisman et al. 2009a).   
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1.4. Liver regeneration and adaptation to hepatotoxicants 
Many studies of APAP induced liver injury focus on single doses.  However, a number of 
publications have explored the effects of the drug on liver physiology, and how the change 
in physiology affects the metabolism of subsequent doses (Roberts et al. 1983; Shayiq et al. 
1999; Kim et al. 2009).  The liver is the primary site of detoxification, and as such is 
particularly vulnerable to cellular damage from electrophiles and free radicals.  It has 
therefore evolved the capacity to self-renew.  It is becoming apparent that the metabolic 
phenotype of actively proliferating cells is altered in comparison to quiescent liver (Dalhoff 
et al. 2001; Aleksunes et al. 2008a).  What remains unclear is the origin of cells contributing 
to the process of regeneration, and the metabolic profile of each cell compartment, and 
therefore the implications for the fate of repeat doses further to toxicity.  In the quiescent 
liver there exists a dynamic equilibrium between cell birth and death in order to tightly 
regulate organ mass.  Mitotic events are comparatively rare, with cellular turnover 
estimated to be <0.1 % (Fausto and Campbell 2003); though mature hepatocytes have an 
almost unlimited capacity to renew (Overturf et al. 1997).   
In this context, the response the liver demonstrates to injury is not true organ 
regeneration; strictly it is defined as compensatory hyperplasia, and is precisely regulated 
by the metabolic needs of the organism (Riehle 2011).  Rather than regrow an exact replica 
of destroyed tissue, restoration of liver mass is achieved by proliferation of cells (mitosis) 
and increase in the size of cells (growth) (Fujiyoshi and Ozaki 2011).  Mass is restored very 
rapidly, as is function; however, tissue architecture is somewhat disorganised and over 
time becomes more structured.   
Adaptation refers to the capacity of an organism to change its phenotype in response to a 
noxious stimulus in order to better survive in its environment.  Due to the phenotypic shift 
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exhibited by proliferating liver, the processes of regeneration and adaptation may 
therefore be regarded as intimately related in the context of APAP toxicity.   
1.4.1. Proposed mechanisms for liver regeneration 
The processes underpinning liver regeneration are at present incompletely characterised, 
but tremendous research endeavours are being focused on this important subject.  
Although early findings have in some cases been contradictory, the currently accepted 
hypothesis for liver regeneration proposes that the mechanism of cellular restitution 
depends on the previous state of the liver.  If the remaining liver has the capacity to 
proliferate (as seen in partial hepatectomy models) then mature hepatocytes will respond 
to paracrine signals inducing mitosis.  If the liver’s proliferative capacity is somehow 
compromised (for example by fibrosis, hepatitis or age) then liver progenitor cells (LPCs) 
are recruited.  In rodents these cells are seen to originate from periportal zones, and they 
proliferate and differentiate in chords that extend towards centrilobular zones in order to 
restore mass and function.  This hypothesis is presented graphically in Figure 1.4. 
The partial hepatectomy model of liver regeneration presents an appropriate platform for 
probing alterations in phenotype as a consequence of cellular proliferation:  it is well 
characterised, highly reproducible and is an example of ‘clean’ liver injury, since a lobe or 
lobes may be excised without extensively damaging surrounding tissues.  In 1983, 
examination of hepatocytes isolated from rats which had undergone partial hepatectomy 
showed significant loss of total CYP450 alongside an increase in GSH (Roberts et al. 1983), 
thought to be mediating in vitro resistance to a panel of hepatotoxicants. Subsequent 
publications validated these findings at both protein and mRNA levels (Tygstrup et al. 1996; 
Favre et al. 1998).  Alongside these data, other studies showed evidence that the 
regeneration-associated hepatoprotective phenotype was also detectable in models 
employing toxic liver injury.  In rats, regeneration after partial hepatectomy provided  
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Figure 1.4: Mechanisms of liver regeneration 
Legend:  When injury is sustained in healthy liver, mature hepatocytes re-enter mitosis in 
order to restore organ mass (left side).  If, however, the organ’s proliferative capacity is 
impaired or mitosis is blocked, then liver progenitor cells (LPC) are activated (right side).  
LPCs proliferate and differentiate in chords extending from the bile duct (BD) towards the 
centrilobular region.  Adapted from Dollé et al. (2010) 
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resistance to carbon tetrachloride induced toxicity (Zhang et al. 1999), and cell division 
stimulated by a low thioacetamide exposure mediated resistance to toxicity arising from a 
second, higher exposure (Mangipudy et al. 1995).  The phenomenon has also been 
demonstrated in human primary hepatocytes.  In human cells CYP450 activity was 
downregulated when cultures were treated with hepatocyte growth factor, a potent 
mitogen (Donato et al. 1998). 
Liver regeneration is relevant to drug metabolism and adaptation to repeated toxicity, 
since actively regenerating liver tissue exhibits a different profile of drug metabolising 
enzymes compared to quiescent liver.  This phenotypic shift has been demonstrated in a 
range of models of regeneration, including drug-induced liver injury, partial hepatectomy 
and even during postnatal development (Mangipudy et al. 1995; Zhang et al. 1999; Dalhoff 
et al. 2001; Limaye et al. 2006; Aleksunes et al. 2008a).  It is clear that new cells arising 
from these mediators of liver injury exhibit a phenotype that exerts some kind of 
protection over the regenerating organ, perhaps permitting non-essential activities to be 
sidelined in favour of short-term preservation of critical function.  The precise nature of the 
phenotypic shift, however, is less apparent, although the functional consequence is an 
enhanced resistance to drug toxicity, thereby linking regeneration to adaptation.   
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1.5. Adaptation and APAP 
Where adaptation to a noxious substance arises from earlier exposure to the same 
substance, the process is termed autoprotection.  Studies of APAP-induced autoprotection 
have implicated a number of possible candidate proteins in the process of adaptation, 
including  CYP2E1 (Shayiq et al. 1999), the key CYP450 involved in APAP metabolism (Patten 
et al. 1993; Chen et al. 1998) and multidrug resistance-associated protein 4 (MRP4), a 
basolateral  efflux transporter protein (Aleksunes et al. 2008a).  However, the true breadth 
of the biological processes that underpin the adaptive response to chemical exposure in 
general, and to APAP in particular, are not known.  Exploring this should begin to reveal 
what adaptation during drug exposure in the liver normally consists of, and therefore 
provide a starting point for the investigation of sources of inter-individual variability in 
response to drug exposure.   
Pretreatment of cultured primary hepatocytes with APAP,  and also incubation with growth 
factors, diminished CYP450 expression and prevented the bioactivation of APAP on a 
subsequent toxic challenge (Grunnet et al. 2003), intimating a link between regeneration 
and adaptation arising specifically from the action of APAP.  In this study, cells treated with 
growth factors had higher GSH concentrations, showing that actively proliferating cells 
have a greater capacity to buffer oxidative stress.  In rodents, although APAP toxicity is 
known to reduce CYP450 abundance (Shayiq et al. 1999), a subtoxic dose has the inverse 
effect of inducing CYP450 (Kim et al. 2009) raising questions about where on the spectrum 
of physiological stress (i.e. from hormesis to surmounting a toxic challenge) lies the 
optimum range for inciting adaptation. 
In 2013, a proteomic investigation of adaptation to APAP in a mouse model was published, 
revealing metabolic detoxification processes were activated in mice pretreated with APAP 
prior to a toxic challenge (O’Connor et al. 2013).  These processes were mediated by the 
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transcription factor Nrf2.  Nrf2 has also been shown to activate the hepatotrophic factor 
ALR (augmenter of liver regeneration) via the ARE (Dayoub et al. 2013); and to be necessary 
for normal cellular proliferation to occur (Zou et al. 2015), reinforcing links between 
oxidative stress and hepatic regeneration, and in doing so indicating a novel survival 
mechanism for damaged cells. 
A summary of the current understanding of APAP-induced autoprotection in rodents is 
shown in Figure 1.5. 
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Figure 1.5: APAP-induced autoprotection in rodents 
Legend: Where animals are naive to APAP (left side) and receive a toxic challenge, injury 
progresses in a well-characterised pattern.  Intracellular accumulation of the reactive 
metabolite NAPQI in CYP450-rich centrilobular (CL) regions causes oxidative stress and 
suppresses the antioxidant response mediated by Nrf2.  The naive liver is quickly 
overwhelmed by widespread necrosis, and the organ fails.  If animals have received an 
injurious prior exposure to APAP (right side), this pre-exposure initiates protective changes 
in the liver, detectable as reduced CYP450, increased GSH and cellular proliferation as the 
organ recovers.  A subsequent toxic challenge is tolerated due to enhanced detoxification 
and repair processes.  Injury arising from the second exposure regresses, the organ heals 
and the animal survives.  (Shayiq et al. 1999; Dalhoff et al. 2001; Fan et al. 2014) 
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1.6. Aim 
The aim of this thesis is to investigate the molecular mechanisms of adaptation to chemical 
stress in two preclinical models using the model hepatotoxin APAP.  In the first 
experimental chapter, two preclinical models of repeated APAP exposure are 
characterised, and a global proteomic analysis of rat liver provides insight into the changes 
in abundance of a subset of proteins common to all animals throughout the duration of the 
timecourse.  The second experimental chapter probes deeper into the molecular events 
surrounding adaptation to repeated exposure in the rat, interrogating proteomic data using 
pathway analysis software, and focusing on the role of the key enzyme involved in the 
bioactivation of APAP, CYP2E1, at different timepoints in the model through 
immunohistochemistry and liver microsome experiments.  The final experimental chapter 
compares the regenerative response in the rat and mouse, probing for proteins identified 
as key to the process of adaptation in the work of previous chapters.    
1.6.1. Hypothesis 
Adaptation to repeat APAP exposures is a complex process involving multiple pathways and 
phases, commensurate with a sophisticated response across the liver to ensure survival 
upon re-exposure to subsequent normally noxious exposures. 
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2.1. Introduction 
Adaptation to chemical stress can be induced by many pharmaceutical compounds.  The 
process has important implications for both public health and drug development.  The 
factors governing hepatic adaptation to the popular analgesic and antipyretic 
acetaminophen (paracetamol, APAP) represent valuable research avenues, since APAP 
toxicity represents a leading cause of emergency hospital admissions through accidental 
and intentional overdose.  Knowledge of the mechanism of hepatic adaptation is limited, 
and the research focus to date has been on select proteins implicated in APAP metabolism.   
In this chapter, data have been presented from a rodent model of hepatic adaptation to 
drug toxicity from a whole proteome perspective.  Quantitative mass spectrometry has 
been used to show that the expression of 30 % of proteins detected in the rat liver is 
altered during adaptation to APAP.  Genetic manipulation in mouse of a key protein which 
dictates how the liver adapts to chemical stress, Nrf2, has limited effect.  It is therefore 
likely that the process of adaptation is far more sophisticated than was previously realised.  
These data give the first insight into the unexpected complexity and dynamic nature of the 
biological response to drug-induced liver injury. 
2.1.1. Adaptation to chemical stress 
Adaptation in a biological setting can be defined as a change in the phenotype of an 
organism that allows it to better survive in its environment following exposure to a noxious 
stimulus.  In the setting of drug safety, some individuals may tolerate exposure to a 
potential toxin, some may develop a transient injury but adapt and recover, whilst it has 
been suggested that others fail to adapt and develop a serious adverse drug reaction 
(Watkins 2005). In humans, some volunteers administered a therapeutic dose of APAP 
displayed elevations in circulating liver enzymes (clinical markers of liver injury), which then 
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resolved (Borlak et al. 2013).  Adaptation is therefore likely to be an important defensive 
mechanism to prevent progressive injury resulting from drug toxicity.   
This phenomenon, sometimes termed “autoprotection”, has been particularly investigated 
in order to gain insight into the complex problem of drug induced liver injury (DILI), which is 
probably the most important drug safety issue in pre-clinical and clinical drug development.  
A clearer mechanistic understanding of the processes driving both DILI and adaptation is 
necessary in order to design safer medicines.  Adaptation to normally toxic successive 
doses of a drug has been shown to confer protection in the liver and also other organs 
following administration of a diverse range of compounds including carbon tetrachloride, 
thioacetamide, 2-butoxyethanol and S-1,2-dichlorovinyl-L-cysteine (Dambrauskas and 
Cornish 1970; Thakore and Mehendale 1991; Mangipudy et al. 1995; Sivarao and 
Mehendale 1995; Vaidya et al. 2003).   
2.1.2. APAP-induced adaptation in the literature 
The most widely studied drug that elicits adaptation is APAP (Buttar et al. 1976; Poulsen 
and Thomsen 1988; Shayiq et al. 1999; Dalhoff et al. 2001; Aleksunes et al. 2008a; 
O’Connor et al. 2013).  Previous research into APAP adaptation has indicated that 
metabolic detoxification processes are activated, which alter the fate of subsequent 
exposures (O’Connor et al. 2013).  Specific candidate proteins shown to be altered by the 
initial exposure of an adaptogenic protocol include CYP2E1 and CYP1A2 (Shayiq et al. 1999), 
both enzymes which are directly implicated in the bioactivation of APAP to its reactive 
metabolite NAPQI; also the basolateral efflux transporters MRP3 and MRP4 (Aleksunes et 
al. 2008a); and more recently, the xenobiotic detoxicant FMO3 (Rudraiah et al. 2014).  Due 
to its regulatory role in protection from oxidative stress, the transcription factor Nrf2 has 
been implicated in adaptation to APAP.   Nrf2 is necessary for the induction of MRP3 and 
MRP4 (Aleksunes et al. 2008b), and genetic activation of Nrf2 confers resistance to acute 
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APAP toxicity (Okawa et al. 2006).  Additionally, data are accumulating which indicate that 
the phenotype of regenerating tissue exerts a hepatoprotective effect, as demonstrated by 
studies which have employed the antimitotic colchicine to restore susceptibility in rodent 
models of adaptation (Shayiq et al. 1999; Dalhoff et al. 2001; Aleksunes et al. 2008a).  
2.1.3. Summary 
Studies of adaptation to APAP have thus far been largely restricted to proteins with a likely 
direct role in APAP metabolism, for example, CYP2E1.  APAP pretreatment has previously 
been associated with changes in metabolic detoxification processes, with implications for 
the metabolism of subsequent drug exposure.  However, there has not yet been a whole 
proteome approach to the investigation of adaptation to APAP, so the full extent of the 
response has not been revealed to date.   
In this study, rats and mice were exposed every 24 hours to low, medium or high doses of 
APAP, and clinical chemistry and necropsy were performed to characterise and validate the 
model.  Although rats and mice both showed an adaptive response, the mouse group 
showed a greater degree of overt toxicity than the rat.  Based on these data, livers from the 
rat high APAP exposure group were taken forward for proteomic analysis as a model of 
resistance to repeat APAP exposure.  It is shown here that almost 30 % of the detected 
proteome is significantly altered during adaptation, indicating that the breadth of the 
effects of adaptation is much greater than previously thought.  This has been confirmed by 
examination of adaptation in an Nrf2 null mouse model, which demonstrated that 
adaptation still occurs in the absence of this key cytoprotective transcription factor. 
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2.2. Methods 
2.2.1. Materials 
8-plex isobaric tags for relative and absolute quantification (iTRAQ) protein labelling 
kit/reagents were purchased from AB Sciex (Framingham, MA, USA). Sequencing grade 
trypsin was obtained from Promega UK (Southampton, Hants, UK).  LC-MS grade dH2O and 
methanol, ethylene diamine-tetracetic acid (EDTA), ammonium bicarbonate and potassium 
chloride were from Fisher Scientific (Loughborough, UK). All other reagents were of 
analytical grade and quality and purchased from Sigma (St. Louis, MO).  Antibodies for 
NQO1, PCNA and β-actin were purchased from Abcam (Cambridge, UK; Cat. nos ab2346, 
ab29 and ab6276 respectively).  Antibody for GSTP1 was from Assay Designs (Enzo Life 
Sciences, Farmingdale, NY) (Cat. No. MSA-102) and antibody for vimentin was from Sigma 
(Cat. No. V6389). 
2.2.2. Animals 
All animal work was undertaken by Almirall S.A. (Barcelona, Spain), including toxicological 
assessment as described in 2.2.4.  Male Crl:WI (Han) rats and male Crl:CD1 (ICR) mice (6-8 
weeks of age) were obtained from Charles River Laboratories (Lyon, France) and allowed 1 
week to acclimatise prior to the study. Six animals were housed per cage, on a 12 h 
light/dark cycle (lights on 0800, lights off 2000), temperature of 22 ± 2 oC and humidity of 
55 ± 15 %.  Standard food and tap water were provided ad libitum. Care of animals was 
undertaken in compliance with the European Community Directive 86/609/CEE for the use 
of laboratory animals and with the Autonomous Catalan law (Decret 214/1997). All 
experimental procedures were approved by the Almirall Ethics Committee before initiation 
of the study. 
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2.2.3. Study design 
APAP was dissolved in vehicle (0.5 % methylcellulose and 0.1 % Tween 80 in distilled water, 
10 mL/kg) and administered by gavage without previous fasting period. Formulations were 
prepared daily and control animals received the vehicle solution alone.  Rats received a 
dose of 500, 1000 or 1500 mg/kg, and mice received 250, 500 or 750 mg/kg.  Animals (n = 
6) received either a single dose of APAP at 0 h (for 2, 4, 6 or  24 h) or vehicle (for 2 or 24 h), 
or were dosed at 24 h intervals for up to 72 h, with sacrifices 24 h after each dose.  An 
outline of the dosing protocol is shown in Figure 2.1.  
 
 
 
 
Figure 2.1: Study design for repeat APAP exposure in rat and mouse  
Legend: Green triangles denote APAP administration.  Rats received either 500, 1000 or 
1500 mg/kg at each time point; mice received 250, 500 or 750 mg/kg.  Red triangles 
indicate cull times.  Animals were sacrificed at 2, 4, 6 and 24 h after the first dose, and at 24 
hours after the last dose received in all other groups.  Roman numerals denote the number 
of doses received. 
 
Body weight was recorded daily during treatment to assess the general wellbeing of the 
animals.  Terminal blood samples without previous fasting were collected from the 
retroorbital plexus under isoflurane anaesthesia (4 % induction, 1.5-3 % maintenance) into 
serum separator tubes for clinical chemistry analysis. Blood samples were centrifuged for 
10 min at 3000 rpm and serum collected. After centrifugation, each sample was stored at -
80 oC until analysis.  Immediately after blood collection, animals were exsanguinated by 
cutting the abdominal aorta under isoflurane anaesthesia. 
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2.2.4. Toxicological assessment  
A Synchron Clinical System cx7® (Beckman, Brea, CA) was used to determine alanine 
aminotansferase (ALT, IU/L) and aspartate aminotransferase (AST, IU/L).  The liver and 
brain were weighed to calculate liver-to-brain weight ratios (in %) for each animal.  Samples 
of liver were harvested and frozen in liquid nitrogen before storage at -80 oC. The hepatic 
median lobe was preserved in 10 % neutral buffered formalin, embedded in paraffin, 
sectioned and stained with haematoxylin and eosin (H&E) for subsequent histological blind 
examination under light microscopy.  Distribution, incidence and score of hepatic lesions in 
each animal group were recorded according to the Predictive Safety Testing Consortium’s 
“Recommended Histopathology Practices in Novel Liver Biomarker Qualification Studies".  
Scoring criteria are defined in Table 2.3. 
2.2.5. Glutathione sample preparation 
GSH analysis by mass spectrometry (MS) was performed by Dr. Joanne Walsh.  Rat and 
mouse livers (n = 4 per treatment group) were homogenised using the method of 
Bouligand et al. with minor modifications (Bouligand et al. 2006).  50-100 mg of liver tissue 
was homogenised in acidic (pH 2) homogenisation buffer (1.15 % w/v potassium chloride, 1 
mM EDTA and 2 mM batho-phenanthroline disulphonate in 0.1 % v/v formic acid (FA)) 
using a Mixer Mill 220 (Retsch, Haan, Germany) (30/s; 3 min).  Samples were centrifuged 
(16 000 g, 15 min, 4 °C) and the supernatant retained.  The pellets were reserved for 
protein concentration determination by the method of Lowry (Lowry et al. 1951).  
GSH and GSSG (oxidised glutathione) standards (0.1-10 µM) were prepared from 1 mM 
stock solutions. 50 µL of internal standard (stable isotope labelled GSH [GSH-Gly(13C2,
15N)]) 
was added to 50 µL of standards or homogenised samples.  50 µL of matrix (pooled mouse 
liver homogenate, 5 mg/mL protein) was also spiked into standards.  In order to derivatise 
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the thiol groups, 100 µL of iodoacetamide (IAA) derivatisation solution [10 mM IAA in 10 
mM ammonium bicarbonate with NH3OH 0.5 % (v/v); pH 9.5] was added, and the solutions 
were incubated (1.5 h; room temperature (RT)).  Reactions were performed in amber 
microfuge tubes for light sensitive samples (Eppendorf UK Ltd, Stevenage, UK). 
50 µL of ice cold sulphosalicylic acid solution (10 % w/v) was added in order to stop the 
reaction and precipitate proteins.  Samples and standards were vortexed and centrifuged 
(16 000 g, 15 min, 4 °C) before being filtered (1500 g, 20 min) using a 96 well MultiScreen 
filter plate (Millipore Ltd, Watford, UK). All solutions were made up to a final volume of 1 
mL with 0.1 % (v/v) FA, and 100 µL transferred to a glass vial for LC-MS/MS analysis.   
2.2.6. Glutathione LC-MS/MS analysis 
The Dionex UltiMate 3000 High Performance Liquid Chromatography system (Thermo 
Fisher, UK Ltd, Surrey, UK) was used in combination with a Kinetex 2.6 μm C18 100 Å 100 x 
2.1 mm column (Phenomenex, Macclesfield, UK), in order to achieve separation of 
analytes. The column oven was held at a temperature of 30 °C. The injection volume was 
10 µL, with the syringe washed with 5 % methanol prior to each injection.  The flow rate 
was 100 µL/min with mobile phases 0.1 % (v/v) FA in dH2O (solvent A) and 0.1 % (v/v) FA in 
methanol (solvent B).  The elution gradient (0 min, 0 % B; 0-5 min, 0-20 % B; 5-10 min, 20 % 
B; 10-15 min, 0 % B) had a total run time of 15 minutes. An ABSciex Q Trap mass 
spectrometer (ABSciex UK Ltd, Warrington, UK) was used for analyte detection using a 
multiple reaction monitoring (MRM) method.  The parameters used for each analyte are 
detailed in Table 2.1 
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Analyte Q1 mass Q3 mass DP (volts) CE (volts) CXP (volts) 
CM-GSH 366.3 237.0 65.0 16.0 10.0 
GSSG 613.4 355.2 83.0 32.0 10.0 
CM-GSH-IS 369.1 84.0 71.0 53.0 2.0 
Table 2.1: Parameters used for MS/MS analyte detection  
DP = declustering potential; CE = collision energy; CXP = collision cell exit potential; CM = 
carboxymethyl; IS = internal standard. 
 
2.2.7. iTRAQ labelling and mass spectrometric analysis of liver homogenates 
Rat liver samples (n = 4 animals per timepoint, 1500 mg/kg group, ~100 mg wet weight) 
were homogenised in 0.5 M triethylammonium bicarbonate (TEAB)/0.1 % sodium dodecyl 
sulphate using a Mixer Mill 220 (Retsch, Haan, Germany), and centrifuged at 14000 g for 10 
mins.  Aliquots of each sample (100 μg protein) were denatured, reduced and sulphydryl 
groups were capped with methylmethane thiosulphate (MMTS) according to the 
manufacturer’s 8-plex protocol (Life Technologies, Paisley, UK). The samples were digested 
with trypsin overnight, labelled with iTRAQ isobaric tags and mixed in equal proportions.  
Unbound reagent and trypsin were removed by cation exchange chromatography.  
Fractions were desalted using a macroporous C18 column (Agilent, Santa Clara, CA) on a 
Vision workstation and dried by centrifugation under vacuum (SpeedVac; Eppendorf, 
Stevenage, Herts, UK). Sample analysis was kindly performed by Dr. Roz Jenkins using a 
Triple TOF 5600 mass spectrometer (AB Sciex, Warrington, Cheshire, UK).  Samples were 
delivered into the instrument by automated in-line liquid chromatography Eksigent 
NanoUltra cHiPLC System mounted with microfluidic trap and analytical column 
(15 cm × 75 μm) packed with ChromXP C18-CL 3 μm via a nano-electrospray source head 
and 10 μm inner diameter PicoTip (New Objective, Woburn, MA). The precolumn was 
washed for 10 min at 2 μL/min with 2 % acetonitrile (ACN)/0.1 % FA. A gradient from 2 % 
ACN/0.1 % FA (v/v) to 50 % ACN/0.1 % FA (v/v) in 90 min was applied at a flow rate of 300 
nL/min.  
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The MS was operated in positive ion mode with survey scans of 250 ms, and with an 
MS/MS accumulation time of 100 ms for the 25 most intense ions (total cycle time 2.5 s). A 
threshold for triggering of MS/MS of 100 counts per second was used, together with 
dynamic exclusion for 12 s and rolling collision energy, adjusted for the use of iTRAQ 
reagent in the Analyst method. Information-dependent acquisition was powered by Analyst 
TF 1.5.1 software, using mass ranges of 400-1600 atomic mass units (amu) in MS and 100-
1400 amu in MS/MS. The instrument was automatically calibrated after every fifth sample 
using a beta-galactosidase digest.  
2.2.8. iTRAQ protein identification and statistical analyses 
Liver samples from rats treated with 1500 mg/kg APAP or vehicle control were analysed 
across four iTRAQ runs with a comparator pooled sample included in each run for 
normalisation between iTRAQ experiments.  Samples (n = 3 or 4) for each exposure group 
were randomised across the four runs to minimise label bias.  Ratios for each iTRAQ label 
were obtained, using the common pool as the denominator.  Data analysis was performed 
using ProteinPilot software (Version 3, Life Technologies, Paisley, UK).  The data were 
analysed with MMTS as a fixed modification of cysteine and biological modifications.  The 
SwissProt database was searched with a confidence interval of 95 % and also screened in 
reverse to facilitate false discovery rate (FDR) analysis.  Proteins identified from peptides 
with more than 95 % confidence and a global FDR of less than 1 % were included in the 
statistical analysis.  
The limma package within the R programming environment (Team, 2005) allowed 
simultaneous comparisons between multiple treatments using design and contrast 
matrices.  This open source software generates a linear regression model to facilitate the 
analysis of differential protein expression.  Mean fold changes were calculated and analysis 
conducted on the logged fold-change values.  Unadjusted (raw) p values and p values 
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following FDR correction for multiple testing were determined.  Volcano plots were 
generated, as was a heatmap of significantly changed proteins common to all animals, and 
principal component analysis (PCA) was performed.    
2.2.9. Western immunoblotting 
In order to confirm changes in key proteins identified by iTRAQ, buffered liver 
homogenates of standardised protein concentration (n = 4) were separated on a 
polyacrylamide gel.  Resolved proteins were transferred onto nitrocellulose membrane (GE 
Healthcare, Little Chalfont, Buckinghamshire, UK) and Ponceau-S stained to confirm even 
protein loading before blocking with 10 % milk protein diluted in tris-buffered saline 
containing 0.05 % Tween 20 (TBS-T).  Antibodies were diluted in TBS-T with the addition of 
2 % milk protein and applied according to individual protocols (Table 2.2).  All secondary 
antibodies were horseradish peroxidise (HRP)-conjugated.  Membranes were treated with 
Western Lightning Plus Enhanced Chemiluminescence (Perkin Elmer, Waltham, MA) before 
exposure to X-ray film (GE Healthcare).  Exposed films were scanned using a GS800 scanner 
(Bio-Rad, Hercules, CA) and relative band intensity was analysed using Quantity One 
software (Bio-Rad).  Proteins of interest were normalised to actin, then expressed relative 
to the mean of the control group.   
Protein GSTP1 NQO1 PCNA Vimentin Actin 
Manufacturer Assay Designs Abcam Abcam Sigma Abcam 
Code msa-102 ab2346 ab29 v6389 ab6276 
MW (kDa) 26 31 29 54 40 
Host species rabbit goat mouse mouse mouse 
Block duration overnight 30 min 30 min 30 min overnight 
Primary dilution  1:10 000 1:2000 1:2000 1:5000 1:20 000 
Primary incubation 1h overnight overnight overnight 30 min 
Secondary dilution  1:10 000 1:5000 1:5000 1:5000 1:10 000 
Secondary incubation 1h 1h 1h 1h 1h 
Table 2.2: Antibody conditions for western immunoblot 
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2.2.10. Nrf2 knockout study 
Data from a previously conducted study performed by Dr. Laura Randle was included due 
to its pertinence to the mechanism of adaptation to chemical stress.  In Dr. Randle’s study, 
the Nrf2-dependent response of the mouse to repeat APAP exposure was investigated.  
Mice (C57BL6J background) were treated daily with increasing doses of APAP in a 
recapitulation of the protocol described by Shayiq et al. (1999) (Figure 2.2).    
 
 
 
Figure 2.2:  Study design for repeat APAP exposure in Nrf2 knockout mice   
Legend: In a study performed by Dr. Laura Randle, Nrf2(+/+) and Nrf2(-/-)  mice were each 
assigned to groups A B C and D.  Groups A and B received incremental doses of APAP every 
24 h over a period of 8 days (range 150 – 600 mg/kg), with a final challenge on day 9 of 
1000 mg/kg APAP or saline.  Groups C and D received saline pretreatment and either toxic 
challenge or saline on day 9.  Animals were culled 5 hours after dosing on day 9.  All doses 
shown in mg/kg. 
 
All experiments were undertaken in accordance with criteria outlined in a licence granted 
under the Animals (Scientific Procedures) Act 1986, and approved by the Animal Ethics 
Committee of the University of Liverpool. Generation of the Nrf2 knockout mouse and 
genotyping of progeny was performed as described previously (Itoh et al. 1997; McMahon 
et al. 2001).  Non-fasted male littermate Nrf2(+/+) and Nrf2(-/-)  mice of 10-12 weeks of age 
were used throughout the study.  Mice were housed between 19 °C – 23 °C, under 12 h 
light/dark cycles and given free access to food and water.  Dosing began at 10 am each day. 
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APAP 15 mg/mL or 30 mg/mL was freshly prepared in warmed saline (0.9 %) depending on 
the dose to be administered.  After pilot dose ranging studies confirmed the dose 
dependent nature of APAP-induced hepatotoxicity, male Nrf2(+/+) mice and Nrf2(-/-) 
littermates received increasing daily doses of APAP (2 x 150 mg/kg, 2 x 300 mg/kg, 2 x 450 
mg/kg, 2 x 600 mg/kg in 0.9 % saline, i.p.) over 8 days, or an equal volume of saline vehicle 
alone (0.9 %, i.p. ) (n = 4 mice per treatment group).  On day 9, both groups were further 
challenged with 1000 mg/kg APAP (0.9 % saline, i.p.) or saline (n = 4-8 mice per treatment 
group).  Mice were culled by exposure to a rising concentration of CO2 followed by cervical 
dislocation 5 h after the final toxic APAP dose on day 9 (approximately 3 pm) and survival 
data were analysed. 
2.2.11. Data evaluation and statistical analysis 
Clinical chemistry and toxicological data are expressed as mean plus standard error of the 
mean (SEM).  Body weight, liver to brain ratio, and serum ALT and AST data for vehicle- and 
APAP-treated animals were compared to time-matched controls by one-way ANOVA with 
Tukey post-hoc test.  Western immunoblotting, iTRAQ and GSH data were analysed using a 
one-way ANOVA with Dunnetts post-hoc test.  The software used was GraphPad PRISM 
(version 6.03 for Windows, GraphPad Software, San Diego, USA).  A p value < 0.05 was 
considered statistically significant.    
  
Chapter 2: Rodent adaptation to repeat APAP exposure 
 
37 
 
2.3. Results 
In this model of adaptation to repeat APAP exposure, rats were dosed orally with 500, 1000 
or 1500 mg/kg APAP either once at 0 h with sacrifice at 2 h, 4 h, 6 h or 24 h; or at 24 hour 
intervals for up to 72 hours with sacrifices 24 hours after the final dose administered.  Mice 
were also treated following an identical protocol but using doses of 250, 500 and 750 
mg/kg (Figure 2.1). 
2.3.1. Bodyweight 
Bodyweight was monitored daily from the beginning of APAP administration to assess 
individual animal welfare throughout the dosing period. 
2.3.1.1. Rat 
No differences in bodyweight were observed in rats treated at 500 mg/kg compared to the 
corresponding vehicle group (Figure 2.3a).  In contrast, bodyweight from rats treated at 
1000 and 1500 mg/kg was significantly lower than that of control animals after 96 hours of 
daily APAP administration.  No mortality was observed in rats at any dose tested. 
2.3.1.2. Mouse 
Mice treated with APAP at 250 mg/kg presented no reduction in bodyweight whereas 
treatment with both 500 and 750 mg/kg resulted in a loss of bodyweight which was 
significant after 48 hours of daily APAP administration, but animals recovered thereafter 
(Figure 2.3b).  1/48 mice in the 500 mg/kg group was found dead at 96 h; and 2/48 in the 
750 mg/kg group were found dead, one at 48 h and one at 96 h.   
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Figure 2.3: Bodyweight in rat and mouse 
Legend: In rat (a), after 96 hours of daily APAP administration at 1000 and 1500 mg/kg, rats 
showed significantly lower bodyweight than time-matched control animals.  No significant 
difference was seen at any other timepoint.  In mouse (b) after 48 hours of daily APAP 
administration at either 500 or 750 mg/kg, mice showed significantly lower bodyweight 
than control animals.  No significant difference was seen at any other timepoint. 
  
a 
b 
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2.3.2. Liver mass  
Liver mass was calculated relative to brain mass in order to control for changes in growth 
over the study duration.   
2.3.2.1. Rat 
In rats, no statistical significance was seen when comparing liver to brain mass in each 
treatment group to ratios for control animals (Figure 2.4a). 
2.3.2.2. Mouse 
In mice, the relative mass of the liver was significantly decreased at 48 h in the 750 mg/kg 
group (Figure 2.4b).   
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Figure 2.4: Liver to brain mass in mouse 
Legend:  In rat (a) when growth was controlled for by expressing liver mass relative to brain 
mass, no statistical significance was seen at any point.  In mouse (b) after 48 hours of daily 
APAP administration at 750 mg/kg, mice showed significantly lower liver to brain mass ratio 
than control animals.  No significant difference was seen at any other timepoint. 
  
a 
b 
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2.3.3. Histopathology 
A histopathological review of liver samples was scored according to Table 2.3.  
Score Description Observation 
0 No injury Histologically normal 
 
1 Minimal A microscopic change ranging from inconspicuous to barely 
noticeable but so minor, small, or infrequent as to warrant no 
more than the least assignable grade  
2 Mild A microscopic change that is a readily noticeable but not a 
prominent feature of the tissue and/or may be considered to 
be of no functional consequence 
3 Moderate A microscopic change that is a prominent but not a dominant 
feature of the tissue and/or may be considered to have 
limited impact on organ function 
4 Marked A microscopic change that is a dominant feature and may be 
an overwhelming component of the tissue and/or may be 
considered to cause significant tissue or organ dysfunction 
and/or represents an end-stage feature of the tissue (i.e. 
total organ failure) 
Table 2.3: Histopathology scoring of tissue 
 
2.3.3.1. Rat 
Hepatic histological lesions seen after APAP administration in rats are presented in Table 
2.4. Histologically, no apparent lesions were observed at 2, 4 or 6 h after a single APAP 
exposure.  24 h after the first administration, rats treated at all doses showed minimal 
hepatocellular eosinophilia in the centrilobular zone.  Hepatic centrilobular necrosis was 
observed in 1/6 animals dosed at 1000 mg/kg, and presence of mild mixed inflammatory 
infiltrates in the same zone was observed in some animals treated at 1000 and 1500 mg/kg.  
Incidence of hepatic lesions peaked at 48 and 72 hours, notably in 1000 and 1500 mg/kg 
groups.  Lesions were characterised by centrilobular mild hepatocellular eosinophilia and 
moderate to marked hepatocellular coagulative necrosis with associated mild mixed 
inflammatory cell infiltrates.  Centrilobular hepatocellular eosinophilia and necrosis 
accompanied by mixed inflammatory infiltrates were still observed in some animals at 96 h, 
in particular at 1500 mg/kg.  Representative H&E stained sections from rats treated with 
1500 mg/kg APAP can be seen in Figure 2.5.  Blinded and unblinded quantification areas of 
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necrosis across whole liver sections showed a significant 35 % loss of liver cells, 
predominantly hepatocytes, at 48 h only.  No significant areas of necrosis were seen at 
subsequent timepoints (Table 2.5).  
Table 2.4: Main hepatic lesions observed after single or repeat APAP administration in rat  
Legend: Numerical summary of the main hepatic lesions observed in the rat over 96 h 
experimental timecourse.  Incidence of hepatic lesions peaked in animals which received 48 
h or 72 h of daily APAP administration at 1000 and 1500 mg/kg.  CL = centrilobular. 
 
Figure 2.5: Representative images of H&E stained rat liver sections from each timepoint 
in the 1500 mg/kg dose group 
Legend:  Stained sections from the rat 1500 mg/kg APAP exposure timecourse showing the 
progression of tissue injury and recovery.  Mild eosinophilia is visible in centrilobular 
regions at 24 h, and at 48 h centrilobular necrosis can be seen.  Bar = 200 µm 
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Time (h)  % live cells SEM 
24 100 0.00 
48  65**
 
 3.54 
72  96 2.13 
96  95 2.89 
Table 2.5: Quantification of area of necrosis in rats treated with 1500 mg/kg APAP 
Legend:  Regions of cell death presented as a percentage of total area of section analysed, 
following histopathological analysis of groups of animals at each timepoint in 1500 mg/kg 
group.  35 % cell death is seen after 48 h of APAP exposure, coincident with significant ALT 
release (Figure 2.9).  Recovery to ~5 % cell death is seen at later timepoints. 
 
2.3.3.2. Mouse 
Hepatic histological lesions seen after APAP administration in mice are presented in Table 
2.6.  Histological examination of liver sections from mice that received a single 
administration of APAP showed minimal eosinophilia within centrilobular zones (2 h – 24 
h).  The main hepatic lesions appeared at 48 h, particularly in the 500 and 750 mg/kg dose 
groups, and were characterised by the presence of areas of coagulative necrosis in 
centrilobular zones with associated mixed inflammatory cell infiltrates.  Additionally, 
hepatocellular eosinophilia and hypertrophy were seen.  At 72 h and 96 h (500 and 750 
mg/kg), some animals still presented extensive areas of necrosis accompanied by 
mononuclear inflammatory cells whereas others did not present any relevant hepatic 
lesions.   Representative H&E stained sections from mice treated with 750 mg/kg APAP can 
be seen in Figure 2.6.   
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Table 2.6: Main hepatic lesions observed after single or repeat APAP administration in 
mouse   
Legend: Numerical summary of main hepatic lesions observed in the mouse over 
experimental timecourse.  Incidence of hepatic lesions peaked in animals which received 48 
h of daily APAP administration at 500 and 750 mg/kg.  CL = centrilobular, P = periportal, D = 
diffuse. 
Figure 2.6:  Representative images of H&E stained mouse liver sections from each 
timepoint in the 750 mg/kg dose group 
Legend:  Stained sections from the mouse 750 mg/kg APAP exposure timecourse showing 
the progression of tissue injury and recovery. At 48 h centrilobular necrosis can be seen, 
accompanied by inflammatory cell infiltrate and hepatocellular hypertrophy.  Bar = 200 µm 
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2.3.4. Clinical chemistry 
2.3.4.1. Rat 
In rats, a single dose of APAP did not affect serum transaminases at 2, 4 or 6 h (data not 
shown).  Both ALT (Figure 2.7a) and AST (Figure 2.7b) increased markedly at 48 h in the 
1500 mg/kg dose group. At 72 h and 96 h, levels of both transaminases returned to 
baseline values.  Rats displayed a peak serum ALT rise 40-fold above time-matched vehicle 
controls, from 40.8 IU/L to 1643.2 IU/L at 48 h; and a 45-fold serum AST rise over control, 
from 66.7 IU/L to 2987.5 IU/L at 48 h.  Both biomarkers returned to normal levels by 96 h. 
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Figure 2.7: Serum transaminases in rat  
Legend: Serum ALT and AST levels were determined in terminal blood samples from rats at 
all time points.  Both biomarkers were significantly elevated after 48 h of 1500 mg/kg 
APAP, and both biomarkers thereafter returned to baseline levels.  (n = 6) 
 
2.3.4.2. Mouse  
In mice, a single dose of APAP did not affect serum transaminases at 2, 4 or 6 h (data not 
shown).  Both ALT (Figure 2.8a) and AST (Figure 2.8b) increased markedly at 48 h in the 750 
mg/kg dose group. At 72 h and 96 h, levels of both transaminases returned to baseline 
values.  Mice displayed a peak serum ALT rise 200-fold above time-matched vehicle 
controls, from 43.3 IU/L to 8666.2 IU/L at 48 h; and a 67-fold serum AST rise over control, 
from 75.2 IU/L to 5035.6 IU/L at 48 h.  Both biomarkers returned to normal levels by 96 h. 
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Figure 2.8: Serum transaminases in mouse 
Legend: Serum ALT and AST levels were determined in terminal blood samples from mice 
at all time points.  Both biomarkers were significantly elevated after 48 h of 750 mg/kg 
APAP, and both biomarkers thereafter returned to baseline levels.  (n = 6) 
 
2.3.5. Hepatic glutathione 
Reduced GSH was measured by mass spectrometry in whole liver samples taken from rat 
and mouse models.  Both models showed initial depletion of GSH at 2, 4, and 6 h after the 
first exposure to APAP; thereafter, responses diverged. 
2.3.5.1. Rat liver glutathione 
After an initial depletion at 4 h, GSH values fell further still after 24 h of either 1000 or 1500 
mg/kg APAP.  By 48 h of exposure, 500 and 1000 mg/kg groups had recovered to values 
consistent with control, and 1500 mg/kg animals showed significantly elevated values, 
which fell back to levels consistent with 24 h measurement by 96 h.  In contrast, GSH in the 
500 mg/kg group were significantly elevated above control values at 72 and 96 h (Figure 
2.9). 
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Figure 2.9: GSH in rat 
Legend: Analysis of hepatic GSH in rat shows significant depletion at 4h in rats that received 
1000 or 1500 mg/kg APAP.   GSH remained low in these groups after 24 h of exposure.  At 
the peak of toxicity, after 48 h of exposure, GSH is elevated in the 1500 mg/kg group alone.  
Thereafter in this group it falls significantly below control values by 96h.  #, + and * denote 
significance for 500, 1000 and 1500 mg/kg group respectively. (n = 4) 
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2.3.5.2. Mouse 
Although the trend was one of loss of GSH at early timepoints, significance was only seen in 
the 250 mg/kg group at 2 and 4 h.  Thereafter no significant deviation from control values 
was detected at any later timepoint (Figure 2.10). 
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Figure 2.10: GSH in mouse 
Legend: Analysis of hepatic GSH in mouse shows significant depletion at 2 and 4 h in 
animals that received 250 mg/kg APAP.  Thereafter, no significant mean deviation from 
control values is seen.  # denotes significance for 250 mg/kg group. (n = 4) 
 
2.3.6. Quantitative mass spectrometry  
Based on the results of the clinical chemistry and histopathology analyses, the rat was 
selected for further investigation.  iTRAQ analysis was performed in order to assess the 
changing phenotype of the rat liver during adaptation to repeat APAP exposure.  This 
technique allows unambiguous identification and quantification of proteins expressed in a 
complex tissue matrix, and presents a snapshot of the hepatoproteome at each of the 
timepoints examined.  Global proteomic analysis of rat liver tissue identified 2181 unique 
proteins, of which 1169 were common to all animals and all time points, and were 
therefore amenable to statistical analysis.  Lists of significantly perturbed proteins can be 
seen in Supplementary Tables 1a-d. 
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2.3.6.1. Volcano plots and Principal Component Analysis 
Global changes at each timepoint have been visualised as volcano plots, in which 
significance (y) is plotted against fold change (x), allowing the most changed proteins to be 
easily identified.  Although changes can be seen at 24 h (Figure 2.11a), at 48 h (Figure 
2.11b, peak toxicity) the volcano plots show the most disparate protein abundance, as 
indicated by the number of red points (FDR ≤ 0.05) and blue points (p < 0.05) in the plot.  
Large numbers of protein changes are still observed at 72 h (Figure 2.11c) and 96 h (Figure 
2.11d).    Whilst some proteins in this analysis were increased in abundance as a 
consequence of dosing, the majority of significantly altered proteins were less abundant 
when compared to control animals, indicated by red points clustering on the left side of 
each plot.  PCA was performed to identify the proteins contributing to the most apparent 
differences in the data set as a whole.  Comparing principal component (PC) 1 to PC 4 
allowed separation of data points into three distinct groups, thereby identifying groups of 
proteins contributing to the major differences between these groups (Figure 2.11e, 
Supplementary Table 2).  Numerical descriptions of significant changes are shown in Table 
2.7, showing that almost 30 % of the detected proteome is altered by repeat APAP 
exposure.    
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Figure 2.11: Analysis of trends in the rat proteomic data set   
Legend: Volcano plots show changes in abundance against significance, allowing changed 
proteins to be visually identified. a) At 24 h, only one protein has significance after 
adjustment for FDR (shown in red).  b) At 48 h this number has risen to forty-six; c) at 72 h 
it is twenty-five; d) at 96 h, it is sixteen. e) A PCA plot allowing identification of groups of 
proteins contributing to the most apparent differences seen in the data set.  Control 
animals, and those receiving single exposures can be seen to the top right of the plot; 
repeat exposures at 48 h and 72 h cluster to the top left and 96 h clusters to the bottom of 
the plot. (n = 3-4) 
 
Table 2.7: Numerical description of significant changes at each timepoint  
Legend: Relative changes in protein abundance in rat liver in response to repeat APAP 
exposure. The number of proteins that were increased or decreased in abundance in rat 
liver at each timepoint compared to control animals is indicated. The total number of 
changed proteins is expressed as a percentage of the total number of proteins quantified in 
the analysis (1169). 
  
Timepoint 
(h) 
Doses 
Proteins 
increased 
abundance  
(p < 0.05) 
Proteins 
decreased 
abundance  
(p < 0.05) 
Total 
Percentage of 
quantifiable 
proteome different 
relative to control 
24 1 30 43 73 6.24 
48 2 116 199 315 26.95 
72 3 111 145 256 21.90 
96 4 86 125 211 18.05 
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2.3.6.2. Heatmapping and validation western immunoblotting 
The subset of 1169 proteins common to all animals at every timepoint is expressed as a 
heatmap (Figure 2.12). This demonstrates similarity in protein expression levels between 
control and single dose livers (24 h).  By contrast, the profile of the same proteins in the 
repeat dose livers (48 h and 72 h) appears markedly changed.  By 96 h a further shift in the 
protein expression profile is seen, consistent with the clustering shown using PCA in Figure 
2.11e.   
 
Figure 2.12: Heat map of proteins common to all animals at all timepoints   
Legend: Heat map representing the 1169 proteins common to all samples and all time- 
points identified distinct changes in protein abundance in repeat-dosed animals (red 
indicates increased abundance, blue indicates decreased abundance). 
Chapter 2: Rodent adaptation to repeat APAP exposure 
 
52 
 
These observations are supported by immunoblot data obtained from four proteins (Figure 
2.13), selected from the iTRAQ mass spectrometric data for their different properties as 
sentinels of metabolic function or regeneration: GSTP1 (glutathione-s-transferase pi), 
NQO1, PCNA (Proliferating cell nuclear antigen), and vimentin.  NQO1 and GSTP1 are 
important enzymes in the detoxification of NAPQI, the toxic metabolite of APAP.  PCNA is a 
marker of replication (Galand and Degraef 1989), and indicates a surge in proliferative 
activity in the rat livers which peaks at 72 h. Vimentin is a classical marker of progenitor 
cells  and is upregulated in cells that are undergoing epithelial to mesenchymal transition, a 
process implicated in wound healing and organ fibrosis (Eckes et al. 2000). 
 
Figure 2.13: Validation of selected significantly perturbed proteins by western 
immunoblot   
Legend: Representative images of western immunoblots for selected significantly 
perturbed proteins GSTP1, NQO1 and vimentin (VIM) are presented, showing n = 2 animals 
for each protein of interest.  Actin is included as a loading control.  
 
Comparison of western immunoblot data of liver lysates for these selected significantly 
perturbed proteins with data obtained for the same proteins by MS analysis demonstrated 
a positive correlation, validating the techniques employed (Figure 2.14). 
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Figure 2.14: Correlation of immunoblot and mass spectrometric data  
Legend: For each protein shown in Figure 2.13, densitometric values for abundance have 
been plotted against mass spectrometric, generating correlation plots showing positive 
association.   
 
2.3.7. Hepatotoxic assessment of Nrf2(+/+) and Nrf2(-/-) mice 
In Dr. Randle’s study, after 8 days pretreatment with increasing doses of APAP, Nrf2(+/+) and 
Nrf2(-/-) mice were given a toxic challenge, and survival at 5 h post dose was quantified 
(Figure 2.15).  In Nrf2(+/+) animals, a toxic challenge in naive animals resulted in 50 % 
mortality.  The same toxic challenge in the APAP pretreatment group caused no mortality, 
demonstrating the protective effect of pretreatment in wild type animals.   
In Nrf2(-/-) animals, a toxic challenge administered to naive animals was 100 % lethal, 
reflecting increased susceptibility caused by the silencing of the Nrf2 mediated oxidative 
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stress response.  However, APAP pretreatment allowed 50 % of the Nrf2(-/-) animals to 
survive a toxic challenge that was 100 % lethal after saline pretreatment, demonstrating 
that Nrf2-mediated transcription is not the only mechanism of adaptation to toxic insult in 
this model, and indicating that the processes underpinning adaptation exhibit redundancy. 
 
 
Figure 2.15: Effect of pretreatment on survival of toxic challenge in Nrf2(+/+) and  
Nrf2(-/-) mice   
Legend: Hepatotoxic assessment of Nrf2(+/+) and Nrf2(-/-) mice after a toxic APAP challenge in 
saline or APAP pretreated mice.  In Dr. Randle’s experiment, Nrf2(+/+) and Nrf2(-/-) mice were 
dosed daily with a single i.p. dose of APAP (150-600 mg/kg) or saline vehicle control over 8 
days before a 5 h toxic APAP challenge (1 g/kg). Survival was observed 5 h after the toxic 
dose and plotted as percentage survival.    
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2.4. Discussion 
DILI is a major problem both in the clinic and for the pharmaceutical industry. Our relative 
lack of understanding of the physiological and toxicological mechanisms involved can lead 
to the loss of potentially effective drugs during development.  APAP poisoning is itself also 
a significant clinical problem (Larson et al. 2005).  Furthermore, APAP is probably the most 
extensively characterised hepatotoxin in pre-clinical models, and therefore provides a 
means to interrogate the various processes of adaptation and regeneration in the liver, 
which are also relevant to humans and may be applicable to other drugs associated with 
DILI.   
2.4.1. Summary of findings 
In this chapter, adaptation has been demonstrated in both rat and mouse models of 
repeated exposure to APAP, suggesting that the phenomenon of adaptation is not species-
selective, but rather is a conserved process with relevance to humans.  The two species 
were investigated because of their widespread use in preclinical toxicity testing; because of 
their similarity to aspects of human APAP hepatotoxicity (Bushel et al. 2007; Kienhuis et al. 
2009; McGill et al. 2012a; Hadi et al. 2013); and because the mouse is more amenable to 
genetic modification in order test the role of specific genes in the process.  Both species 
were dosed using an identical experimental protocol, and the doses were chosen in order 
to monitor adaptation across a range of sub-toxic, threshold toxic and overtly toxic doses of 
APAP, to ensure that the drug exposure is relevant to what may occur in humans.  Animals 
were dosed either once at 0 h with sacrifice at 2, 4, 6, or 24 h; or at 24 h intervals for up to 
72 h with sacrifice 24 h after the final exposure (Figure 2.1).  No mortality was seen in the 
rat model, and three animals died in the mouse model – one treated with 500 mg/kg 
(threshold toxicity) was found dead at 96 h; and two treated with 750 mg/kg (overt 
toxicity) were found dead, one at 48 h and one at 96 h.  Significant loss of bodyweight was 
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seen in both models, but only after 96 h of treatment at 1000 and 1500 mg/kg in rat (Figure 
2.3a), and at 48 h of treatment at 500 and 750 mg/kg in the mouse (Figure 2.3b).  However, 
when growth was controlled for by expressing liver mass relative to brain mass, no 
significant deviation from control was seen in the rat (Figure 2.4a), and in the mouse, 
significance was only observed after 48 h of treatment at 750 mg/kg (Figure 2.4b).  This 
suggested that, although growth rates may have been affected by APAP exposure, 
significant liver tissue loss only arose in the mouse 750 mg/kg (overt toxicity) group, which 
was supported by histopathology and toxicology observations.   
 Hepatotoxicity in each model was assessed by histopathological analysis (Tables 2.4-2.6; 
Figures 2.5 and 2.6), alongside the classical serum biomarkers of liver injury, ALT and AST 
(Figures 2.7 and 2.8). At overtly toxic exposures, both models showed significant 
hepatocellular injury.  At 48 h, mice treated with 750 mg/kg exhibited peak ALT and AST 
elevations of 200 and 67 fold above vehicle controls compared to 40 and 45 fold elevations 
respectively in rats treated with 1500 mg/kg.  Both markers had returned to baseline levels 
by 72 h, despite ongoing daily exposure.  Basal serum transaminase values are seen to be 
approximately equivalent in rats and mice.  Assuming that intracellular transaminase is also 
therefore equivalent, the mice showed a greater degree of tissue injury than the rats.  
Histological analysis was consistent with these observations, showing significant cellular 
injury in both models after 48 h of APAP, with a greater degree of tissue degeneration in 
the mouse.  Liver damage resolved over the ensuing timepoints, with limited observable 
fresh injury in either model. 
Analysis of hepatic GSH in each model revealed depletion at 4 h after the initial exposure in 
1000 and 1500 mg/kg groups in the rat (Figure 2.9), which fell further still by 24 h of 
exposure.  This was in contrast to the mouse (Figure 2.10), in which significant depletion 
was seen at 4 and 6 h after initial exposure, but interestingly only in the 250 mg/kg (sub-
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toxic) group.  By 24 h of exposure, no significant deviation from control GSH values was 
seen, and this remained the case for the duration of the timecourse.  In the rat, however, 
animals exposed to 1500 mg/kg for 48 h (overt toxicity) showed significant GSH elevation, 
which fell over successive timepoints to a value consistent with the depletion seen at 24 h 
of exposure.  In the 1000 mg/kg group, despite depletion at 4 h post initial exposure, no 
further significant change was seen.  The 500 mg/kg (sub-toxic) group, although initially 
unaffected by exposure, showed significant elevations in GSH after 72 h and 96 h of 
exposure.   
The rat model was taken forward for proteomic analysis due to the animal’s greater 
resistance to toxicity and higher propensity for adaptation.  Although ALT levels were 
significantly elevated in both models at 48 h, the degree of overt liver tissue degeneration 
observed at the time point was lower in the rat, thus allowing robust proteomic analysis.  In 
the rat model, observations were therefore likely to be of physiological adaptation 
phenomena rather than consequences of severe toxicity.  Proteomic analysis of livers from 
rats exposed to 1500 mg/kg APAP identified 2181 unique proteins.  Of those, 1169 were 
found to be common to all animals at all timepoints, and were therefore taken forward for 
statistical and in silico analysis.  Analysis of this subset of detected proteins showed a gross 
alteration in abundance in animals that had received multiple doses compared to control 
and single-dosed animals (Figures 2.11 and 2.12). Although some proteins increased in 
abundance as a consequence of dosing, the majority became less abundant (Table 2.7), and 
at the peak of toxicity, almost 30 % of the detected proteome was significantly altered, 
showing the breadth of impact upon hepatic phenotype of adaptation to repeat APAP 
exposure.   In order to validate the proteomic findings, four significantly perturbed proteins 
were selected from the dataset and probed in liver homogenate by western immunoblot 
(Figure 2.13).  These data correlated closely with the original findings (Figure 2.14), 
increasing the degree of confidence in the results. 
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Adaptation in the mouse was contextualised by the presentation of pertinent work 
performed by Dr. Laura Randle.  Dr. Randle’s study investigated the effects of genetic 
manipulation of a well characterised mediator of the cellular stress response, Nrf2 (Figure 
2.15).  Whilst Nrf2(-/-) mice showed a greater susceptibility to APAP toxicity compared to 
wild types (reflecting the importance of the Nrf2 mediated response to oxidative stress in 
the liver),  following pretreatment with APAP an adaptive response was still evident in the 
absence of Nrf2, albeit to a lesser degree.  Nrf2-mediated transcription is therefore not the 
only mechanism of adaptation to repeated toxic insult in this model, and provides a 
demonstration that the process of adaptation involves more of the hepatoproteome than 
previously thought. 
The work presented in this chapter shows that hepatotoxicity upon exposure to APAP 
initiates a complex and dynamic adaptive change in the liver involving large numbers of 
proteins.  As well as engendering protection from subsequent basally noxious exposures, 
the change seems to support injury resolution whilst maintaining critical organ function.  
Collectively these processes ensure survival. 
2.4.2.  Relation of findings to literature 
Adaptation has been demonstrated previously in rodents using a range of compounds 
including carbon tetrachloride, thioacetamide, 2-butoxyethanol and S-1,2-dichlorovinyl-L-
cysteine (Dambrauskas and Cornish 1970; Thakore and Mehendale 1991; Mangipudy et al. 
1995; Sivarao and Mehendale 1995; Vaidya et al. 2003) as well as the classic hepatotoxicant 
APAP (Strubelt et al. 1979; Poulsen and Thomsen 1988; Shayiq et al. 1999; Kim et al. 2009).  
Consistent with previous studies, data in this chapter show the typical hepatocellular 
centrilobular injury characteristic of APAP injury. In the rat model of APAP autoprotection, 
significant hepatotoxicity was only observed at a dose of 1500 mg/kg, confirming that the 
rat is relatively resistant to APAP toxicity as reported earlier (Buttar et al. 1976; Strubelt et 
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al. 1979; Poulsen and Thomsen 1988).  While hepatotoxicity was evident at 48 h, 
significantly less or no necrosis was observed at 72 and 96 h, despite repeated exposure to 
APAP.  Liver function was maintained at these points, as assessed by serum transaminases.  
These observations demonstrate an adaptive response in this model, protecting the liver 
from further injury, and this adaptation involves changes in a large proportion of the 
expressed hepatoproteome.   
Observations of changes in GSH after initial APAP exposure in the overt toxicity groups in 
this study (Figures 2.9 and 2.10) seem to be in keeping with those reported by McGill et al. 
(2012b) in a paper which compared changes in total liver GSH over a 24 h period following 
an intraperitoneal administration of APAP.  In this publication, both species showed initial 
GSH depletion at 1 and 3 h post exposure.  At 24 h, GSH levels in the mouse had recovered 
back to pre-exposure values, whereas GSH in the rat had not.  However, some of the GSH 
data presented here, particularly with respect to later timepoints and lower doses, are 
challenging to interpret.  The publication cited above highlights the short latency between 
oxidative insult, GSH depletion and subsequent recovery.  It is therefore possible that GSH 
observations in the present study are inadequately resolved due to the 24 h lapse between 
dosing and sampling in all except the initial exposures.   
However, it is interesting that the early pattern of GSH loss and repletion in the mouse 
model are further supported by Fan et al. (2014), who also explored the role of Nrf2 in the 
process of liver regeneration after acute toxicity.  This group showed Nrf2 to be induced by 
APAP toxicity, with concomitant increases in a panel of gene products regulated by the 
transcription factor.   Whilst adaptation has been shown in the present work to occur even 
in the absence of Nrf2, its genetic ablation attenuates the adaptive response. Collectively 
these data suggest that, whilst Nrf2 is an important element of the adaptive response to 
liver injury, it is by no means the only mechanism through which the liver defends itself.   
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Expanding further the theme of liver regeneration, proliferating liver is known to show 
enhanced resistance to toxicity (Chanda et al. 1995; Shayiq et al. 1999; Dalhoff et al. 2001).  
Consistent with the findings presented here in Figure 2.13, rats which had been pretreated 
with APAP showed a regenerative response, determined through expression of PCNA in 
hepatocytes, upon a second toxic challenge (Dalhoff et al. 2001). This publication also 
showed that new hepatocytes have a greater capacity for GSH production, allowing 
regenerating liver to detoxify NAPQI more efficiently.  In the present work, significantly 
elevated GSH was measured after 48 h of APAP in the rat 1500 mg/kg group, which 
correlated with the onset of increased PCNA expression, but pursuing this association 
further would enable clearer relationships to be established in this model.   
2.4.3.  Implications of findings and questions raised 
Adaptation is a poorly-characterised phenomenon, and initial data shown here suggest it to 
be a much wider ranging process than previously thought, involving a large percentage of 
proteins in the liver in a complex and dynamic phenotypic change.   Review of the literature 
indicates that adaptation protects the liver from subsequent noxious exposures, facilitates 
repair of hepatocellular injury, and preserves critical organ functions.  Characterisation of 
the models presented here are in keeping with this definition of adaptation, permitting 
rodents to survive repeated overtly toxic APAP exposures.  Further interrogation of these 
models may facilitate a clearer understanding of the processes influencing an organism’s 
ability to adapt to chemical stress.  In turn, this knowledge will have important implications 
for the management of human liver injury.   
One of the key questions raised by the work presented here is whether the phenotypic 
changes seen in the rat liver are due to true differential regulation, or simply a 
consequence of catastrophic loss of hepatocyte mass resulting from drug exposure.  The 
hypothesis that the selective destruction of centrilobular hepatocytes after APAP exposure 
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leaves only cells which are less vulnerable to subsequent injury is worthy of further 
investigation, and will be addressed by some of the work presented in the next chapter.  
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3.1. Introduction 
Work in the preceding chapter has begun to characterise the effects of daily exposure to 
APAP (paracetamol, acetaminophen) in two preclinical species.  Both rat and mouse show 
interesting responses with some clear similarities (onset of toxicity, transaminase release, 
centrilobular tissue injury consistent with known APAP pharmacology).  In rats that have 
received an overtly toxic daily exposure of 1500 mg/kg APAP, a global analysis of the 
hepatoproteome has identified gross shifts in the expression of a subset of detected 
proteins that were common to all rat livers at all timepoints.   
Susceptibility to toxicity can be seen as a function of a number of factors in an organism, 
including i) the ability to reduce exposure to the toxin through constitutive detoxification 
processes; ii) the ability to adapt phenotypically to exposure; and iii) the ability to form new 
healthy tissue through regeneration.  Rats are known to be less susceptible to toxicity than 
mice (Gregus et al. 1988; McGill et al. 2012b).  Rats have a higher capacity than mice for 
detoxification through GSH conjugation, and therefore a greater capacity to buffer 
oxidative stress (Grover and Sims 1964).  They have been shown to have a robust 
propensity for adaptation to chemical stress, examined through numerous studies of both 
autoprotection (Buttar et al. 1976; Strubelt et al. 1979; Poulsen and Thomsen 1988) and 
heteroprotection (Sato and Lieber 1981; Chanda et al. 1995).  Rats also exhibit a concerted 
proliferative response following ablation of liver tissue by surgical or chemical means 
(Roberts et al. 1983; Zhang et al. 1999; Kurumiya et al. 2000).  Because they are susceptible 
to liver injury by APAP overexposure, and yet exhibit a clear propensity for adaptation to 
chemical stress, rats present a valid model for the investigation of hepatic adaptation to 
repeat APAP exposure.   
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3.1.1. Further analysis of rat proteomic data 
In order to clarify the nature of the adaptive response to repeat APAP challenge, in this 
chapter the proteomic data were analysed in greater detail.  The rat’s response to repeat 
APAP dosing was probed using pathway analysis software.  This enabled identification of 
canonical pathways perturbed by dosing, and the contribution specific proteins made to 
the changes seen.    
3.1.2. Use of microsomes to investigate metabolism  
Data generated by the proteomic analysis have indicated alterations in abundance of a 
large number of proteins including key drug metabolising enzymes.  However, this provided 
no context of the subtleties of enzyme activity regulation in vivo.  It was therefore of value 
to examine change in the activity of these enzymes in response to dosing.  One method 
available to researchers for investigating phase I metabolic activity in animal liver is the use 
of microsomes.  Liver microsomes do not naturally occur in vivo, but are vesicular 
fragments of endoplasmic reticulum which can be isolated when hepatocytes are disrupted 
and subjected to ultracentrifugation.  When physiological conditions are recapitulated in an 
in vitro microsomal incubation, enzymes within the microsomes retain metabolic activity 
and will transform any substrates present, allowing activity levels to be assessed.   
Subsequent to the pathway analysis outlined above, microsomes from a subset of rat livers 
were prepared and incubated with either APAP or chlorzoxazone (CZX) to test the ability of 
each liver to break down APAP by any enzymatic pathway, and to specifically probe the 
activity of CYP2E1, respectively.  An excess of GSH allowed the highly unstable APAP 
metabolite NAPQI to be trapped as a GSH conjugate via a nonenzymatic reaction, resulting 
in the product APAP-GSH.  An NADPH regenerating system was employed in order to 
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ensure the essential cofactor was present in excess for the entire duration of the 
microsomal incubations.    
3.1.3. Selection of subset of animals for microsome study 
In order to examine the metabolic consequences of repeated APAP exposure, a subset of 
rat livers were selected from which to create microsomes.  Alongside livers from 2 h vehicle 
control treated animals, livers from the 48 h APAP group (2 doses at 1500 mg/kg) and 96 h 
APAP group (4 doses at 1500 mg/kg) were chosen.  These two groups have both received 
repeated APAP exposure, but crucially, the 48 h APAP group exhibited acute toxicity 
whereas the 96 h APAP group did not.   
3.1.4. Use of immunohistochemistry to investigate protein localisation 
Immunohistochemistry (IHC) allows the visualisation of distribution of a protein or proteins 
of interest across a mounted section of tissue.  The technique exploits the relationship 
between antigens present in tissues and their corresponding antibodies.  Further to 
findings from the proteomic analysis and microsomal enzyme activity studies, IHC was 
employed to examine the tissue distribution of the key CYP450 in APAP metabolism, 
CYP2E1. 
3.1.5. Summary  
Observations in the preceding chapter show the destruction of CYP450-rich tissue in 
centrilobular regions which typify APAP-induced liver injury in the rat repeat exposure 
model.   Proteomic analysis identified changes in protein abundance which were not 
restricted to a small number of proteins or known pathways, and these changes will be 
explored in more depth using computer software.  Further experimental work is included 
to validate the proteomic findings, and particular focus has been applied to the role of 
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CYP2E1 in the evolution of toxicity and adaptation.  Work in this chapter aims to examine 
the abundance, enzymatic activity and tissue distribution of CYP2E1, and relate these 
findings to earlier data.   
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3.2. Methods 
3.2.1. Materials 
For preparation and incubation of microsomes, NADPH regenerating system was purchased 
from Corning (Woburn, MA).  Parent drugs for LC-MS/MS analysis were obtained from 
Sigma-Aldrich (Gillingham, UK); internal standards from Toronto Research Chemicals 
(Toronto, Canada) and Alsachim (Illkirch-Graffenstaden, France). Metabolites were 
obtained from the same sources.  Sources and concentrations of analytes and internal 
standards are given in Tables 3.1 and 3.2 respectively.   
Compound Abbreviation Supplier Product 
Code 
Stock 
(mM) 
Acetaminophen APAP SA A7085 50 
3-Cysteinylacetaminophen Trifluoroacetic Acid 
Salt 
APAP-Cys TRC C994750 20 
4-Acetamidophenyl β-D-Glucuronide APAP-Gluc SA A4438 50 
Acetaminophen Glutathione Disodium Salt APAP-GSH TRC A161223 5 
3-Methoxy Acetaminophen APAP-MeO TRC M226050 50 
3-(N-Acetyl-L-cystein-S-yl) Acetaminophen 
Disodium Salt 
APAP-NAC TRC A172100 10 
Acetaminophen sulphate potassium salt APAP-Sulph SA 89604 5 
Table 3.1: Sources of analytes and stock solution concentrations 
 
Compound Abbreviation Supplier Product 
Code 
Stock 
(mM) 
Acetaminophen-D4 D4-APAP ALSACHIM C1235 10 
3-[N-Acetyl-L-cystein-S-yl] Acetaminophen-D5 
Sodium Salt (Major) 
D5-APAP-NAC TRC A172102 5 
3-Cysteinylacetaminophen-D5 (major), 
Trifluoroacetic Acid Salt 
D5-APAP-Cys TRC C994752 5 
4-Acetamidophenyl β-D-Glucuronide-D3 Sodium 
Salt 
D3-APAP-Gluc TRC A158502 5 
4-Acetaminophen-D3 Sulphate Potassium Salt D3-APAP-
Sulph 
TRC A161232 10 
Table 3.2: Sources of internal standards and stock solution concentrations 
 
For conducting IHC, sodium citrate buffer was obtained from Dako (Ely, UK).  Avidin/biotin 
blocking kit was from Abcam (Cambridge, UK).  SignalStain Boost IHC Detection Reagent 
(rabbit HRP) was from Cell Signaling Technology (Boston, MA).  Entellan was from Merck 
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(Kenilworth, NJ).  Antibody against glutamine synthetase (GS) was from Abcam (Cambridge, 
UK) All other reagents were of analytical grade and quality and purchased from Sigma (St. 
Louis, MO). 
3.2.2. Ingenuity Pathway Analysis 
Pathway analysis was performed using Ingenuity Pathway Analysis (Qiagen, Venlo, Limburg, 
Netherlands).  Accession numbers for all proteins detected were uploaded to Ingenuity 
along with experimental observations (p value and log ratio).  Significance cutoff was set at 
0.05 using unadjusted p values, directional fold change was set (i.e. up/down), and the 
reference dataset was the user-defined proteome.  Protein lists for each time point and 
directional change were compared, and analysed using the canonical pathways tool which 
maps proteins identified to classical pathways.   
3.2.3. Preparation of rat liver microsomes 
Pieces of frozen liver approximately 500 mg in mass were taken from stored samples and 
homogenised using a motor-driven homogeniser in ice cold 0.067 M phosphate buffer, pH 
7.4, with the addition of 1.15 % (w/v) KCl.  Using a Beckman UL60 ultracentrifuge and 
TI70.1 rotor, homogenates were spun at 4 oC for 25 minutes at 115,000 rpm to remove 
cellular debris.  The pellet was discarded and the supernatant spun for a further 65 minutes 
at 37,000 rpm in order to pellet the microsomes.  The supernatant was discarded, and the 
pellet containing the microsomal fraction was homogenised in phosphate buffer with KCl 
using a Wheaton 2 mL manual glass homogeniser.  The resuspended pellet was centrifuged 
a third time for 65 minutes at 37,000 rpm, and resuspended in < 1mL phosphate buffer 
(without KCl).  Aliquots were taken for protein determination using the method of Lowry, 
and also for spectrophotometric determination of CYP450 activity.  Samples were snap 
frozen before transfer to -80 oC.  
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3.2.4. Spectrophotometric analysis of microsomes 
Once the microsome preparation protocol had been completed, each sample was analysed 
spectrophotometrically in order to confirm the presence of active CYP450.  Based on the 
methods of Omura and Sato (1964), microsome samples were standardised to a protein 
concentration of 1 mg/mL with phosphate buffer.  Sodium dithionite crystals were added, 
and CO was bubbled through the suspension for one minute.  Samples were transferred to 
a cuvette and read at 450 nm.   
Isolation of microsomes and spectrophotometric analysis was performed on all livers from 
each named group, and the highest yielding samples from control (n = 4), 48 h APAP (n = 3), 
and 96 h APAP (n = 3) were taken forward for microsomal incubation, giving ten in vivo 
conditions in total.   
3.2.5. Incubation of microsomes with APAP 
Microsomes from individual animals were incubated in duplicate in glass vials in a shaking 
water bath at 37 oC in accordance with the tables shown below (Tables 3.3 and 3.4).  APAP 
was dissolved in phosphate buffer.  An excess of GSH was present in each reaction (1 mM 
final concentration), as was an appropriate concentration of NADPH regeneration 
substrates A and B.  Reactions were stopped by addition of the withdrawn incubate 
fraction to an equal volume of ice cold ACN containing the evaporation standard 
fluconazole (prepared in 200 µL capacity microcentrifuge tubes and kept on ice) at 0.5 h, 1 
h, and 4 h post addition of microsomes to incubation solution.  Stopped incubates were 
immediately frozen at -80 oC pending analysis.  
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Tube Condition* Buffer Drug A 
 
B GSH 
(100 mM) 
Microsomes Total 
A C1 186 2 0 0 2 10 200 
B C2 186 2 0 0 2 10 200 
C 0 1 176 0 10 2 2 10 200 
D 0 2 176 0 10 2 2 10 200 
E L1 174 2 10 2 2 10 200 
F L2 174 2 10 2 2 10 200 
G M1 174 2 10 2 2 10 200 
H M2 174 2 10 2 2 10 200 
I H1 174 2 10 2 2 10 200 
J H2 174 2 10 2 2 10 200 
Table 3.3: Composition of each microsomal condition in microlitres for APAP incubations 
 *Refer to Table 3.4 for description of condition abbreviation 
Table 3.4: Key to microsomal incubation conditions for APAP turnover experiment 
 
3.2.6. Incubation of microsomes with CZX 
Microsomes from individual animals were incubated in duplicate in glass vials in a shaking 
water bath at 37 oC in accordance with the table shown below (Tables 3.5 and 3.6).  CZX 
was dissolved in methanol.  An excess of GSH was present in each reaction (1 mM final 
concentration), as was an appropriate concentration of NADPH regeneration substrates A 
and B.  Reactions were stopped by addition of the withdrawn incubate fraction to an equal 
volume of ice cold ACN containing the evaporation standard fluconazole (prepared in 200 
µL capacity microcentrifuge tubes and kept on ice) at 5, 10, 15, 20, 30, 45, 60 and 90 
minutes post addition of microsomes to incubation solution.  Stopped incubates were 
immediately frozen at -80 oC pending analysis.  
Condition Abbreviation Description 
APAP-free 0 APAP-free incubation to control for 
spontaneous metabolite generation 
Low APAP L 10 µM APAP added to incubation 
Medium APAP M 100 µM APAP added to incubation 
High APAP H 1 mM APAP added to incubation 
No NADPH C 1 mM APAP but no NADPH regeneration 
solutions included to control for passive 
turnover 
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Tube Condition* Buffer Drug/veh A B GSH  
(100 mM) 
Microsomes Total 
A p1 71.4 21 10.5 2.1 21 84 210 
B p2 71.4 21 10.5 2.1 21 84 210 
C c1 36 9 0 0 9 36 90 
D c2 36 9 0 0 9 36 90 
E v1 30.6 9 4.5 0.9 9 36 90 
F v2 30.6 9 4.5 0.9 9 36 90 
Table 3.5: Composition of each microsomal condition for CZX incubations 
*Refer to Table 3.6 for description of condition abbreviation 
Table 3.6: Key to microsomal incubation conditions for CZX turnover experiment 
 
3.2.7. Analysis of incubates by LC-MS/MS 
Mass spectrometric analysis of microsomal incubates was kindly performed by Dr. Mark 
Bayliss using the methods described below.  Test samples were treated with ACN to 
remove matrix-based interferences. They were diluted with water prior to analysis by LC-
MS/MS on a Sciex API 4000 (Warrington, UK) equipped with a Turbo V™ electrospray 
source (ESI).  The gradients were based on mobile phases containing 0.1 % v/v FA in both 
water (A) and ACN (B).  Drugs and metabolites were detected using MRM.   
3.2.7.1. Measurement of APAP and its major metabolites 
Separations were performed  on a 2.6 µm Kinetex® XBC18  column (50 x 2.1 mm internal 
diameter) obtained from Phenomenex  (Macclesfield, UK),  at a temperature of 40 °C and a 
flow-rate of  0.5 mL/min.  The following gradient was used:  0 min 0 % B, 0.3 min 0 % B then 
2.3 min 50 % B.  The column was flushed with 100 % B, and then returned to 0 % B using a 
Condition Abbreviation Description 
CZX P 1 µM chlorzoxazone in methanol added to 
incubation – 0.1% final vehicle 
concentration 
NADPH control C 1 µM chlorzoxazone but no NADPH 
regeneration solutions included to control 
for passive turnover 
Vehicle control V Methanol alone (0.1 %) added to incubation 
to control for vehicle effects 
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flow-rate of 0.7 mL/min, giving a programmed cycle time of 4.2 minutes.  A panel of 
deuterated internal standards was employed (Table 3.2).  The MS was operated in negative 
ion mode for measuring all but one of the putative major metabolites and high 
concentrations of APAP.  It was operated in positive ion mode for measuring the remaining 
metabolite and low concentrations of APAP. 
3.2.7.2. Measurement of chlorzoxazone and its putative major 
metabolite, 6-hydroxy chlorzoxazone  
Separations were performed on a 2.7 µM Halo® C18 column (50 x 2.1 mm internal 
diameter) obtained from HiChrom (Reading, UK), and  at a temperature of 40 °C and a flow-
rate of  0.6 mL/min. The following gradient was used:  0 min 5 % B, 0.5 min 5 % B, 1.5 min 
95 % B, 2 min 95 % B, 2.1 min 5 % B and 2.6 min 5 % B. D4-diclofenac was employed  as the 
internal standard. The MS was operated in negative ion mode. 
3.2.8. CYP2E1 localisation via immunohistochemistry 
Immunohistochemical staining for CYP2E1 was carried out by Dr. Mariona Auli at Almirall S. 
A.   Formalin-fixed, paraffin-embedded liver sections were cut at 3 m. Sections were 
mounted on poly-L-lysine coated slides, air-dried, then deparaffinised in xylene, and 
hydrated through graded alcohols to distilled water. Endogenous peroxidase activity was 
blocked using 3 % H2O2 in methanol for 20 min. After washing in Tris-buffered saline (TBS), 
slides were transferred into a slide holder containing sodium citrate buffer and heated in a 
pressure cooker for 5 min for antigen retrieval. After 30 min cooling to RT, slides were 
rinsed in TBS containing 0.05 % Tween 20 (TBS-T) and endogenous avidin/biotin binding 
sites blocked.  Slides were then washed in TBS-T and incubated at RT with 20 % normal goat 
serum in TBS-T for 1 h to block nonspecific binding. Slides were further incubated overnight 
(4 oC) with rabbit anti CYP2E1 monoclonal antibody at a working dilution of 1:1750 in 20 % 
normal goat serum/TBS-T. The primary antibody was omitted for negative controls. 
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SignalStain Boost IHC Detection Reagent was used as secondary antibody (1 h, RT). The 
reaction was developed using 3', 3’-diaminobenzidine (DAB) tetrahydrochloride as 
chromogen. Sections were counterstained with Harris haematoxylin, dehydrated and 
mounted using Entellan. 
3.2.9. Western immunoblot 
Western immunoblots were performed according to the method described in Chapter 2, 
section 2.2.9.  GS antibody was used at a dilution of 1:20 000 for 1 h at RT, and secondary 
(anti-rabbit) was 1:10 000 overnight at 4 oC.  CYP2E1 antibody was generously provided by 
Magnus Ingelman Sundberg (Karolinska Institute, Sweden) and used at a dilution of 1:20 
000 for 1 h at RT, and secondary (anti-rabbit) was 1:10 000 overnight at 4 oC.   
3.2.10. Data evaluation and statistical analysis 
Western immunoblot data were analysed as described in Chapter 2, section 2.2.11.  
Microsomal data were analysed in GraphPad PRISM (V6.03 for Windows, GraphPad 
Software, San Diego, CA) using an ordinary two-way ANOVA with Dunnett’s post-hoc test.  
Statistical analysis of proteomic data was performed by Dr. Joanne Walsh using a linear 
model in the R programming environment (ANOVA with Dunnett’s post-hoc test).  Error 
bars on charts represent SEM. 
Mathematical modelling of microsomal enzyme activity data was generously performed by 
Dr. Steven Webb, University of Liverpool.  Literature estimates for Km are reported to be 
30-300 times larger (Muzeeb et al. 2005; Guo et al. 2014) than the CZX concentration 
considered (1 µM).  It was therefore possible to adopt linear kinetics for CYP2E1 activity 
(enzyme velocity = α[S], where [S] = CZX concentration and α = Vmax/Km) instead of the full 
nonlinear Michaelis-Menten form.  Solving the resulting first order ordinary differential 
equation yielded the following expression for 6’-OH CZX formation versus time (using 
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notation [P](t) to denote concentration at time t (min)): [P](t) = [S](0)(1-exp(-αt/V)), where 
[S](0) = initial CZX concentration (1 µM) and V is the sample volume (0.02 mL).  A Levenberg 
Marquardt (non-linear regression) algorithm was used to then find best fit values for α = 
Vmax/Km for control, 48 h APAP and 96 h APAP groups.  In each group, estimates shown here 
for α = Vmax/Km were found to lie within acceptable literature ranges.  Under the 
assumption that enzyme-substrate binding affinity (1/Km) is unaffected by microsomal 
conditions, ratios of α estimates were then used to compare relative enzyme activities.  
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3.3.  Results 
3.3.1. Identification of perturbed canonical pathways 
In the previous chapter, a global proteomic analysis of liver tissue from rats which had 
received a daily 1500 mg/kg (overtly toxic) exposure to APAP was described.  Within this 
data set, 1169 proteins were found to be common to all animals at all examined 
timepoints. Using Ingenuity Pathway Analysis it was possible to assign these detected 
proteins to accepted canonical biochemical pathways and rank the pathways in order of 
most perturbed across the timecourse.  The top 25 most perturbed canonical pathways are 
presented below (Figure 3.1, and lists of proteins are provided in Supplementary Table 3), 
and values shown on the heatmap are the negative log of p values.  All significant changes 
are in red blocks, and the intensity of the shading corresponds with the degree of 
significance.  The left panel shows significant difference of increased protein abundance, 
and the right panel shows significant difference of decreased protein abundance.  
Consistent with data presented in Chapter 2 (Figures 2.13 and 2.14; Table 2.7), the protein 
changes indicate a trend towards widescale decreased abundance, particularly in the 48 h 
APAP group, reflecting the peak observed incidence of centrilobular injury.   
A subset of proteins assigned to the canonical pathways ‘LPS/IL-1 mediated inhibition of 
RXR function’ (identified as the most perturbed pathway) and ‘Xenobiotic metabolism 
signalling’ (highly relevant to drug toxicity) have also been displayed as a heatmap in order 
to identify the contribution of specific proteins to the process of adaptation (Figure 3.2).   
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 Figure 3.1: Ingenuity identification of top 25 most perturbed canonical pathways across timecourse 
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Figure 3.2: Changes in abundance of specific 
proteins assigned to two canonical pathways 
chosen for their pertinence to APAP adaptation 
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Figure 3.1: Ingenuity identification of top 25 most perturbed canonical pathways across 
timecourse  
Legend: Top 25 most perturbed canonical pathways over 96 h timecourse of repeat APAP 
exposure.  Values shown are negative log (p) and significant changes are shown in red.  The 
left hand panel shows increased abundance proteins, and the right hand panel shows 
decreased abundance.  The total number of significantly perturbed proteins for each 
canonical pathway is shown on the far right.  There is some redundancy in these pathways. 
 
Figure 3.2: Changes in abundance of specific proteins assigned to two canonical pathways 
chosen for their pertinence to APAP adaptation 
Legend: Heat map of perturbed proteins assigned to ‘LPS/IL1 mediated inhibition of RXR 
function’ and ‘Xenobiotic metabolism signaling’ pathways, presented in hierarchical 
clusters using paired Euclidean distances.  Red denotes increased abundance and yellow 
denotes decreased abundance.  Reflecting the data shown in section 2.3.6.1, Figure 2.11, 
control and single dose (24 h APAP) animals cluster away from repeat dosed animals  
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3.3.2. Shifts in abundance of drug metabolism proteins across the timecourse 
Changes in drug metabolism proteins seen in the 48 h APAP group (as indicated by 
Ingenuity Pathway Analysis) were then explored in more depth (Figure 3.3).  Phase I, II, and 
III drug metabolising proteins exhibited a trend towards decreased abundance after two 
successive doses.  Thirteen out of the twenty-three CYP450s identified, the single most 
important set of proteins that govern how the liver initially processes a drug, were found to 
be present at lower abundance at 48 h.  This included CYP2E1, which is largely expressed in 
the centrilobular region of the liver; and CYP2C6, which is expressed across all zones of the 
liver (36 % and 30 % of control values, respectively), although both of these proteins 
increased after 96 h.  The majority of detected phase I and II proteins decreased during the 
process of adaptation to APAP.  Notable exceptions to this loss of abundance are NQO1, 
which recycles  APAP’s toxic metabolite NAPQI back to APAP (Moffit et al. 2007); and 
GSTP1, which quenches electrophiles such as NAPQI through conjugation with glutathione 
(Ketterer et al. 1983).  Both enzymes were more abundant at 48 h (273 % and 269 % of 
control values respectively, Figure 3.3c).  The changes in the phenotype of the liver shown 
here after two and four successive doses of APAP may profoundly influence the fate of 
subsequent doses.   
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Figure 3.3: Changes in phase I, II and III drug metabolising proteins in 48 h and 96 h APAP 
groups compared to vehicle control treated animals 
Legend: Phase I drug metabolising proteins show widescale decreased abundance at 48 h 
(a) with some recovery by 96 h (b) when compared to vehicle control values (dashed line).  
Similar trends are seen when looking at phase II/III proteins at 48 h (c) and 96 h (d).  
Notable exceptions to the trend of decreased abundance are CYP2E1 at 96 h, pertinent to 
APAP metabolism; and GSTP1 and NQO1 at both 48 h and 96 h, involved in detoxification.  
 
3.3.3. Albumin as a clinical marker of hepatic function 
In an effort to further explore the biological significance of the observed changes, 
expression in the liver of the clinical marker of function, albumin, was analysed (Figure 3.4).  
Over the timecourse, it can be seen that despite the dramatic losses of some proteins in 
response to dosing, hepatic albumin itself does not significantly deviate from control 
values.  In the context of clinical chemistry data from Chapter 2, and along with results for 
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phase I, II and III proteins shown in section 3.3.2, this lends further weight to the 
hypothesis that the liver is undergoing an active change in phenotype in order to adapt to 
repeat exposure.  
 
 
 
 
 
 
 
Figure 3.4:  Intracellular expression of albumin across the timecourse 
Legend: Expression of albumin in rat livers across 96 h repeat APAP exposure timecourse.  
No significant deviation from control value is seen. 
 
3.3.4. Microsomal analysis of drug metabolism  
In order to validate data gathered by global proteomic analysis and clarify the nature of the 
hepatic response to repeat APAP exposure, microsomes were made from remaining frozen 
rat liver tissue.  Livers were selected from the 2 h vehicle control treated group, and the 48 
h and 96 h APAP groups.  
3.3.4.1. Spectral properties of microsomes 
Cytochrome P450 enzymes have unique spectral properties.  Under reducing conditions, a 
pink compound is formed when the enzyme binds to carbon monoxide (hence ‘P’), with 
absorption in the 450 nm range.   
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Animal no. 
Treatment 
group 
CYP450*  
(nmol/mg) 
Protein 
(mg/ml) 
1 2h Vehicle 0.22 16.25 
2 2h vehicle 0.40 15.16 
3 2h vehicle 0.46 10.72 
4 2h vehicle 0.33 19.09 
106 48 h APAP 0.19 5.27 
107 48 h APAP 0.35 7.00 
108 48 h APAP 0.23 6.00 
154 96 h APAP 0.42 10.17 
155 96 h APAP 0.43 11.40 
156 96 h APAP 0.28 10.47 
Table 3.7: CYP450 concentration and protein concentration of microsomal preparations  
*CYP450 concentration was calculated using the equation   
[CYP450] nmol/mg protein = ([protein] mg/ml x 1000 x net absorbance)/91 
Where 91 is the molar extinction coefficient of CYP450 
 
Values for microsome preparations taken forward are shown in Table 3.7.   The reference 
range for adult rat liver microsomes is 0.4-1.0 nmol/mg (Gibson and Skett 2001).  Perhaps 
unsurprisingly given the storage duration of the samples in question (>3 years at -80 oC), 
concentrations were at or below the low end of this range.  However, when taking protein 
concentration and sample mass into consideration, there was a sufficient quantity of each 
sample to permit small-scale microsomal incubations 
3.3.4.2. Microsomal formation of APAP-GSH 
A large number of CYP450s are expressed in the liver, and substrate specificity overlaps 
extensively.  Although supratherapeutic APAP is primarily metabolised by CYP2E1, other 
P450s including CYP1A2 are also involved (Patten et al. 1993).  Examining the formation of 
APAP-GSH provides biologically relevant information as to the turnover of the drug in the 
liver without giving specific identity to the CYP450s involved.   Figure 3.5 shows the 
formation of APAP-GSH in each of the microsomal conditions that control, 48 h APAP and 
96 h APAP tissue were exposed to.  A statistically significant difference is seen in the 
highest microsomal concentration of APAP, 1 mM.  In this condition, significantly more 
APAP-GSH is generated by the 96 h APAP tissue when compared to control and 48 h APAP, 
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showing perhaps surprisingly that metabolism of APAP is not diminished by the destruction 
of centrilobular regions, and is in fact increased after 96 h of repeated exposures.   
 
  
 
 
 
 
 
 
 
 
Figure 3.5: Microsomal formation of APAP-GSH in rat 
Legend: Control, 48 h and 96 h microsomes were incubated with APAP to examine the 
turnover of test drug.  Three concentrations of APAP were used, and significance is seen in 
the top dose group (1 mM).  More adduct is formed at 96 h than control or 48 h. 
 
3.3.4.3. Microsomal formation of 6’-OH CZX 
Alongside investigation of APAP metabolism, incubations of microsome preparations with 
CZX were also conducted.  CZX is a probe substrate which is specific for CYP2E1, and 
generation of the metabolite 6’-OH CZX indicates the degree of activity of CYP2E1 in the 
livers examined.  Figure 3.6 shows the turnover of 1 µM CZX by liver microsomes from 2 h 
vehicle treated animals, as well as 48 h APAP and 96 h APAP treatment groups.  Compared 
to control animals, CYP2E1 activity is significantly reduced in the 48 h APAP group, 
coincident with maximal hepatocellular injury.  In the 96 h APAP group the opposite is 
observed, and CYP2E1 activity is significantly increased compared to the control group.   
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These observations of both increased APAP metabolism and CYP2E1 enzyme activity in the 
96 h APAP group are unexpected, given that no further significant toxicity is seen at later 
timepoints despite ongoing exposure to APAP.  
 
  
 
 
 
 
 
 
Figure 3.6: Microsomal turnover of the CYP2E1 probe substrate chlorzoxazone in rat 
Legend: Rate of formation of 6’-OH CZX by control, 48 h APAP and 96 h APAP microsomes.  
CYP2E1 activity is reduced in the 48 h APAP group compared to control.  The rate of 
formation of 6’-OH CZX is increased in the 96 h APAP group.  
 
3.3.5. Localisation of Cytochrome P450 2E1 during liver injury, adaptation and 
regeneration 
Bioactivation of APAP by CYP2E1 results in the generation of the toxic metabolite NAPQI.  
In an attempt to understand the mechanism by which CYP2E1 increases in abundance and 
activity at later timepoints without exacerbating cellular toxicity, IHC was employed to 
examine the spatial shifts in CYP2E1 expression across rat liver sections. 
Immunohistochemical detection of CYP2E1 distribution in fixed liver sections revealed a 
change in localisation of expression through the timecourse (Figure 3.7).  Basally, CYP2E1 is 
mainly expressed in centrilobular regions.  Upon APAP challenge, CYP2E1 staining became 
diffuse and extended into midzonal regions.  2 doses produced acute centrilobular necrosis, 
with markedly reduced CYP2E1 staining in centrilobular regions.  At later timepoints, 
staining extended diffusely into periportal regions which were CYP2E1-negative in control 
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animals.  At the final timepoint (96 h), half of the animals presented a similar diffuse 
staining of periportal regions, and half of the animals presented staining similar to control 
animals.   
A strong positive correlation has been seen between the different detection methods used 
to examine CYP2E1 abundance.  Positive association has been shown between 
densitometric and MS data (Figure 3.8a), and visual comparison of densitometry to IHC 
stain intensity reveals remarkably similar patterns of abundance over the timecourse.  The 
pattern of loss and repletion of CYP2E1 is in contrast to the changes in abundance of GS, 
chosen as a comparator sentinel of centrilobular hepatocytes.  Western immunoblot 
(Figure 3.8b) reveals that, as with CYP2E1, in the 48 h APAP group a dramatic loss of the 
protein is seen.  Thereafter, whilst CYP2E1 expression recovers, GS expression does not.  
This indicates that the process of adaptation is a selective one.  
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Figure 3.7: Change in localisation of CYP2E1 in response to treatment 
Legend: Sectioned and stained rat liver from all treatment groups across 96 h repeat APAP 
exposure study.  Upper panels show IHC for CYP2E1 (brown stain on grey background).  
Lower panels show H&E staining of tissue sections showing tissue injury and recovery.  CV 
denotes central vein, PT denotes portal triad. 
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Figure 3.8:  Relative abundance of CYP2E1 and GS, and correlation of MS and 
densitometric quantification methods 
Legend: a) Densitometric analysis of western immunoblot data for basally perivenous 
CYP2E1 and GS, with representative images below.  Left panel shows animals 1 and 2 from 
each treatment group, right panel shows animals 3 and 4.  NB Lane 2 of right panel was left 
intentionally blank and has been digitally cropped for ease of interpretation of figure. 
b) Positive correlation is seen between densitometric and mass spectrometric data for 
target proteins CYP2E1 and GS.   
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3.4.  Discussion 
The rat has been shown to be an appropriate model for the examination of hepatic 
adaptation to repeat APAP exposure.  In this chapter, the proteomic data from the rat 
repeat APAP exposure model have been analysed in greater depth, identifying both 
expected and unexpected canonical pathways as being pertinent to the process of 
adaptation.  Alongside this, the activity and distribution of CYP2E1 in rat liver from the 
model have also been explored, showing the breadth, dynamism and complexity of the 
process of adaptation to repeat APAP exposure. 
3.4.1. Summary of findings and relation to literature 
Ingenuity analysis of proteomic data allowed mapping of differentially expressed proteins 
onto canonical pathways (Figure 3.1), revealing the breadth of the adaptive process, and 
the extent of loss of protein abundance over the timecourse.   Although Figure 3.1, showing 
the top 25 most perturbed canonical pathways, indicates widespread loss of protein 
abundance particularly at the peak of toxicity, a number of pathways showed increased 
abundance, including ‘acute phase response signalling’, ‘Nrf2-mediated oxidative stress 
response’ and ‘glutathione-mediated detoxification’ which are all well-characterised 
reactions to toxic injury. 
The result of heat mapping the proteins implicated in two key pathways identified by 
Ingenuity (‘LPS/IL1 mediated inhibition of RXR function’ and ‘Xenobiotic metabolism 
signaling’; Figure 3.2) validated data shown in the preceding chapter: the proteomic profile 
of repeat dosed animals diverges from that of control and single dosed animals, as is seen 
in section 2.3.6.1.   The scope of this divergence again reinforces the notion that the 
adaptive changes to metabolism in the liver seen after repeat exposure to APAP are likely 
to profoundly influence the fate of subsequent xenobiotic exposures. 
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Beyond confirming existing knowledge that several CYPs relevant to APAP metabolism are 
down-regulated upon repeat APAP exposure, it can be seen here that liver tissue from 
repeat dosed rats shows a significantly reduced abundance of proteins across all phases of 
drug metabolism (Figure 3.3).  This reduction in expression may represent a key facet of 
adaptation, providing an environment which facilitates compensatory hyperplastic activity, 
thereby preserving critical function.  At the peak of toxicity, the mean of all detected 
CYP450s is reduced to approximately 60 % of control values.  This change in phenotype is 
likely to be, at least partly, a consequence of the changing cell population in the liver over 
time.  The initial toxic insult clearly destroys vulnerable hepatocytes at the centre of the 
lobule.  CYP450 enzymes show predominantly centrilobular expression, and the differential 
expression of CYP450s in intact zones may account for the overall change seen at 48 h.  
Nevertheless, a number of CYP450s are pan-zonally expressed in rat liver (Oinonen and 
Lindros 1998), and of the ones that are also identified in the present work (CYP1A, 2B, 2C6 
and 2C7 - a close homologue of the pan-zonal CYPEtOH2 (Foster et al. 1986; Wojcik et al. 
1988; Omiecinski et al. 1990; Bühler et al. 1992)), all are significantly less abundant in the 
48 h APAP group, dropping to around 30 % of control (with the exception of CYP2C7 which 
is not significantly changed by repeat APAP exposure).  This suggests an active change in 
the phenotype of intact cells, as has been previously postulated, indicating a global 
dedifferentiation resulting in decreased liver-specific protein expression as part of an 
adaptive response to injury (Ito et al. 1991; Kurumiya et al. 2000), rather than a passive 
destruction of CYP450-rich tissue. 
To further elucidate the complex mechanism of adaptation, CYP2E1 activity and localisation 
in response to repeat APAP exposure was examined.  Consistent with proteomic data 
obtained for CYP2E1 abundance, microsomal activity assays showed a loss of CYP2E1 
activity in the 48 h APAP group which was contemporary with the onset of acute injury 
(Figure 3.6), although overall formation of APAP-GSH by any pathway (Figure 3.5) was not 
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diminished at this timepoint.  Despite continued APAP exposure, however, the 96 h APAP 
group exhibited a rebound of both expression and activity of CYP2E1, alongside an increase 
in turnover of APAP to APAP-GSH.  This was not consistent with the fall in toxicity observed 
after 48 h of APAP.   
The microsomal data suggests that other factors must be involved in the process of 
adaptation, since CYP2E1 is more active in the 96 h APAP group which would result in 
greater formation of NAPQI, but a corresponding increase in cellular injury in this group is 
not seen.  Examination of the tissue distribution of CYP2E1 provides something of a clue to 
how this may happen.  Immunohistochemical staining of liver sections from each treatment 
group revealed a diffuse redistribution of CYP2E1 into basally CYP2E1-negative regions 
(Figure 3.7).  Importantly, the pattern of loss and restoration seen with total liver CYP2E1 
was not observed for another similarly perivenous enzyme, GS (Figure 3.8), suggesting that 
this process is selective.   From these observations it is hypothesised that diffuse re-
expression of CYP2E1 may perhaps prevent the intracellular threshold of NAPQI toxicity 
being reached, thereby avoiding the initiation of further waves of cell death at later 
timepoints.  Furthermore, in the regions where NAPQI is generated after redistribution of 
CYP2E1 expression, there are known to be higher intracellular concentrations of the 
reducing buffer GSH (Sastre et al. 1992).  This phenomenon of CYP2E1 redistribution as an 
adaptive response has been seen after treatment with carbon tetrachloride (Irie et al. 
2010) and ethanol (Bertola et al. 2013), but has not been detected previously after 
treatment with any pharmaceutical compound.   
 
Figure 3.1, which identifies the top 25 most perturbed canonical pathways, also indicates 
other pathways which could be relevant to the process of adaptation.  For example ‘EIF2 
signalling’, which may indicate increased transcriptional activity; ‘aryl hydrocarbon receptor 
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signalling’ which not only regulates CYP450 expression but also has a role in regulation of 
progenitor cell recruitment (Procházková et al. 2011); and ‘aldosterone signalling’ which 
has recently been linked with the processes of proliferation and fibrosis in liver injury 
(Parlakgumus et al. 2013).    
3.4.2. Implications of findings and questions raised 
Adaptation in the rat model of repeat APAP exposure has been established through the 
lack of variance in expression of the clinical marker of hepatic function albumin, as well as 
that of the transaminases ALT and AST (shown in the preceding chapter) at later 
timepoints.  The preferential restitution of CYP2E1 over GS tells of the selective nature of 
the process.  In this model, Ingenuity identification of canonical pathways perturbed by 
dosing revealed a set of proteins that are greatly dysregulated in the process of adaptation, 
which contribute to future hypothesis generation.  Data shown in this chapter demonstrate 
that the process of adaptation is not only temporal in scope but also spatial, as re-
expression of CYP2E1 in a diffuse pattern may be an important element of the ability of 
these rats to withstand ongoing exposure.    It is possible that other proteins pertinent to 
adaptation are also altered spatially, and this may have an impact on the liver’s function 
with regard to processing xenobiotics.   
Based on the degree of overt liver tissue degeneration seen in the mouse in Chapter 2, the 
process of adaptation is less easy to validate in the mouse model.  The work in the final 
experimental chapter will therefore explore patterns of similarity and difference between 
the two rodent models. 
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4.1. Introduction 
Both rats and mice are used extensively preclinically, and there are established differences 
in the way each species processes xenobiotics (Bogaards et al. 2000; Martignoni et al. 
2006).  Furthermore, acetaminophen (APAP) toxicity is known to vary considerably among 
preclinical species (Davis et al. 1974; Ioannides et al. 1983; Gregus et al. 1988; McGill et al. 
2012b).   
As stated in the previous experimental chapters, rats can tolerate far higher exposures to 
APAP than mice can, and this relates to the way the drug is processed by each species.  Rats 
and mice show differences in the expression profile of CYP450 enzymes, although APAP-
metabolising enzymes CYP2E1 and CYP1A2 are highly conserved among rat, mouse and 
human (Martignoni et al. 2006).  Other differences are seen when comparing rates of GSH 
depletion and restitution on exposure to APAP (Davis et al. 1974; McGill et al. 2012b),  and 
also the accumulation of products of APAP metabolism in the urine and bile (Gregus et al. 
1988).  It is therefore vital to thoroughly evaluate the characterised preclinical species and 
select the best available model of specific aspects of human drug toxicity.   
4.1.1. Markers of toxicity 
In order to compare the initial toxic effects of APAP in the livers of rats and mice, three 
markers were selected.  CYP2E1 was chosen because of its role in the generation of the 
toxic metabolite NAPQI.  CYP1A2 was investigated because of its similar centrilobular 
distribution and lesser role in APAP metabolism.  GS was also compared as a sentinel of 
perivenous hepatocytes (Häussinger et al. 1991), but one without involvement in APAP 
toxicity.   
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4.1.2. Markers of adaptation 
The canonical pathway entitled ‘Nrf2-mediated oxidative stress response pathway’ was 
identified as significantly differentially regulated in rats the preceding chapter (Figure 3.2), 
and the transcription factor itself plays an important role in regulating the phenotypic 
response to cellular stress due to its interaction with the ARE, a promoter governing 
transcription of a panel of cytoprotective genes.  However, as a function of this role, Nrf2 is 
both highly transient and present at very low abundance.  Nrf2 rarely exists in an unbound 
state, free of its cytosolic repressor, Keap1, or molecules associated with either 
proteosomal degradation or transcription of nuclear DNA.  It therefore presents a technical 
challenge to detect directly.   
Both GCLC, the catalytic subunit of the glutathione synthetic enzyme glutamate-cysteine 
ligase, and the quinone reductase NQO1, arise from transcripts downstream of the ARE.  
Expression of these genes is therefore accepted as being regulated by Nrf2 (Wild et al. 
1999; Jaiswal 2000).   The abundance of these enzymes has been examined in both models 
in order to indirectly probe the activation state of Nrf2.   
4.1.3. Markers of regeneration 
To examine the regenerative response in the rat and mouse repeat APAP exposure models, 
two established markers of cellular proliferation were selected.  PCNA is a sliding clamp 
which encircles DNA during the genome replication phase of the cell cycle (Smith 2013).  
Global proteomic analysis identified PCNA as one of the most significantly increased 
abundance proteins in the 72 h APAP group (Chapter 2, section 2.3.6.2; Supplementary 
Table 1c).  Ki67 is a protein of unknown biological function that is strictly associated with all 
active phases of the cell cycle (Scholzen and Gerdes 2000).  Since turnover of hepatocytes 
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in the quiescent liver is low (Klochendler et al. 2012), any increase in proliferative activity 
will be easily detected and confirmed using two independent markers.    
4.1.4. Summary  
Data shown in Chapter 2 explored some of the toxicological responses to repeat APAP 
exposure in rats and mice, identifying a number of similarities.  Chapter 2 also highlighted 
some potentially important differences between the two models; in particular, GSH 
depletion (Figures 2.11 and 2.12) and the degree of tissue degeneration (Figures 2.7 and 
2.8).  Chapter 3 interrogated the complexity of the adaptive response in the rat, showing 
selective loss of the drug metabolism phenotype, and also alterations in the distribution 
and expression of CYP2E1 over the time course.  Guided by the findings of the preceding 
chapters, the present chapter aims to identify some of the biochemical responses to repeat 
APAP exposure that may account for the interspecies differences observed. 
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4.2. Methods 
4.2.1. Materials 
CYP1A2, PCNA, GS, NQO1 and Ki67 antibodies were from Abcam (Cambridge, Cambs, UK; 
Cat. no. ab22717 (mouse), ab29 (mouse), ab49873 (rabbit), ab2346 (goat) and ab16667 
(rabbit) respectively).  Vimentin antibody was from Sigma (St. Louis, MO; cat. no. V6389, 
mouse).  CYP2E1 antibody, raised in rabbit, was a kind donation from Magnus Ingelman-
Sundberg, Karolinska Institute, Sweden.  All other reagents were of analytical grade and 
quality and purchased from Sigma (St. Louis, MO).   
4.2.2. Western immunoblot  
Western immunoblot was performed as described in Chapter 2, section 2.2.9.  Samples 
were prepared from livers taken from rats in the 1500 mg/kg APAP group and mice in the 
750 mg/kg group (n = 4).  CYP1A2 antibody (ab22717, Abcam, UK) was used at a dilution of 
1:3000 overnight at  1 h at 4 oC, and secondary (anti-mouse) was 1:10 000 for 1 h at 4 oC.  
GCLC (ab53179, Abcam, UK) was used at a dilution of 1:10 000, in this case using bovine 
serum albumin as a blocking and non-specific binding agent.  Secondary antibody (anti-
rabbit) was 1:5000 for 1 h at RT. 
Alongside immunoblot analysis of samples from individual animals, in some instances rat 
and mouse liver samples from each dose group (n = 4) were also pooled and resolved on 
the same gel to facilitate comparison of responses.  These have been clearly indicated. 
4.2.3. Immunohistochemistry 
Ki67 IHC was performed as described in Chapter 3, section 3.2.8, with the following 
modifications: For antigen retrieval, slides were heated in a pressure cooker for 4 cycles of 
3 min heat followed by cooling until depressurisation occurred; and slides were incubated 
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overnight (4 oC) with anti-Ki67 antibody at a working dilution of 1:200 in 20 % normal goat 
serum/TBS-T. 
4.2.4. Statistical analysis  
Statistical analysis was performed as described in Chapter 2, section 2.2.11 
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4.3. Results 
4.3.1. Toxicity 
The onset of toxicity can be seen as the initial phase in the repeat APAP exposure model, 
and has been characterised by toxicological assessment in Chapter 2.  Some clear 
similarities between the two rodent models have been demonstrated in this way, 
particularly with regard to the pattern of hepatocellular injury and transaminase release; 
however, the mouse model exhibited a greater degree of overt tissue degeneration over 
the experimental timecourse.  In an attempt to clarify the animals’ response to the toxic 
phase of exposure, western immunoblot has been performed to detect three enzymes 
which inform the evolution of this phase.  The assays have been performed on lysates from 
individual animals, which were then analysed densitometrically to permit statistical analysis 
(Figure 4.1).  The assays were also performed on samples which had been pooled according 
to treatment group in order to allow intra-gel comparison of the two models (Figure 4.2).   
CYP2E1 and CYP1A2 are both directly implicated in APAP metabolism, and were seen to be 
substantially depleted in the 48 h APAP group in both models, reflecting peak 
hepatocellular injury.  CYP2E1 diminished to 44 % of control in rat in this group, and in 
mouse it fell to 8 %.  Consistent with data from the rat shown in Chapter 3 (Figure 3.8), 
there was a 120 % increase of CYP2E1 in mouse at 24 h APAP, although in contrast to the 
rat data (which showed CYP2E1 was 187 % of pooled control at 96 h) there was no 
apparent rebound in the 96 h group.   CYP1A2 fell to 18 % and 7 % of control in rat and 
mouse 48 h APAP groups respectively.  The pattern of loss and recovery of CYP1A2 in the 
two models was closely conserved.   
GS, a marker of perivenous hepatocytes, showed a similar pattern to CYP2E1 and CYP1A2, 
with significant loss of abundance observed in the 48 h APAP groups for both rat and 
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mouse (20 % and 1 % of controls respectively).  In the rat, GS was quantified at 1 % of 
control in both the 72 h and 96 h APAP groups.  The mouse model showed partial recovery 
of expression in 72 h and 96 h APAP groups.  These later treatment groups were quantified 
at 48 % and 39 % respectively.  
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Figure 4.1: Densitometric analysis of western immunoblot data for perivenous enzymes 
Legend: Densitometric analysis of western immunoblots comparing CYP2E1, CYP1A2 and 
GS in liver lysates (n = 4 animals) from each treatment group in both the rat and mouse 
models of repeat APAP exposure.  Densitometric values are normalised to actin and 
expressed as a percentage of the mean of control group animals.  In all instances, a 
reduction in expression is seen in the 48 h APAP treatment group, corresponding to loss of 
cells from the perivenous region.  
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Figure 4.2: Western immunoblot of perivenous enzymes in rat and mouse – pooled 
samples 
Legend: Representative western immunoblots comparing CYP1A2, CYP2E1 and GS in 
pooled liver lysates from each treatment group in both the rat and mouse models of repeat 
APAP exposure.  Pooled n = 4 animals per lane.  
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4.3.2. Detoxification and phenotypic adaptation 
The analysis of proteomic data described in Chapter 3 identified the Nrf2-mediated 
oxidative stress response pathway as being significantly perturbed by daily APAP exposure 
in rats, and therefore implicated in the processes of detoxification and phenotypic 
adaptation.  Since the transcription factor Nrf2 itself was not detectable in the proteomic 
data set and could not reliably be detected by western immunoblot, GCLC and NQO1 were 
probed in individual (Figure 4.3) and pooled (Figure 4.4) liver lysates as surrogate markers 
of Nrf2 activation.    
GCLC, the rate-limiting factor in repletion of GSH, was not markedly altered by dosing, 
except in the rat 96 h APAP group, where a significant increase to 195 % of pooled control 
was seen.  In mouse, although a loss was seen in the 48 h APAP group, GCLC was not 
significantly changed in any dosing group.    
In rats, an increase in abundance of NQO1 was seen from 48 h onwards, reflecting the 
recycling of NAPQI back to APAP.  Significance was seen in the 48 h APAP group (488 % of 
control) and 96 h APAP group (699 % of control).  This was not mirrored in the mouse: as 
seen with GCLC data, a loss of NQO1 was seen in the 48 h APAP group, although none of 
the groups showed statistical significance.  
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Figure 4.3: Densitometric analysis of western immunoblot data for APAP detoxification 
enzymes 
Legend: Densitometric analysis of western immunoblots comparing GCLC and NQO1 in liver 
lysates (n = 4 animals) from each treatment group in both the rat and mouse models of 
repeat APAP exposure.  Densitometric values are normalised to actin and expressed as a 
percentage of the mean of control group animals.  Dashed line indicates control value.   
 
Figure 4.4: Western immunoblot of APAP detoxification enzymes in rat and mouse – 
pooled samples 
Legend: Western immunoblots comparing GCLC and NQO1 in pooled liver lysates from 
each treatment group in both the rat and mouse models of repeat APAP exposure.  Pooled 
n = 4 animals per lane. 
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4.3.3. Regenerative changes 
A large part of an organism’s ability to adapt to repeated APAP toxicity lies in its capacity 
for swift and organised liver regeneration.  Review of the proteomic data shown in earlier 
chapters showed that, in the 72 h APAP group, proteins associated with cell cycle, 
proliferation and repair pathways were over-represented.  One of the most prominent 
proteins at 72 h was the cytoskeletal protein vimentin, which is a marker of mesenchymal 
cells and is vital for cell migration and tissue remodelling (Eckes 2000).  This observation 
was confirmed by western immunoblot (Figure 4.5).  Basally close to the limit of detection, 
vimentin rises to almost 7000 % of control values after 72 h of daily APAP exposure.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5: Densitometric analysis of immunoblot data for vimentin expression in rat 
Legend: Densitometric analysis of western immunoblots for vimentin in liver lysates (n = 4 
animals, representative immunoblots shown) from each treatment group in the rat model 
of repeat exposure.  Densitometric values are normalised to actin and expressed as a 
percentage of the mean of control group animals.  N. B.: Actin is itself slightly elevated in 
the 72 h APAP group, which may be a consequence of tissue remodelling. 
%
 o
f 
c
o
n
tr
o
l 
m
e
a
n
C
24
 h
48
 h
72
 h
96
 h
0
2000
4000
6000
8000
10000
***
Chapter 4: The regenerative response in rats and mice is incompletely conserved 
 
106 
 
In order to compare the regenerative responses of rat and mouse, the marker of cell 
cycling and tissue repair, PCNA, was examined in individual (Figure 4.6) and pooled liver 
lysates (Figure 4.7) in each treatment group.  In rat, a significant increase in PCNA 
abundance was observed in all repeat exposure groups, peaking in the 72 h APAP group at 
3162 % of control.  In mouse, the emergent picture was very different, with an initial loss of 
expression in the 24 h APAP group, then a trend towards increased abundance at later 
timepoints, albeit without statistical significance.   
 
 
 
 
Figure 4.6: Densitometric analysis of western immunoblot data for PCNA expression in 
rat and mouse 
Legend: Densitometric analysis of western immunoblots comparing PCNA in liver lysates (n 
= 4 animals) from each treatment group in both the rat and mouse models of repeat APAP 
exposure.  Densitometric values are normalised to actin and expressed as a percentage of 
the mean of control group animals.   
 
 
Figure 4.7:  Western immunoblot of PCNA in rat and mouse – pooled samples 
Legend: Western immunoblots comparing PCNA expression in pooled liver lysates from 
each treatment group in both the rat and mouse models of repeat APAP exposure.  Pooled 
n = 4 animals per lane. 
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In the rat model, the change in expression of PCNA (Figure 4.6) was seen to be closely 
consistent with that seen for vimentin (Figure 4.5), and an analysis of correlation is shown 
(Figure 4.8) which shows a significant R2 value of 0.938. 
 
 
 
 
 
 
 
 
Figure 4.8: Correlation of densitometric data for vimentin and PCNA in rat 
Legend:  A strong correlation is seen between the protein expression profile of markers of 
tissue repair and remodelling, vimentin and PCNA, in rat liver lysates.   
 
IHC was used in Chapter 3 to track the tissue distribution of CYP2E1, identifying a spatial 
element to the process of adaptation in rats.  To gain an additional dimension of 
understanding of the regenerative response in each model, here the marker of replication 
Ki67 was also investigated by IHC in rats and mice.  Although software permitting 
quantitative image analysis was not available, visual assessment of the slides from each 
treatment group suggested a remarkably similar pattern of expression between PCNA and 
Ki67 in each model.  Representative images are shown in Figure 4.9.  The rat again shows 
an early and robust increase in cells expressing Ki67, closely reflecting the profile seen for 
vimentin in Figure 4.5 and PCNA in Figure 4.6.  Positively stained cells were observed 
throughout the sections, with greatest densities seen in the perivenous regions, 
corresponding to areas that had sustained prior tissue injury and cell death.  In the mouse, 
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mitotic events appeared basally more common.  They diminished in the 24 h APAP group 
before gradually increasing in the 96 h APAP group, again both diffusely throughout the 
section and in higher densities surrounding central veins.  Observations for Ki67 staining 
were consistent with the abundance of PCNA (Figure 4.6) in both models.  A detailed image 
comparing Ki67 staining in rat and mouse liver at 72 h is presented in Figure 4.10, showing 
the concerted proliferative response in the rat compared to the absence of immunogen in 
the mouse tissue.   
Chapter 4: The regenerative response in rats and mice is incompletely conserved 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9: Ki67 staining in rat and mouse 
Legend: Representative image from each treatment group in the rat and mouse model, showing liver sections stained for the replication marker Ki67.  
Immunogen is brown against a blue haematoxylin counterstain.  Although more mitotic events were observed basally in the mouse, the rat showed a 
greater ability to mount a proliferative response to tissue injury.  Bar = 100 µm. 110
 
C
h
ap
ter 4
: Th
e regen
erative resp
o
n
se
 in
 rats an
d
 m
ice is in
co
m
p
letely co
n
served
 
Chapter 4: The regenerative response in rats and mice is incompletely conserved 
 
 
 
Figure 4.10: Detail of Ki67 staining in rat and mouse 72 h APAP treatment groups  
Legend:  Detail of Ki67 staining 
in rat and mouse 72 h APAP 
treatment groups showing the 
abundance of actively 
replicating cells in the rat, in 
particular in the region 
surrounding the central vein.  
This is in stark contrast to the 
same group in the mouse 
model, showing absence of 
immunogen in mouse tissue.  
Immunogen is brown against a 
blue haematoxylin 
counterstain.  Bar = 100 µm.
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4.4. Discussion 
Data presented in earlier chapters show the gross change in hepatic phenotype in the rat in 
response to repeated APAP exposure.  Data shown in Chapter 3 suggest that the drug 
metabolising phenotype of the liver is suppressed in favour of a proteome supporting 
essential functions and repair.  In this chapter, the response of rats and mice to repeated 
APAP exposure was compared over a 96 h period.  Rats received 1500 mg/kg daily and mice 
received 750 mg/kg daily.  In both models, significant toxicity was seen in the 48 h APAP 
group.  Selected markers of toxicity, adaptation and regeneration were examined in each 
model, revealing differences at every point in the process (Table 4.1).  Understanding the 
way each species behaves in response to repeated chemical stress is necessary to make an 
appropriate choice for preclinical modelling of drug toxicity and liver regeneration.   
Table 4.1: Summary of key differences identified in rat and mouse responses to repeat 
APAP exposure 
Legend: Despite initial similarities between the two models in terms of characteristic APAP-
induced hepatocellular injury, after repeated exposures the responses of rats and mice 
diverge.  
4.4.1. Summary of findings and relation to literature 
Consistent with data shown in Chapter 2, some clear similarities exist between the two 
models of repeat APAP exposure investigated.  Both rats and mice in the 48 h APAP group 
 RAT  MOUSE  
TOXICITY  Loss of all markers at 48 h; 
Induction of CYP2E1 at 24 h 
and 96 h  
Loss of all markers at 48 h; 
recovery of GS expression at 
72 and 96 h  
ADAPTATION  Induction of Nrf2-dependent 
proteins  
No induction of Nrf2-
dependent proteins  
REGENERATION  Robust proliferative 
response, peaking at 72 h  
No significant proliferative 
response  
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showed a marked loss of CYP2E1 and CYP1A2 as a consequence of repeat exposure, 
reflecting destruction of the CYP450-rich centrilobular regions of the liver.  However, the 
robust induction of CYP2E1 seen in the rat 24 h APAP and 96 h APAP groups was not 
reflected by the mouse cohorts.  Comparison of GS abundance revealed a picture that was 
initially similar, with loss of the marker of perivenous hepatocytes in the 48 h APAP group 
in both models.  Interestingly, the mouse 72 h APAP group showed rapid partial restitution 
of GS despite ongoing tissue injury, in contrast to the rat model, which had not recovered 
GS expression by the end of the time course (Figure 4.1).  It is unclear at this point which 
cells could be responsible for the re-expression of GS in the mouse, since data shown in 
Chapter 2 (Section 2.3.3.2) showed that some animals continued to sustain extensive tissue 
injury in each dose group.   
Activation of Nrf2 is an important step in the process of detoxification and restoration of 
redox equilibrium pursuant to oxidative stress.  It has previously been demonstrated in 
both the rat (Ahmed et al. 2011) and the mouse (Goldring et al. 2004) in response to APAP 
exposure.  Data presented in Figure 4.3 suggest more effective Nrf2 activation in rat than in 
mouse.  This observation is in keeping with the rats’ known greater resistance to toxicity, 
and is supported by findings shown in Chapter 3 which identified the involvement of the 
Nrf2-mediated response to oxidative stress in the rat (Figure 3.1).   
However, the use of surrogate markers is not without pitfalls, and in order to have greater 
confidence in these findings it would be valuable to ascertain experimentally a number of 
additional factors to assist with interpretation of the data.  These factors include i) the 
degree of temporal lag between Nrf2 activation and detectable upregulation of 
downstream gene products in these models; ii) the degree of crosstalk between Nrf2 and 
other transcription factors that interact with the ARE upstream of the surrogate markers in 
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question; and iii) the degree of upregulation that constitutes biological significance in this 
context.   
A model of APAP-induced liver injury examined by Fan et al. (2014) displayed elevated 
NQO1 at the protein level 48 h after exposure.  These data are consistent with findings for 
the rat model in the present work, reinforcing the notion that Nrf2 is activated in the 
process of adaptation in the rat.  The findings are in contrast to the mouse model which in 
this repeat exposure context does not exhibit elevated NQO1, suggesting that either Nrf2 is 
not activated in this context, or its activity is suppressed as a consequence of repeat APAP 
exposure. 
 
Whilst it is tempting to conclude that Nrf2 activation alone is responsible for the induction 
of NQO1 and GCLC in the rat model presented here, it must be borne in mind that crosstalk 
between different transcription factors and the ARE have been documented.  Besides Nrf2, 
the transcription factors Jun, Fos and Fra also bind to the ARE and influence the 
transcription of ARE-governed genes (Venugopal and Jaiswal 1996).   Furthermore, the Fos 
protein Fra1 has been shown to protect mice from APAP-induced liver injury (Hasenfuss et 
al. 2014).  Collectively, these observations raise the possibility that, despite the fact that 
the Nrf2-mediated oxidative stress response pathway was identified through pathway 
mapping, the upregulation of detoxification proteins seen here in the rat may be driven by 
other transcriptional pathways besides Nrf2.   
 
The cytoskeletal protein vimentin was probed by immunoblot in the rat (Figure 4.5) and 
findings were consistent with proteomic data (Chapter 2, Figure 2.13).  Vimentin is strongly 
associated with mesenchymal cells and wound healing (Eckes et al. 2000), but is also 
established as a marker of dedifferentiating primary hepatocytes in culture (Schuetz et al. 
1988).  The latter association may lend further weight to the observations that mature 
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hepatocytes re-entering mitosis undergo phenotypic dedifferentiation in a manner very 
similar to that seen in cultured primary cells (Ito et al. 1991), and that this dedifferentiation 
is part of the liver’s strategy to limit further toxicity in the aftermath of extensive liver 
injury.   
A similar profile of expression to that seen with vimentin is also seen when PCNA is 
examined in the rat (Figure 4.6) and in fact, correlation between the two markers of 
regeneration is close (Figure 4.8).  PCNA expression in the mouse, however, is very 
different.  Although statistical significance was not seen, immunoblot data showed an initial 
loss of expression of PCNA, with a trend towards increased expression at later time points 
in some animals, which peaked in the 96 h APAP group.  Image analysis was not performed 
on Ki67 IHC, but visual evaluation of the data obtained using this assay seemed to be in 
keeping with the profile of expression of PCNA in both models (Figure 4.9).  A stark visual 
contrast is notable between rat and mouse in the 72 h APAP group.  In this group the rats 
showed the greatest increase in abundance of proteins contributing to repair and 
regeneration, according to the proteomic data.  Figure 4.10 shows a large number of Ki67 
immunopositive cells in the rat liver, particularly clustering around the centrilobular region.  
In the mouse, stained liver from the equivalent experimental group shows an almost 
complete absence of Ki67 immunopositive cells, suggesting that tissue remodelling 
processes in the mouse model are very different.   
4.4.2. Implications of findings and questions raised 
Although there are some common responses to repeat APAP exposure in the models 
explored, striking differences have been identified at every phase of toxicity, adaptation 
and regeneration in repeat dosed mice and rats.  These differences are particularly 
apparent when comparing Nrf2 activation and tissue remodelling activity.  Something is 
known of how rats are adapting to repeated APAP exposure in this model by virtue of the 
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analysis of proteomic data conducted in the previous chapter.  What remain less clear are 
the mechanisms by which the mice are able to withstand a similar stress.   
Although controversy exists over the mode of cell death in APAP overdose, necrosis is 
generally accepted as the predominant mechanism (Jaeschke et al. 2014). Necrosis is 
characterised by cell swelling and lysis, vacuolation, karyorrhexis and karyolysis (Gujral et 
al. 2002).  Both species suffer an initial depletion of absolute cell number, and whereas the 
rat has been shown to initiate a strong regenerative response in the immediate aftermath 
of cellular injury, when judged by the same criteria, the mouse does not.  However, with 
the exception of three animals that were found dead, the mice in this study were able to 
withstand repeat exposure over the time period examined.  How therefore is the mouse 
liver adapting and regenerating?   
Using knockout animals, Nrf2 has recently been identified as a novel regulator of 
hepatocyte mitosis (Zou et al. 2015).  Although the mouse cohort in the present work was 
not deficient in Nrf2, mice showed an apparent lack of activation of Nrf2 under these 
experimental conditions.  Given that the mice also failed to initiate a significant mitotic 
response, these observations seem in accord with the findings of the publication.  Using an 
inducer of Nrf2 may therefore be valuable in stimulating hepatocyte mitosis and treating 
APAP-induced liver injury.   
It is also worth noting here that, whilst PCNA and Ki67 are validated markers of DNA 
replication, in this context DNA replication does not necessarily equate to cell division.  A 
peculiarity of hepatocytes is their propensity for polyploidy.  Around 70 % of all mature 
hepatocytes in rodents are tetraploid (Fausto and Campbell 2003).  It would seem 
therefore that hepatocytes do not necessarily undergo conventional cell division.  As well 
as polyploidy, a significant number of hepatocytes are binucleate, and it is thought that 
these binucleate cells represent a functional reserve (Wheatley 1972).  It has been 
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observed that the number of binucleate cells diminishes after partial hepatectomy 
(Wheatley 1972), so it is possible that one facet of recovery in the mouse is reductive cell 
division, whereby a binucleate parent cell gives rise to two mononucleate daughter cells.   
Consistent with observations made in Chapter 2, section 2.3.3.2, further research has 
shown that in mice, the initial response to loss of liver tissue is hypertrophy (Miyaoka et al. 
2012).  This physical enlargement of remaining hepatocytes to reconstitute organ mass was 
shown to precede proliferation, and proliferation would only occur if hypertrophy was 
insufficient to restore mass.  In 30 % partial hepatectomy (a cell loss roughly equivalent 
with that seen at the peak of toxicity in the present model), hepatocyte division was not 
observed (Miyaoka et al. 2012).  So perhaps another facet of the mouse’s strategy for 
survival could be explored by interrogating hepatocyte volume, nuclear number and ploidy 
in response to APAP toxicity.   
In some ways the mouse is considered a closer analogue of human APAP toxicity than the 
rat (Jaeschke et al. 2014), and yet as discussed here there are still many facets of the 
mouse’s adaptation to repeated exposure that are poorly understood.  What is clear is that 
although some common features exist between rats and mice, other elements of the 
process of adaptation are unique to each species.  Furthermore, adaptation is incredibly 
intricate and complex, and the work presented here merely scratches the surface of the 
process.  Reviewing the data, it seems impossible to attribute adaptation to a single 
pathway or group of molecules – an appropriate biological characteristic since an 
organism’s survival can depend on it.  
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5.1. Summary of model and key findings 
The aim of this thesis was to investigate the molecular mechanisms of adaptation to 
chemical stress using the model hepatotoxin acetaminophen (APAP).  In the first 
experimental chapter, two preclinical models of repeated APAP exposure have been 
characterised through clinically accepted toxicological and histopathological assessments, 
establishing APAP-induced toxicity in the high dose APAP exposure groups in both rat and 
mouse models.  A global proteomic analysis of rat liver has given insight into the changes in 
abundance of a subset of proteins common to all rats throughout the duration of the 
repeat exposure study, demonstrating that the process of adaptation to repeat APAP 
exposure is not mediated by a single enzyme or pathway, but rather by a dynamic shift in 
expression of a large number of hepatic proteins.   
The second experimental chapter probed deeper into the molecular events surrounding 
adaptation to repeat exposure in the rat, and interrogated the proteomic data using 
pathway analysis software.  This interrogation mapped significantly differentially abundant 
proteins onto established canonical pathways, and permitted the identification of 
phenotypic shifts in response to dosing.  These phenotypic shifts gave an indication of what 
may constitute adaptation.  A graphical summary of the model is shown in Figure 5.1.  
Other work in this chapter focused on the role of APAP’s major bioactivator, CYP2E1, at 
different time points in the rat high dose APAP exposure model through 
immunohistochemistry and liver microsome experiments.  This work identified a marked 
change in both spatial and temporal expression of CYP2E1, and alterations in the enzyme’s 
activity which did not seem to correlate with the degree of toxicity seen at the timepoints 
examined.   
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Figure 5.1: Graphical summary of the rat model of adaptation to APAP 
Legend: Visual representation of key observations made of the rat’s response to repeat 
APAP exposure.  Cell death and ALT release is seen at 48 h, preceded by an increase in 
CYP2E1 abundance, although the clinical marker of liver function albumin remains 
unaffected throughout.  Cellular injury rapidly resolves, as phenotypic shifts alter the drug 
metabolism profile of the liver and initiate proliferative activity to restore lost tissue. 
 
The final experimental chapter compared and contrasted the regenerative response in the 
rat and mouse high dose APAP exposure groups, probing for proteins identified as key to 
the processes of toxicity, adaptation and regeneration based on the work of previous 
chapters.   Whilst common observations were made, differences between the two models 
were observed in every equivalent time point.  Both models showed loss of centrilobular 
hepatocytes, but the mouse model displayed partial restoration of expression of GS, 
accepted as a sentinel of immediately perivenous hepatocytes.  The Nrf2-mediated 
oxidative stress response is known to be conserved between murine models and man, but 
under these experimental conditions, the rat seemed to mount an oxidative stress 
response to liver injury, demonstrated through analysis of the surrogate markers of Nrf2 
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activation GCLC and NQO1.  The mouse, on the other hand, did not show significant 
elevation of these markers.  The rat was also shown to have a far greater capacity for 
proliferative activity than the mouse, raising questions concerning which other mechanisms 
might mediate the mouse’s adaptation and survival.   
5.1.1. Relation of findings to hypothesis 
The original hypothesis was that adaptation to repeat APAP exposures is a complex process 
involving multiple pathways and phases, commensurate with a sophisticated response 
across the liver to ensure survival upon re-exposure to subsequent normally noxious 
exposures.  Data presented here from the rat model fully support the hypothesis, showing 
that there is a great breadth of hepatic responses, and that these responses are dynamic 
and concerted, effectively protecting the animal from sustaining further injury whilst 
preserving critical hepatic function.  In the mouse, although adaptation has been 
demonstrated, initial analyses presented here suggest that some of the mechanisms 
underpinning adaptation in the mouse may be markedly different to those seen in the rat.  
As the mouse is in some regards accepted to be a closer model of human APAP toxicity, 
further characterisation of these mechanisms and their divergence from what is known of 
the rat may shed light on the processes of human adaptation to chemical stress.  
Understanding the consequences of failure in any of these processes would enable the 
development of improved strategies for clinical management of APAP-induced liver injury.  
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5.2. Limitations of study and opportunities for further research 
As with any scientific study, the data presented here must be interpreted within the 
context and the limitations of the experimental framework.  The original animal studies 
were conceived, designed and conducted by Almirall S. A. as a means of modelling acute 
liver failure.  Since the animals in each of the studies did not succumb to liver failure as a 
result of repeat APAP exposure, but rather adapted to the exposure and became resistant 
to its effect, the study presented a valuable opportunity to investigate the process of 
adaptation.   
5.2.1. Choice of experimental timepoints 
The initial objectives of the studies informed the choice of timepoint for dosing and 
sacrificing the animals.  Consequently, the timepoints examined in this thesis were not 
necessarily the most appropriate with which to characterise the many facets of adaptation.  
Analysis of the study data has shown that the hepatic response over the 96 hour period is 
highly dynamic.  It is possible that some of the more subtle responses may have been 
missed due to their transient nature. A good example of this is the transcription factor 
Nrf2, which is known to be transiently induced within 1-2 hours of stress in vivo (Goldring 
et al. 2004).  Therefore an attempt to recapitulate any of this work might include a number 
of sampling points after each administration in order to capture the more transient 
changes in phenotype.   
5.2.2. Selection of proteomic data for analysis 
Any proteins that were not detected in all liver samples from every group in the rat 1500 
mg/kg proteomic analysis were excluded from the data analysis.  Although this decision 
was taken in order to permit robust statistical analysis, excluding proteins which did not 
appear in all dose groups may, again, have resulted in some important changes being 
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overlooked.    Any proteins that were basally undetectable in some samples but present in 
others have been excluded from the analysis, as well as any that were expressed by only 
some of the animals in any given exposure group.  A subsequent evaluation of the model 
may reveal new leads in the search for mediators of adaptation.  Re-examination of raw 
data alongside immunostained histological specimens may highlight additional relevant 
responses, selectively identifying potential contributions of non-parenchymal cells to 
adaptation. 
5.2.3. Duration of experimental timecourse 
Although what constitutes ‘chronic’ exposure in an animal model can vary greatly 
depending on both the species and pharmaceutical agent in question, the International 
Conference on Harmonization (ICH) Guidance for Industry makes recommendations on 
preclinical repeated dose toxicity testing.   A minimum study duration of 2 weeks is 
suggested, which can be extended to several months dependent on the anticipated 
duration of treatment in humans (ICH 2010).   The Organisation for Economic Co-operation 
and Development (OECD) assert that repeated dose oral toxicity testing in rodents (where 
adverse effects may occur after multiple or continuous exposures) should be performed for 
28 days with a 14 day washout period (OECD 2008), and sub-chronic oral toxicity testing 
(where toxicity may occur after repeated or continuous exposure for up to 10 % of the 
organism’s lifespan (ISO 2006)) should be carried out for 90 days (OECD 1998). 
The first study to identify the phenomenon of adaptation to APAP (Buttar et al. 1976) 
looked at sub-acute exposure, defined in the paper as twice-daily exposure for a period of 
seven days.  Data from these animals were compared to an acute exposure group which 
received a single treatment.   Following on from the hepatoprotective effects observed in 
this study, a subsequent publication (Strubelt et al. 1979) sought to elucidate the 
mechanisms of the phenomenon.  This work found that after a sub-acute exposure 
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consisting of four daily doses, with a further exposure on the sixth day, again, adaptation 
had occurred.  Also of interest in the work presented by Strubelt was the notion that these 
hepatoprotective changes persisted beyond the duration of exposure, as animals which 
received a final exposure on day six of this study showed only a partial reversal of the 
hepatic adaptations that APAP induced.   Since these publications, more recent studies 
have shown that longer term exposures continue to confer protection in animal models 
(Poulsen and Thomsen 1988; Dalhoff et al. 2001).   
From the clinical perspective, adaptation to long-term APAP exposure is described in a 
number of publications including a case study in which a clinician developed tolerance to a 
prescription opioid/APAP formulation with no liver injury (Shayiq et al. 1999).  
Furthermore, an analysis of a multicentre retrospective study of repeated supratherapeutic 
ingesters of APAP revealed that just over one third of the subjects identified as such 
experienced hepatotoxicity, suggesting that the remainder were able to either tolerate or 
adapt to repeated exposure despite often complex sociomedical backgrounds (Alhelail et 
al. 2011).  However, little data exist concerning whether these protective changes persist in 
the aftermath of treatment.   
The duration of the present work is in keeping with the animal studies cited above which 
explore the adaptive effects of APAP exposure; yet, in this context, the current work falls 
into the broad grey area between acute and chronic exposure.  Although not a preclinical 
trial and therefore not the subject of industry guidelines, when viewed in such a context 
the model of adaptation presented in this thesis may have been somewhat limited by its 
duration.  Whilst 4 days of bolus dosing is in some regards a reasonable reflection of a 
human therapeutic APAP exposure to medicate minor illness or injury, given the dynamic 
nature of the responses provoked by repeat exposure it would be worthwhile assessing 
whether the detected changes continue to evolve over a longer time period.  Doing so 
Chapter 5: Concluding Discussion 
125 
 
would also enable researchers to ascertain the duration of the hepatoprotective changes 
after the initial exposure. 
5.2.4. Controlling for food consumption 
A further factor that should be considered in the interpretation of data is whether the 
animals were consuming food normally.  Rats and mice in the work presented here had 
unrestricted access to standard laboratory rodent feed for the duration of the study, but 
data for food consumption was not recorded when the study was conducted.  Tissue injury 
and inflammation cause sickness behaviour, a hallmark of which is anorexia (Maes et al. 
2012).  Some animals may have stopped eating after the initial APAP exposure due to the 
degree of liver injury sustained.  This means that they would have received subsequent 
doses in an effectively fasted state, which may be confounding the results.  A recent study 
focusing on nutritional state as a risk factor for toxicity arising from ongoing exposure to 
therapeutic doses of APAP (Kondo et al. 2012) found that rats which had their food intake 
restricted to mimic chronic human undernourishment were more susceptible to APAP 
induced liver injury than rats fed ad libitum.  Rats in the restricted feed group showed 
reduced liver GSH.  GSH production is dependent on dietary availability of sulphur-
containing amino acids (Tateishi et al. 1981; Glazenburg et al. 1983), which could 
potentially have become limited in animals in the present study.  Loss of abundance of GSH 
has direct implications for an organism’s ability to neutralise APAP’s reactive metabolite 
NAPQI, and the influence of GSH abundance on the process of adaptation is one which may 
merit further exploration.   
Most researchers agree that hepatic GSH depletion is the critical trigger for acetaminophen 
hepatotoxicity (Bessems and Vermeulen 2001).  In the context of current understanding of 
GSH and APAP metabolism (and as has been shown in Chapter 2), it is likely to be the loss 
of GSH upon initial exposure to APAP that initiates a transcriptional shift in the liver which 
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comprises part of the adaptive process.  Depletion of GSH by the reactive metabolite 
NAPQI in this model of adaptation may indeed be a necessary step to prime the liver for 
adaptation. Arguably, based on what is known of APAP toxicity, if GSH is not depleted by 
the initial exposure, the degree of toxicity is insufficient to warrant adaptation.  
Interestingly though, the Glazenburg study referenced above found that, despite extreme 
restriction of dietary sulphur with concomitant reduction of hepatic GSH to  just 20 % of 
that of control rats, formation of APAP-GSH was unaffected. This suggests that upon APAP 
exposure, GSH can be synthesised rapidly and in significant quantities even under dietary 
restriction.  This may relate to the observation in the present work of a sudden increase in 
GSH measured at 48 h in the rat, coincident with peak APAP toxicity, which later fell 
(Chapter 2, Figure 2.9).  In contrast, a subsequent rodent study showed that insufficient 
dietary sulphur resulted in increased susceptibility to APAP toxicity, and the protective 
effect of reduced CYP450 formation (as a consequence of suppressed protein synthesis) 
was insufficient to offset the potentiating effect of the reduced ability to detoxify NAPQI 
(Price and Jollow 1989).  In humans, however, short-term restriction of dietary sulphur did 
not affect the elimination of APAP at therapeutic doses (Mannery et al. 2010).  It is clear 
that further research into the interplay between GSH and APAP will be necessary in order 
to understand how the various factors outlined here interact, tipping the physiological 
scale in favour of susceptibility or resistance to injury. 
5.2.5. Influence of non-parenchymal cells 
A further element that has not been specifically probed here is the influence of non-
parenchymal cells upon the process of adaptation.  As has been seen in Chapter 3 from IHC 
data, the contribution to the liver mass from non-parenchymal cells increases over time.  
This is due to infiltration of immune cells and expansion of small, densely staining cells 
(presumed, but not demonstrated, to be fibroblasts) in areas where hepatocytes have been 
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lost; as well as the loss by cell death of the hepatocytes themselves.  Whilst these cells are 
likely to have been excluded from the proteomic data if their contribution both differed 
from that of the parenchyma and was basally undetectable, it would be valuable to identify 
all the cell types mediating the adaptive process.   
Performing stains for individual cell types in liver sections as suggested in section 5.2.2 
would be a valid initial step, and one which might help to identify changes in the 
subpopulations of, for example, endothelial cells, macrophages and fibroblasts.  The use of 
laser capture microdissection (Espina et al. 2006) in subsequent work would permit the 
excision and analysis of specific cells from liver tissue sections.  Use of immunostains to 
assist in identification would enable the separation of hepatocytic proteins from the 
contribution of non-parenchymal cells, and facilitate the examination of hepatocytes from 
different zones of the liver in order to characterise the adaptive phenotype in regions both 
proximal and distal to the foci of injury.   
5.2.6. Identity of repopulating cells 
APAP-induced injury can cause loss of hepatocytes on a significant scale.  In the aftermath 
of injury in the rat model we see ‘foci of regeneration’ (Chapter 4, Figure 4.10): high 
concentrations of Ki67-positive cells in and around the spaces where hepatocytes have 
been lost through APAP toxicity.  IHC data shows some of the cells re-entering mitosis are 
clearly identifiable by morphological characteristics as mature hepatocytes, but there is at 
least one further population of cells focused around centrilobular regions and consisting of 
small, densely staining bodies whose identity is unknown.  Referring back to literature 
presented in the general introduction, there are thought to be two mechanisms of cellular 
restitution after liver injury.   One relies on mature hepatocytes re-entering the cell cycle, 
and the other is mediated by the expansion and differentiation of multipotent cells 
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(referred to here as liver progenitor cells, or LPCs) from the areas in proximity to the bile 
ducts, presented as the streaming liver hypothesis. 
Controversy continues to reign over exactly which populations of cells contribute to the 
repopulation of a previously damaged liver with phenotypically mature hepatocytes, and 
under which circumstances different populations do so.  Recent publications in this field 
have become ever more eloquent, using genetic manipulation to trace the fate of different 
cell populations in the liver.  A high-profile paper appearing in Nature Genetics used fate-
tracing techniques to label LPCs, establishing the involvement of stem-cell-derived cells in 
both homeostatic and reconstitutive activity in the liver (Furuyama et al. 2011).   
In the same year, a second publication sought to test the findings of Furuyama et al., but 
rather than labelling LPCs, this group labelled mature hepatocytes of mouse livers in order 
to determine loss of reporter signal either in response to injury or as a normal homeostatic 
mechanism (Malato et al. 2011).  Its findings were in definite contrast to the work by 
Furuyama et al. despite using the same mediators of clean (2/3 partial hepatectomy) and 
toxic (CCl4) injury.  The authors speculate that the experimental protocol employed in the 
preceding publication resulted in low-level toxicity which may have recruited LPCs, thereby 
confounding results.   
The following year, again using fate tracing methods, Gastroenterology published a paper 
which concluded that chronic injury is repaired by LPCs but acute injury is not (Español-
Suñer et al. 2012).  These findings reinforced the established streaming liver hypothesis, 
which proposed that stem cells are only recruited if the mitotic capacity of mature 
hepatocytes is impaired in some way. 
Further confounding issues in the same year, a work was presented which expanded on 
previous publications exploring hypertrophy and unconventional cell division as an organ-
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specific method of recovery from injury (Miyaoka et al. 2012).  The authors of this paper 
argued that the accepted paradigm for liver regeneration was too simplistic, since these 
factors were not acknowledged.   
In 2013, a publication was presented showing that under conditions of both toxic injury and 
partial hepatectomy, widespread interconversion was seen between hepatocytes and 
biliary epithelial cells (Yanger et al. 2013).  The following year, the same group published 
data showing that, after toxic liver injury, virtually all new cells were derived from existing 
hepatocytes (Yanger et al. 2014).   
It should be noted that the data presented above are all gathered from mouse models, 
since mice are so much more amenable to genetic manipulation.  Publications in this 
research area remain sparse for rat and human.  However, when reviewing the work 
presented in this thesis in the context of current literature, it seems probable that the rat 
model of adaptation presented herein is one in which repopulation of the liver is achieved 
predominantly through mitotic activity of existing hepatocytes.  The injury is chemical in 
nature, and exposure is not sustained over a long period of time.  The animals used were 
young, with no experimental impairments to their mitotic capacity, so it seems unlikely that 
there would be any involvement of LPCs in the repair process.  The accumulation of 
literature portraying the intricate phenomenon of regeneration is at present reminiscent of 
the Indian proverb concerning blind men describing an elephant, each part intricately 
rendered and yet seemingly at odds with other descriptions of the same beast.  Perhaps, 
then, until it is clear how each of these beautifully detailed investigations fit together to 
form a complete representation, the most important point to consider is the functional 
change that regenerating liver exhibits.  Regardless of the cell type mediating recovery, 
literature shows that increased cellular proliferation in the liver has been associated with 
enhanced resistance to toxicity via alterations in expression of xenobiotic metabolising 
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enzymes; and that blocking proliferation using the antimitotic colchicine abrogates 
resistance (Shayiq et al. 1999; Dalhoff et al. 2001; Aleksunes et al. 2008a).  This change in 
phenotype described has important implications for the fate of subsequent exposures to 
any xenobiotic.   
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5.3. Further considerations in the investigation of adaptation 
5.3.1. Evidence for hepatic functional reserve 
Expanding on the paper cited above by Miyaoka et al. describing both cellular hypertrophy 
and unconventional cell division as mediators of hepatocellular restitution (Miyaoka et al. 
2012), the concept of hepatic functional reserve may prove pertinent to the bigger picture 
of adaptation.  The liver has a profound ability to compensate for injury, and it is 
established clinically that by the time symptoms of liver injury arise, the degree of damage 
to the organ is likely to be severe (Asrani and Kamath 2013).  Several possible mechanisms 
for functional reserve can be identified in the literature.   
As an alternative interpretation of ‘functional heterogeneity’, the idea that a subset of 
hepatocytes in the liver are transcriptionally inactive or incompletely active was proposed 
in 2011 in a study that examined acetylated histones as markers of active gene 
transcription (Shi et al. 2011).  This group found that in human cirrhosis, as the parenchyma 
was lost through disease progression, the ratio of cells positive for markers of transcription 
gradually increased.  These findings correlated with work performed in a mouse partial 
hepatectomy model which showed that remaining cells after surgery were extensively 
activated, and this activation was independent of regenerative activity.   
Widespread incidence of hepatocytic aneuploidy has been documented in rodents and 
humans (Duncan et al. 2010, 2012), and is thought to act as a ‘survival of the fittest’ 
mechanism in the liver, allowing rapid adaptation to stress through selection of the 
strongest phenotype.  Proliferating hepatocytes produce a highly diverse population of 
daughter cells, allowing rapid adaptation to noxious stimuli.   
Although the functional consequence of adaptation has been described in the work 
presented, establishing the means by which adaptation and regeneration occur is by no 
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means as simple as examining the frequency of mitotic events.  Any of the mechanisms 
summarised here could be active in the rodent models presented.  In the rat model, mitotic 
events are implicated in adaptation, and evidence of mature hepatocytes dividing to 
restore cell number and mass has been presented histologically.  Given the critical 
importance of adaptation to the organism’s survival, it is likely that there is redundancy in 
the process and as such, other mechanisms may also be implicated in this model.   
The mouse model, interrogated at lower resolution, hints at alternative predominant 
processes, since mitotic events were seen to be comparatively rare.  The concepts 
presented by Miyaoka et al. concerning cell division in the absence of DNA replication as 
well as cellular hypertrophy; those proposed by Shi et al. relating to a cellular reserve of 
transcriptionally inactive hepatocytes; and those concerning genetic heterogeneity 
discussed by Duncan et al. may all be contributing to the mouse’s apparent ability to adapt 
to repeated APAP toxicity in the absence of concerted mitotic activity.   
5.3.2. Novel modes of inter-cell communication 
Liver cells are able to secrete and recapture extracellular vesicles, often referred to in the 
literature as exosomes.  Recent research has identified the importance of these actively 
secreted vesicles, which contain small molecules that impart information to recipient cells 
or tissues.  Exosomes were first demonstrated to contain genetic information in 2007 
(Valadi et al. 2007), and are detectable in a wide range of biofluids, making them an 
attractive target for biomarker identification.  The discovery that nucleic acids can be 
transferred between cells has engendered a paradigm shift in the current understanding of 
gene regulation.  It is now generally accepted that exosomal traffic presents a means of 
post-transcriptional gene regulation.    
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Hepatocytes are known to secrete exosomes (Conde-Vancells et al. 2008),  and both the 
abundance and the cargo of these vesicles are changed in response to liver injury (Royo 
and Falcon-Perez 2012).  A key constituent of hepatocyte-derived exosomes is the liver-
specific microRNA miR-122 which is emerging as a sensitive and specific early biomarker of 
liver injury, as well as a post-transcriptional regulator of the hepatic phenotype.  miR-122 
has been characterised as a biomarker of APAP-induced liver injury in preclinical models 
(Wang et al. 2009) and also in humans (Starkey Lewis et al. 2011; Ward et al. 2014), where 
data suggest it may be an improvement on the gold standard biomarker of hepatocellular 
injury, ALT.   
Less clear thus far is whether miR-122 may play a part in mediating adaptation to toxicity.  
miR-122 represents about 70 % of the liver’s total microRNA content.  It is completely 
conserved in all the species it has been identified in, and has a wide range of endogenous 
targets within major pathways including tumour suppression, cholesterol metabolism and 
iron homeostasis (Jopling 2012).  Experiments using human hepatocellular carcinoma cells 
show that miR-122 is necessary for maintaining the hepatic phenotype (Coulouarn et al. 
2009); and yet, in a chimpanzee model of chronic hepatitis C infection, gene silencing 
resulting in its progressive loss did not seem to cause liver toxicity (Lanford et al. 2010). 
A time-dependent loss of miR-122 from liver tissue has been shown in a mouse model of 
APAP induced liver injury (Starkey Lewis, unpublished data), and loss of miR-122 from liver 
cells is implicated in tissue remodelling and fibrosis associated with steatohepatitis (Csak et 
al. 2015).  Given that microRNAs influence at least one third of all human transcripts 
(Lakner et al. 2011) it seems unlikely that the liver-specific miR-122 would not be involved 
in some part of the process of adaptation.  In humans, an association has been seen 
between elevated miR-122 in both liver tissue and serum, and spontaneous recovery from 
acute liver failure (John et al. 2014).  The authors of this paper noted previous research that 
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has shown haemoxygenase-1 (HO-1) to inhibit proliferation, differentiation and 
antiapoptotic pathways, suggesting this enzyme may negatively influence liver 
regeneration.  The HO-1 transcript is negatively regulated by miR-122, and patients in the 
John et al. study who spontaneously recovered from acute liver failure presented with 
significantly higher miR-122 and lower HO-1 than those who required intervention.   
The question is therefore exactly what role miR-122 plays in mediating adaptation to injury.  
Direct links between miR-122 and the processes of adaptation and regeneration are 
limited, but circumstantially an association exists through exosomes.  In mouse models of 
ischaemia reperfusion injury and partial hepatectomy, exosomes originating from 
hepatocytes have been shown to mediate repair and regeneration (Nojima et al. 2016).  In 
the models characterised in the present work, it would be fascinating to query the 
involvement of exosome-mediated intercellular communication in adaptation to chemical 
stress.   
In the present model, hepatocytes that have sustained toxic injury in the initial hours after 
APAP exposure may be actively secreting exosomes (potentially containing, amongst other 
molecules, miR-122) in response to the chemical stress and redox perturbation brought 
about by the accumulation of NAPQI.  These exosomes are known to be released into the 
bloodstream, and have also been identified in bile (Masyuk et al. 2010).  When reviewing 
this nascent field, an emergent hypothesis is that between centrilobular and periportal 
hepatocytes, communication pathways exist which are mediated by biliary exosomes and 
which help regulate adaptation. In this way, perhaps centrilobular cells could release a 
distress signal which would be detected by cells further along the portocentral axis which 
are initially unaffected by direct toxicity.  The distress signal could conceivably contain 
information on the nature of the insult that the originating cells were suffering, and what 
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phenotypic changes may be necessary in order for the organ as a whole to become more 
resilient in the face of subsequent exposures.   
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5.4. Concluding remarks 
5.4.1. Refining in vivo models of human adaptation to APAP 
Laboratory rodents differ from humans in many ways, in particular their limited genetic 
diversity and the closely controlled influence of diet and environment.  Rodents are the 
preferred choice for preclinical modelling of DILI, but alternative in vivo models have 
historically been utilised and are continually being developed.  Primates have historically 
been used for experimental work due to their high degree of genetic identity with humans, 
but improvements in the human understanding of their capacity to suffer has meant that, 
on ethical grounds, primates are now subjected to preclinical testing with far less 
frequency.  Pigs in particular have been successfully employed in the modelling of APAP-
induced acute liver failure, and to trial interventions aiming to prolong survival or permit 
liver recovery (Lee et al. 2013) but the practicalities of working with such large mammals 
can make this work prohibitively complex and expensive.  The development of genetic 
modification methods over recent decades means that humanised rodents now hold the 
promise of a more faithful reflection of human drug metabolism (Patterson et al. 2012); 
and the zebrafish, although perhaps a less obvious choice for modelling human toxicity and 
adaptation, has been shown to be comparable to established rodent models (Driessen et 
al. 2015) 
Because of the complexity of the in vivo response to xenobiotics, the possibility of 
successfully recapitulating human liver adaptation in its global form in a single model 
seems remote.  However, judicious selection of model organisms alongside increasingly 
sophisticated in vitro and in silico models is allowing ever more authentic representation of 
the processes underpinning human physiology and pathophysiology.  
  
Chapter 5: Concluding Discussion 
137 
 
5.4.2. Relevance of model to human adaptation 
The in vivo models presented in this thesis perhaps most closely reflect repeated 
supratherapeutic APAP use in humans with vulnerability to toxicity.  Obviously, one would 
not expect to see such hepatocellular damage as the model showed at true therapeutic 
exposures in healthy humans, but many people have compromised liver function arising 
from a wide variety of causes.  These may be related to underlying organ pathology, for 
example, viral hepatitis; or due to malnutrition, alcoholism or co-ingestion of other 
pharmaceutical substances (Alhelail et al. 2011).  Additionally, accidental overexposure is 
common (Dart and Bailey 2007). 
In the clinic, the Rumack-Matthew nomogram is used as a means of predicting patients at 
significant risk of developing hepatotoxicity arising from a single APAP exposure (Rumack 
and Matthew 1975).  In cases of toxicity arising from repeat supratherapeutic ingestion, the 
Rumack-Matthew nomogram cannot be used; however, the likelihood of clinically 
significant hepatotoxicity is currently estimated based on AST, ALT, and serum APAP levels 
(O’Malley and O’Malley 2015).  Whilst use of this nomogram has undoubtedly prevented 
many patients progressing to liver failure in the aftermath of APAP overdose, it is limited by 
the assumption of equal susceptibility in all patients.   
Reports in the literature document an association between dental pain and increased risk 
of APAP poisoning through unintentional overexposure (Vogel et al. 2011).  The authors 
suggest that dental pain is likely to be both ongoing and increasing in severity if treatment 
is not sought, leading to longer-term and potentially escalating exposures to APAP.  They 
also point out the well-documented association between starvation and APAP toxicity, with 
particular regard to the limitations chronic toothache may place on food consumption.   
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Therapeutic exposures have also been shown to be toxic in some instances, though 
controversy exists.  Whilst a multicentre randomised study found no effect of therapeutic 
APAP in newly abstinent alcoholics over a three-day treatment (Kuffner et al. 2007), a case 
report of a female alcohol-dependent patient presenting with acute liver injury after taking 
APAP with therapeutic intent is highlighted (Manchanda et al. 2013).  Despite the 
limitations of case reporting, this publication is reviewed with interest because the APAP 
exposure described therein is perhaps more relevant to the issue of human vulnerability to 
toxicity.  The patient in question had taken therapeutic APAP (prescribed for neck pain) for 
one month prior to clinical intervention for liver injury, and again for a further two weeks 
with similar consequences despite warnings to avoid APAP.  Since APAP is routinely 
prescribed for management of ongoing mild to moderate pain, these durations of exposure 
are relevant when considering human toxicity arising from therapeutic APAP use.  The case 
also highlights the importance of communication between healthcare providers, as APAP 
was prescribed a second time despite known alcoholism and administration of treatment 
for APAP poisoning.   
Taking the work presented in this thesis forward, examining rodent blood for markers of 
adaptation, and then comparing findings to patient data and blood samples from clinical 
studies will assist in the translation of findings in rodent models to humans.  An improved 
understanding of the biomolecular signatures associated with both liver toxicity and 
adaptive and regenerative events, as has been contributed  to in some small capacity by 
the work presented in this thesis, will aid in the clinical management of not just binary 
acute/chronic toxicity admissions, but also the management of APAP medication in humans 
with vulnerability to toxicity.   
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5.4.3. Summary 
APAP poisoning, through intentional or accidental means, remains a significant public 
health problem.  An individual’s susceptibility to liver injury is influenced by both genetic 
and environmental risk factors.  It is therefore imperative that the mechanisms 
underpinning both the evolution of toxicity in the liver, and the defensive strategies the 
organ employs in response to chemical insult are characterised.   
The process of adaptation to repeated exposures of this model hepatotoxin is incredibly 
intricate and complex, and the work presented here barely scratches the surface of a 
breathtaking symphony of molecular activity.  The response is clearly not limited to 
proteins associated, even broadly, with drug metabolism, and there is a high degree of 
redundancy in the response.  It seems impossible to attribute adaptation to a single 
pathway or group of molecules – an appropriate biological characteristic since an 
organism’s survival can depend on it.  With sustained endeavours in this fascinating field, it 
is possible that, in years to come, fine manipulation of adaptive and regenerative processes 
in human patients will permit vastly improved outcomes for the types of people who are 
currently in danger of significant morbidity and mortality from not only APAP toxicity, but 
also by extension, many other types of liver injury.     
To adapt is to survive.  
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Supplementary Data 
Supplementary Table 1A:  iTRAQ-based proteomic comparison of liver proteins in vehicle 
control- and APAP-treated rats (24h timepoint). Proteins with expression that was different 
(raw P < 0.05) between control and APAP-treated rats at 24h are listed.  Mean expression 
values relative to a common pool are given for n=4 animals. Proteins are ordered according 
to the ratio between the 24h and control groups (lowest to highest) such that proteins with 
expression that was most markedly reduced at 24h appear at the top of the list. 
aAverage number of peptides used for quantification across the four individual iTRAQ runs.  
bUncorrected raw p value. 
 
Uniprot 
Accession   
Vehicle control 
 
24h 
 
24h/ctrl 
 Name  Peptidesa Mean SD   Mean SD   Ratio p valueb 
Proteins reduced at 24h          
P49890 Estrogen sulfotransferase, 
isoform 6 
18 3.22 0.91  0.14 0.07  0.04 <0.001 
P05369 Farnesyl pyrophosphate 
synthase 
27 1.5 0.39  0.62 0.21  0.42 0.009 
O35760 Isopentenyl-diphosphate 
Delta-isomerase 1 
4 1.38 0.41  0.69 0.27  0.5 0.035 
O88813 Long-chain-fatty-acid--CoA 
ligase 5 
28 1.89 0.67  0.97 0.31  0.52 0.036 
Q9ES38 Bile acyl-CoA synthetase 26 2.8 0.86  1.45 0.44  0.52 0.022 
P52847 Sulfotransferase family 
cytosolic 1B member 1 
16 1.97 0.42  1.06 0.43  0.54 0.025 
P36510 UDP-
glucuronosyltransferase 
2A1 
3 1.35 0.34  0.75 0.29  0.56 0.033 
P63174 60S ribosomal protein L38 5 0.96 0.24  0.56 0.24  0.58 0.041 
Q9WUS0 Adenylate kinase 
isoenzyme 4, 
mitochondrial 
14 1.38 0.19  0.81 0.26  0.59 0.024 
Q4V8F9 Hydroxysteroid 
dehydrogenase-like 
protein 2 
9 0.95 0.24  0.56 0.16  0.59 0.041 
P15083 Polymeric immunoglobulin 
receptor 
16 1.2 0.24  0.73 0.1  0.61 0.007 
Q6AXX6 Redox-regulatory protein 
PAMM 
8 1.54 0.33  0.94 0.1  0.61 0.01 
P16970 ATP-binding cassette sub-
family D member 3 
13 1.69 0.46  1.03 0.07  0.61 0.018 
P02692 Fatty acid-binding protein, 
liver 
69 1.94 0.49  1.18 0.12  0.61 0.017 
P62271 40S ribosomal protein S18 13 1.05 0.27  0.66 0.2  0.63 0.043 
P09527 Ras-related protein Rab-7a 11 0.96 0.11  0.61 0.09  0.63 0.003 
P00173 Cytochrome b5 31 1.37 0.2  0.88 0.21  0.64 0.018 
P27605 Hypoxanthine-guanine 
phosphoribosyltransferase 
12 1.35 0.2  0.87 0.18  0.64 0.012 
Q7TQM4 Sterol O-acyltransferase 2 5 1.32 0.32  0.87 0.15  0.66 0.034 
P29411 GTP:AMP 
phosphotransferase, 
mitochondrial 
7 1.41 0.24  0.94 0.28  0.66 0.049 
P54921 Alpha-soluble NSF 
attachment protein 
10 1.22 0.29  0.81 0.07  0.66 0.023 
P10867 L-gulonolactone oxidase 18 2 0.36  1.35 0.29  0.67 0.03 
P97612 Fatty-acid amide 
hydrolase 1 
26 1.67 0.31  1.15 0.2  0.69 0.033 
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P57093 Phytanoyl-CoA 
dioxygenase, peroxisomal 
10 1.36 0.22  0.95 0.21  0.7 0.04 
Q5XIM9 T-complex protein 1 
subunit beta 
31 0.97 0.08  0.68 0.09  0.7 0.004 
P11507 Sarcoplasmic/endoplasmic 
reticulum calcium ATPase 
2 
30 1.01 0.1  0.75 0.09  0.74 0.007 
P50237 Sulfotransferase 1C1 27 1.95 0.15  1.44 0.3  0.74 0.029 
Q9WUW9 Sulfotransferase 1C2A 5 1.2 0.17  0.89 0.09  0.74 0.015 
P04646 60S ribosomal protein 
L35a 
3 1.04 0.06  0.78 0.16  0.75 0.041 
O88941 Mannosyl-oligosaccharide 
glucosidase 
12 1.12 0.13  0.85 0.08  0.76 0.008 
Q68FP2 Serum 
paraoxonase/lactonase 3 
16 1.43 0.1  1.09 0.15  0.76 0.011 
P29314 40S ribosomal protein S9 13 0.86 0.1  0.65 0.05  0.76 0.009 
P06214 Delta-aminolevulinic acid 
dehydratase 
35 1.5 0.26  1.15 0.08  0.76 0.027 
P97562 Peroxisomal acyl-
coenzyme A oxidase 2 
38 1.45 0.15  1.13 0.15  0.78 0.029 
Q03336 Regucalcin 45 1.98 0.18  1.54 0.25  0.78 0.03 
P85108 Tubulin beta-2A chain 72 1.11 0.05  0.87 0.06  0.78 0.001 
P18445 60S ribosomal protein 
L27a 
9 0.86 0.08  0.68 0.08  0.79 0.023 
Q5XI32 F-actin-capping protein 
subunit beta 
11 1.03 0.11  0.82 0.12  0.8 0.045 
P61107 Ras-related protein Rab-
14 
9 1.11 0.14  0.89 0.04  0.8 0.016 
Q497B0 Omega-amidase NIT2 34 1.58 0.09  1.28 0.13  0.81 0.013 
P41562 Isocitrate dehydrogenase 
[NADP] cytoplasmic 
59 1.21 0.08  1 0.07  0.82 0.007 
Q920J4 Thioredoxin-like protein 1 8 1.12 0.11  0.94 0.06  0.84 0.026 
Q68FS4 Cytosol aminopeptidase 53 1.52 0.14  1.33 0.06  0.88 0.044 
Proteins increased at 24h         
 
P08541 UDP-
glucuronosyltransferase 
2B2 
37 0.46 0.87  2.34 0.85  5.05 0.02 
P02091 Hemoglobin subunit 
beta-1 
179 0.44 0.2  2.03 1.54  4.58 0.029 
P38918 Aflatoxin B1 aldehyde 
reductase member 3 
42 0.2 0.17  0.69 0.31  3.4 0.024 
P13221 Aspartate 
aminotransferase, 
cytoplasmic 
30 0.51 0.2  1.35 0.49  2.66 0.01 
Q62651 Delta(3,5)-Delta(2,4)-
dienoyl-CoA isomerase, 
mitochondrial 
17 0.62 0.2  1.59 0.44  2.55 0.005 
O70199 UDP-glucose 6-
dehydrogenase 
38 0.32 0.1  0.77 0.16  2.42 0.003 
P06866 Haptoglobin 21 0.33 0.15  0.77 0.28  2.35 0.033 
O09171 Betaine--homocysteine 
S-methyltransferase 1 
123 1.06 0.39  2.49 1.05  2.35 0.028 
P09034 Argininosuccinate 
synthase 
95 0.7 0.51  1.62 0.48  2.32 0.045 
P08649 Complement C4 30 0.52 0.34  1.2 0.15  2.31 0.046 
P23562 Band 3 anion transport 
protein 
17 0.9 0.23  2.02 0.98  2.24 0.033 
P27139 Carbonic anhydrase 2 18 0.68 0.32  1.52 0.49  2.23 0.032 
P20059 Hemopexin 24 0.45 0.12  0.98 0.25  2.16 0.007 
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P13255 Glycine N-
methyltransferase 
37 0.86 0.37  1.83 0.71  2.14 0.044 
Q68FT5 Betaine--homocysteine 
S-methyltransferase 2 
82 0.99 0.45  2.08 0.57  2.1 0.028 
P48508 Glutamate--cysteine 
ligase regulatory subunit 
9 0.68 0.26  1.39 0.4  2.05 0.041 
P05182 Cytochrome P450 2E1 29 0.89 0.14  1.74 0.48  1.96 0.006 
Q6URK4 Heterogeneous nuclear 
ribonucleoprotein A3 
20 0.56 0.07  0.99 0.29  1.76 0.027 
Q63416 Inter-alpha-trypsin 
inhibitor heavy chain H3 
10 0.81 0.25  1.31 0.25  1.62 0.036 
P20817 Cytochrome P450 4A14 23 1.06 0.19  1.71 0.45  1.61 0.03 
Q58FK9 Kynurenine--
oxoglutarate 
transaminase 3 
23 1.01 0.27  1.61 0.18  1.59 0.011 
P13635 Ceruloplasmin 19 0.67 0.2  1.05 0.07  1.57 0.031 
P25409 Alanine 
aminotransferase 1 
19 0.85 0.09  1.13 0.14  1.32 0.018 
Q63584 Transmembrane emp24 
domain-containing 
protein 10 
11 0.9 0.07  1.17 0.21  1.31 0.038 
P38062 Methionine 
aminopeptidase 2 
2 0.87 0.12  1.11 0.16  1.28 0.049 
P21571 ATP synthase-coupling 
factor 6, mitochondrial 
13 0.93 0.09  1.17 0.17  1.25 0.045 
P85834 Elongation factor Tu, 
mitochondrial 
26 1.01 0.12  1.23 0.13  1.22 0.045 
P63086 Mitogen-activated 
protein kinase 1 
5 0.83 0.08  1 0.11  1.21 0.041 
Q9Z1W6 Protein LYRIC 7 1.17 0.14  1.38 0.06  1.18 0.037 
P02770 Serum albumin 193 0.97 0.04  1.1 0.08  1.13 0.026 
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Supplementary Table 1B:  iTRAQ-based proteomic comparison of liver proteins in vehicle 
control- and APAP-treated rats (48h timepoint). Proteins with expression that was different 
(raw P < 0.05) between control and APAP-treated rats at 48h are listed.  Mean expression 
values relative to a common pool are given for n=4 animals. Proteins are ordered according 
to the ratio between the 48h and control groups (lowest to highest) such that proteins with 
expression that was most markedly reduced at 48h appear at the top of the list. 
aAverage number of peptides used for quantification across the four individual iTRAQ runs.  
bUncorrected raw p value. 
 
 
 
Uniprot 
Accession 
 
 
Name 
 
 
Peptidesa 
Vehicle control 
 
48h 
 
48h/ctrl 
p 
valueb Mean SD Mean SD Ratio 
Proteins reduced at 48h          
P49890 Estrogen 
sulfotransferase, isoform 
6 
18 3.22 0.91  0.27 0.17  0.08 0.001 
P05183 Cytochrome P450 3A2 15 2.49 0.97  0.29 0.23  0.12 0.001 
P08683 Cytochrome P450 2C11 51 2.53 0.52  0.38 0.23  0.15 0.001 
P09606 Glutamine synthetase 17 2.73 0.78  0.47 0.3  0.17 0.011 
P08010 Glutathione S-transferase 
Mu 2 
70 1.42 0.86  0.31 0.15  0.22 0.022 
Q9ES38 Bile acyl-CoA synthetase 26 2.8 0.86  0.62 0.24  0.22 0.001 
P02761 Major urinary protein 22 2.27 0.42  0.52 0.23  0.23 <0.001 
P10867 L-gulonolactone oxidase 18 2 0.36  0.48 0.09  0.24 <0.001 
P16232 Corticosteroid 11-beta-
dehydrogenase isozyme 
1 
21 2.55 0.83  0.62 0.31  0.24 0.006 
P02692 Fatty acid-binding 
protein, liver 
69 1.94 0.49  0.48 0.32  0.25 0.003 
P52847 Sulfotransferase family 
cytosolic 1B member 1 
16 1.97 0.42  0.51 0.15  0.26 <0.001 
Q8VHE9 All-trans-retinol 13,14-
reductase 
10 1.54 0.84  0.4 0.2  0.26 0.009 
P55051 Fatty acid-binding 
protein, brain 
9 1.61 0.57  0.42 0.47  0.26 0.037 
P24470 Cytochrome P450 2C23 25 1.53 0.32  0.41 0.23  0.26 0.004 
P13107 Cytochrome P450 2B3 27 1.48 0.55  0.4 0.52  0.27 0.033 
P18163 Long-chain-fatty-acid--
CoA ligase 1 
78 1.54 0.13  0.41 0.16  0.27 0.001 
P50237 Sulfotransferase 1C1 27 1.95 0.15  0.53 0.2  0.27 <0.001 
P36365 Dimethylaniline 
monooxygenase [N-
oxide-forming] 1 
13 2.34 0.94  0.64 0.17  0.27 0.002 
Q03336 Regucalcin 45 1.98 0.18  0.55 0.06  0.28 <0.001 
O88813 Long-chain-fatty-acid--
CoA ligase 5 
28 1.89 0.67  0.53 0.3  0.28 0.007 
Q64638 UDP-
glucuronosyltransferase 
1-5 
25 3.79 1.58  1.08 0.77  0.28 0.009 
P30839 Fatty aldehyde 
dehydrogenase 
36 1.74 0.55  0.5 0.08  0.29 0.001 
P17988 Sulfotransferase 1A1 30 1.99 0.34  0.58 0.09  0.29 <0.001 
P05178 Cytochrome P450 2C6 20 1.67 0.62  0.5 0.24  0.3 0.009 
P14141 Carbonic anhydrase 3 70 1.99 1.3  0.59 0.26  0.3 0.046 
P09811 Glycogen phosphorylase, 
liver form 
76 1.4 0.26  0.43 0.13  0.31 0.001 
P00502 Glutathione S-transferase 51 1.57 1.21  0.5 0.35  0.32 0.05 
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alpha-1 
P12928 Pyruvate kinase isozymes 
R/L 
61 1.64 0.53  0.55 0.19  0.34 0.003 
Q64232 Very-long-chain enoyl-
CoA reductase 
35 1.76 0.41  0.6 0.22  0.34 0.003 
O35077 Glycerol-3-phosphate 
dehydrogenase [NAD+], 
cytoplasmic 
39 1.45 0.42  0.51 0.07  0.35 0.001 
Q64611 Cysteine sulfinic acid 
decarboxylase 
25 1.81 0.7  0.64 0.15  0.35 0.003 
P05182 Cytochrome P450 2E1 29 0.89 0.14  0.32 0.17  0.36 0.013 
P15865 Histone H1.4 19 1.04 0.35  0.38 0.12  0.36 0.008 
P31210 3-oxo-5-beta-steroid 4-
dehydrogenase 
51 1.07 0.22  0.39 0.3  0.36 0.014 
Q5U2Q3 Ester hydrolase C11orf54 
homolog 
12 2 0.36  0.74 0.38  0.37 0.006 
Q497B0 Omega-amidase NIT2 34 1.58 0.09  0.59 0.13  0.37 <0.001 
P04799 Cytochrome P450 1A2 7 1.32 0.36  0.49 0.48  0.37 0.024 
Q6AYT9 Acyl-coenzyme A 
synthetase ACSM5, 
mitochondrial 
14 1.53 0.3  0.57 0.17  0.37 0.001 
Q07071 Glucokinase regulatory 
protein 
27 1.71 0.64  0.65 0.23  0.38 0.015 
P43278 Histone H1.0 4 1.51 0.31  0.58 0.19  0.38 0.003 
P16638 ATP-citrate synthase 65 1.93 0.71  0.74 0.12  0.38 0.003 
Q4KLP0 Probable 2-oxoglutarate 
dehydrogenase E1 
component DHKTD1, 
mitochondrial 
35 1.59 0.56  0.61 0.22  0.39 0.006 
P15149 Cytochrome P450 2A2 35 1.28 0.09  0.5 0.07  0.39 <0.001 
P97612 Fatty-acid amide 
hydrolase 1 
26 1.67 0.31  0.65 0.19  0.39 0.002 
P18757 Cystathionine gamma-
lyase 
37 1.4 0.63  0.55 0.21  0.39 0.021 
P19112 Fructose-1,6-
bisphosphatase 1 
72 1.71 0.38  0.67 0.16  0.39 0.002 
Q5PPL3 Sterol-4-alpha-
carboxylate 3-
dehydrogenase, 
decarboxylating 
20 1.74 0.46  0.69 0.25  0.4 0.008 
P05545 Serine protease inhibitor 
A3K 
34 1.5 0.5  0.6 0.28  0.4 0.016 
P00884 Fructose-bisphosphate 
aldolase B 
129 1.31 0.33  0.52 0.16  0.4 0.005 
Q64550 UDP-
glucuronosyltransferase 
1-1 
29 1.54 0.7  0.62 0.21  0.4 0.016 
P29147 D-beta-hydroxybutyrate 
dehydrogenase, 
mitochondrial 
42 1.4 0.23  0.56 0.18  0.4 0.002 
P33274 Cytochrome P450 4F1 14 1.35 0.35  0.55 0.28  0.41 0.029 
P27867 Sorbitol dehydrogenase 26 1.21 0.44  0.5 0.1  0.41 0.011 
Q02253 Methylmalonate-
semialdehyde 
dehydrogenase 
[acylating], mitochondrial 
124 1.22 0.24  0.51 0.06  0.42 <0.001 
Q9Z339 Glutathione S-transferase 
omega-1 
10 1.42 0.4  0.59 0.32  0.42 0.025 
P55159 Serum 
paraoxonase/arylesteras
e 1 
17 1.68 0.55  0.71 0.06  0.42 0.003 
P17764 Acetyl-CoA 60 1.28 0.07  0.54 0.26  0.42 0.014 
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acetyltransferase, 
mitochondrial 
Q63357 Myosin-Id 93 1.01 0.12  0.43 0.22  0.42 0.014 
Q4KLZ6 Bifunctional ATP-
dependent 
dihydroxyacetone 
kinase/FAD-AMP lyase 
(cyclizing) 
64 1.7 0.39  0.72 0.23  0.43 0.005 
Q6AYT0 Quinone oxidoreductase 9 1.37 0.36  0.59 0.21  0.43 0.017 
Q07523 Hydroxyacid oxidase 2 8 1.99 0.34  0.87 0.24  0.44 0.002 
P16303 Carboxylesterase 3 33 1.85 0.85  0.81 0.19  0.44 0.03 
P22791 Hydroxymethylglutaryl-
CoA synthase, 
mitochondrial 
106 1.46 0.4  0.65 0.26  0.44 0.01 
Q62730 Estradiol 17-beta-
dehydrogenase 2 
17 1.72 0.47  0.76 0.36  0.44 0.034 
P13803 Electron transfer 
flavoprotein subunit 
alpha, mitochondrial 
50 1.29 0.23  0.59 0.25  0.46 0.011 
Q63150 Dihydropyrimidinase 29 1.41 0.17  0.64 0.32  0.46 0.02 
P24329 Thiosulfate 
sulfurtransferase 
41 1.33 0.2  0.61 0.08  0.46 <0.001 
P46953 3-hydroxyanthranilate 
3,4-dioxygenase 
25 1.42 0.4  0.66 0.06  0.47 0.003 
Q6DGG1 Alpha/beta hydrolase 
domain-containing 
protein 14B 
12 1.36 0.25  0.64 0.14  0.47 0.002 
P57113 Maleylacetoacetate 
isomerase 
36 1.58 0.34  0.74 0.14  0.47 0.002 
P97532 3-mercaptopyruvate 
sulfurtransferase 
23 1.27 0.28  0.61 0.09  0.48 0.001 
Q5FVQ4 Malectin 8 1.39 0.58  0.67 0.31  0.48 0.043 
P52759 Ribonuclease UK114 51 1.29 0.41  0.62 0.23  0.48 0.035 
P02696 Retinol-binding protein 1 13 1.29 0.23  0.62 0.15  0.48 0.003 
P22734 Catechol O-
methyltransferase 
46 1.49 0.39  0.72 0.22  0.48 0.009 
P08011 Microsomal glutathione 
S-transferase 1 
25 1.57 0.62  0.76 0.34  0.48 0.044 
A0JPQ8 Alkylglycerol 
monooxygenase 
6 1.64 0.2  0.8 0.12  0.49 <0.001 
Q498D5 Regulator of microtubule 
dynamics protein 2 
8 1.34 0.14  0.65 0.21  0.49 0.003 
P30713 Glutathione S-transferase 
theta-2 
19 1.34 0.31  0.65 0.1  0.49 0.002 
Q9QZX8 Solute carrier organic 
anion transporter family 
member 1B2 
3 1.36 0.4  0.67 0.19  0.49 0.009 
Q7TP52 Carboxymethylenebuten
olidase homolog 
16 1.79 0.45  0.88 0.32  0.49 0.018 
P27605 Hypoxanthine-guanine 
phosphoribosyltransferas
e 
12 1.35 0.2  0.66 0.12  0.49 0.001 
P25093 Fumarylacetoacetase 48 1.45 0.12  0.71 0.12  0.49 <0.001 
Q02974 Ketohexokinase 25 1.56 0.28  0.77 0.07  0.5 <0.001 
Q5BK17 Iodotyrosine 
dehalogenase 1 
4 1.75 0.28  0.87 0.22  0.5 0.004 
P57093 Phytanoyl-CoA 
dioxygenase, 
peroxisomal 
10 1.36 0.22  0.68 0.18  0.5 0.004 
Q66HG4 Aldose 1-epimerase 5 1.37 0.18  0.7 0.27  0.51 0.008 
P46720 Solute carrier organic 4 1.41 0.3  0.72 0.1  0.51 0.003 
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anion transporter family 
member 1A1 
Q63060 Glycerol kinase 20 1.68 0.28  0.87 0.19  0.51 0.002 
Q68FP2 Serum 
paraoxonase/lactonase 3 
16 1.43 0.1  0.74 0.11  0.51 <0.001 
P10760 Adenosylhomocysteinase 54 1.29 0.2  0.67 0.25  0.51 0.011 
P23680 Serum amyloid P-
component 
4 1.61 0.24  0.83 0.08  0.52 <0.001 
P23457 3-alpha-hydroxysteroid 
dehydrogenase 
48 1.51 0.36  0.78 0.33  0.52 0.048 
P10860 Glutamate 
dehydrogenase 1, 
mitochondrial 
118 1.63 0.34  0.84 0.15  0.52 0.005 
Q64581 Cytochrome P450 3A18 8 1.5 0.57  0.78 0.17  0.52 0.019 
P06214 Delta-aminolevulinic acid 
dehydratase 
35 1.5 0.26  0.78 0.14  0.52 0.002 
B0BNE5 S-formylglutathione 
hydrolase 
23 1.32 0.33  0.69 0.25  0.52 0.02 
Q562C4 Methyltransferase-like 
protein 7B 
8 1.63 0.7  0.85 0.17  0.52 0.028 
P08461 Dihydrolipoyllysine-
residue acetyltransferase 
component of pyruvate 
dehydrogenase complex, 
mitochondrial 
11 1.13 0.26  0.59 0.06  0.52 0.005 
P41562 Isocitrate dehydrogenase 
[NADP] cytoplasmic 
59 1.21 0.08  0.63 0.15  0.52 0.002 
Q63270 Cytoplasmic aconitate 
hydratase 
36 1.21 0.2  0.64 0.21  0.52 0.01 
P70712 Kynureninase 19 1.41 0.32  0.74 0.13  0.52 0.005 
Q5I0M2 Nicotinate-nucleotide 
pyrophosphorylase 
[carboxylating] 
11 1.28 0.42  0.67 0.27  0.53 0.041 
P62959 Histidine triad 
nucleotide-binding 
protein 1 
8 1.59 0.36  0.84 0.2  0.53 0.008 
Q9WUS0 Adenylate kinase 
isoenzyme 4, 
mitochondrial 
14 1.38 0.19  0.73 0.38  0.53 0.026 
O89000 Dihydropyrimidine 
dehydrogenase [NADP+] 
12 1.36 0.32  0.72 0.32  0.53 0.03 
P00173 Cytochrome b5 31 1.37 0.2  0.73 0.3  0.53 0.02 
P10868 Guanidinoacetate N-
methyltransferase 
16 1.58 0.51  0.85 0.15  0.53 0.018 
Q6P6R2 Dihydrolipoyl 
dehydrogenase, 
mitochondrial 
25 1.16 0.23  0.62 0.23  0.54 0.023 
P11915 Non-specific lipid-
transfer protein 
31 1.23 0.23  0.66 0.31  0.54 0.049 
Q03248 Beta-ureidopropionase 30 1.21 0.25  0.66 0.11  0.54 0.005 
P11884 Aldehyde 
dehydrogenase, 
mitochondrial 
98 1.17 0.24  0.64 0.16  0.55 0.011 
P04762 Catalase 160 1.35 0.36  0.74 0.27  0.55 0.038 
P0C2X9 Delta-1-pyrroline-5-
carboxylate 
dehydrogenase, 
mitochondrial 
43 1.3 0.1  0.71 0.09  0.55 <0.001 
P11348 Dihydropteridine 
reductase 
27 1.29 0.44  0.71 0.15  0.55 0.039 
Q9WVK7 Hydroxyacyl-coenzyme A 
dehydrogenase, 
54 1.22 0.31  0.68 0.18  0.55 0.026 
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mitochondrial 
P10634 Cytochrome P450 2D26 57 1.53 0.31  0.85 0.25  0.56 0.022 
P12938 Cytochrome P450 2D3 46 1.52 0.33  0.85 0.17  0.56 0.01 
P38652 Phosphoglucomutase-1 58 1.05 0.17  0.59 0.13  0.56 0.007 
P51869 Cytochrome P450 4F4 14 1.42 0.51  0.8 0.05  0.56 0.038 
P19643 Amine oxidase [flavin-
containing] B 
29 1.3 0.32  0.74 0.03  0.56 0.003 
Q5FVQ8 NLR family member X1 9 1.14 0.25  0.65 0.26  0.57 0.046 
P84817 Mitochondrial fission 1 
protein 
2 1.28 0.25  0.74 0.09  0.58 0.004 
P07953 6-phosphofructo-2-
kinase/fructose-2,6-
bisphosphatase 1 
13 1.47 0.11  0.85 0.09  0.58 <0.001 
P97524 Very long-chain acyl-CoA 
synthetase 
34 1.53 0.35  0.89 0.25  0.58 0.021 
P07896 Peroxisomal bifunctional 
enzyme 
45 1.24 0.32  0.72 0.22  0.58 0.038 
Q5XIC0 Enoyl-CoA delta 
isomerase 2, 
mitochondrial 
14 1.2 0.24  0.71 0.24  0.59 0.046 
Q5HZY2 GTP-binding protein 
SAR1b 
13 1.22 0.23  0.72 0.11  0.59 0.004 
Q0VGK3 Glycerate kinase 16 1.22 0.15  0.72 0.29  0.59 0.043 
P38718 Mitochondrial pyruvate 
carrier 2/Brain protein 44 
3 1.35 0.43  0.79 0.18  0.59 0.041 
P16617 Phosphoglycerate kinase 
1 
54 1.09 0.24  0.65 0.19  0.59 0.031 
P00481 Ornithine 
carbamoyltransferase, 
mitochondrial 
57 1.3 0.19  0.77 0.12  0.59 0.003 
P81155 Voltage-dependent 
anion-selective channel 
protein 2 
10 1.09 0.22  0.65 0.24  0.59 0.039 
Q68FS4 Cytosol aminopeptidase 53 1.52 0.14  0.9 0.19  0.59 0.003 
P48500 Triosephosphate 
isomerase 
33 1.17 0.32  0.69 0.22  0.59 0.04 
Q68FU3 Electron transfer 
flavoprotein subunit beta 
29 1.17 0.22  0.7 0.2  0.6 0.025 
P00507 Aspartate 
aminotransferase, 
mitochondrial 
73 1.07 0.15  0.64 0.19  0.6 0.016 
Q6UPE1 Electron transfer 
flavoprotein-ubiquinone 
oxidoreductase, 
mitochondrial 
36 1.12 0.12  0.67 0.07  0.6 0.001 
P51635 Alcohol dehydrogenase 
[NADP+] 
24 1.25 0.27  0.75 0.15  0.6 0.014 
P27364 3 beta-hydroxysteroid 
dehydrogenase type 5 
19 1.41 0.31  0.85 0.06  0.6 0.004 
Q6P6V0 Glucose-6-phosphate 
isomerase 
32 1.23 0.31  0.74 0.15  0.6 0.025 
Q9QZH8 Arylacetamide 
deacetylase 
6 1.64 0.55  0.99 0.15  0.6 0.034 
Q6AXX6 Redox-regulatory protein 
PAMM 
8 1.54 0.33  0.93 0.25  0.6 0.026 
P56574 Isocitrate dehydrogenase 
[NADP], mitochondrial 
27 1.1 0.24  0.67 0.18  0.61 0.037 
P49432 Pyruvate dehydrogenase 
E1 component subunit 
beta, mitochondrial 
16 1.2 0.3  0.73 0.2  0.61 0.034 
Q6I7R3 Isochorismatase domain-
containing protein 1 
10 1.44 0.23  0.87 0.12  0.61 0.005 
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P08503 Medium-chain specific 
acyl-CoA dehydrogenase, 
mitochondrial 
26 1.49 0.32  0.91 0.22  0.61 0.017 
P30904 Macrophage migration 
inhibitory factor 
22 1.31 0.21  0.8 0.19  0.61 0.018 
P41034 Alpha-tocopherol 
transfer protein 
16 1.28 0.15  0.78 0.03  0.61 <0.001 
Q562C9 1,2-dihydroxy-3-keto-5-
methylthiopentene 
dioxygenase 
8 1.34 0.34  0.82 0.16  0.61 0.025 
P31044 Phosphatidylethanolamin
e-binding protein 1 
22 1.26 0.27  0.78 0.15  0.62 0.018 
P07153 Dolichyl-
diphosphooligosaccharid
e--protein 
glycosyltransferase 
subunit 1 
56 1.08 0.27  0.67 0.21  0.62 0.049 
P05369 Farnesyl pyrophosphate 
synthase 
27 1.5 0.39  0.93 0.14  0.62 0.024 
P35738 2-oxoisovalerate 
dehydrogenase subunit 
beta, mitochondrial 
13 1.23 0.12  0.76 0.23  0.62 0.016 
Q5M875 17-beta-hydroxysteroid 
dehydrogenase 13 
22 1.09 0.17  0.68 0.1  0.62 0.005 
P50137 Transketolase 80 1.15 0.2  0.72 0.16  0.62 0.016 
P11951 Cytochrome c oxidase 
subunit 6C-2 
4 1.03 0.2  0.64 0.26  0.63 0.05 
Q920P0 L-xylulose reductase 12 1.44 0.45  0.91 0.05  0.63 0.028 
P20070 NADH-cytochrome b5 
reductase 3 
26 1.62 0.42  1.02 0.32  0.63 0.043 
P51650 Succinate-semialdehyde 
dehydrogenase, 
mitochondrial 
10 1.21 0.32  0.76 0.06  0.63 0.019 
Q63276 Bile acid-CoA:amino acid 
N-acyltransferase 
57 1.25 0.27  0.79 0.2  0.63 0.026 
Q5PQT3 Glycine N-acyltransferase 22 1.05 0.24  0.67 0.06  0.64 0.016 
Q9QYU4 Thiomorpholine-
carboxylate 
dehydrogenase 
9 1.31 0.25  0.84 0.17  0.64 0.017 
P25235 Dolichyl-
diphosphooligosaccharid
e--protein 
glycosyltransferase 
subunit 2 
46 1.18 0.28  0.76 0.15  0.64 0.028 
P85971 6-
phosphogluconolactonas
e 
12 1.56 0.23  1.02 0.1  0.65 0.003 
P97562 Peroxisomal acyl-
coenzyme A oxidase 2 
38 1.45 0.15  0.94 0.22  0.65 0.021 
P29266 3-hydroxyisobutyrate 
dehydrogenase, 
mitochondrial 
23 1.21 0.17  0.79 0.15  0.65 0.01 
Q1HCL7 NAD kinase domain-
containing protein 1 
17 1.25 0.18  0.82 0.05  0.66 0.002 
Q923K9 APOBEC1 
complementation factor 
10 1.09 0.26  0.72 0.16  0.66 0.04 
P18297 Sepiapterin reductase 11 1.36 0.27  0.9 0.17  0.66 0.017 
P32089 Tricarboxylate transport 
protein, mitochondrial 
11 1.11 0.09  0.74 0.17  0.67 0.015 
Q6P7R8 Estradiol 17-beta-
dehydrogenase 12 
6 1.15 0.2  0.77 0.1  0.67 0.013 
P07633 Propionyl-CoA 
carboxylase beta chain, 
23 1.21 0.18  0.81 0.17  0.67 0.017 
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mitochondrial 
P85973 Purine nucleoside 
phosphorylase 
41 1.12 0.2  0.75 0.12  0.67 0.016 
P15999 ATP synthase subunit 
alpha, mitochondrial 
122 1.05 0.08  0.71 0.16  0.68 0.012 
O88767 Protein DJ-1 16 1.21 0.2  0.82 0.16  0.68 0.025 
P14942 Glutathione S-transferase 
alpha-4 
12 0.99 0.12  0.67 0.12  0.68 0.008 
Q9JM53 Apoptosis-inducing factor 
1, mitochondrial 
27 1.24 0.13  0.85 0.2  0.69 0.026 
P07872 Peroxisomal acyl-
coenzyme A oxidase 1 
42 1.33 0.25  0.92 0.17  0.7 0.046 
Q923M1 Mitochondrial peptide 
methionine sulfoxide 
reductase 
3 1.19 0.24  0.84 0.12  0.7 0.024 
Q6AYQ8 Acylpyruvase FAHD1, 
mitochondrial 
10 1.15 0.22  0.81 0.11  0.71 0.039 
Q6P7Q4 Lactoylglutathione lyase 8 1.19 0.21  0.85 0.16  0.71 0.046 
Q5XIH7 Prohibitin-2 29 1.66 0.28  1.21 0.24  0.73 0.046 
P52873 Pyruvate carboxylase, 
mitochondrial 
134 1.16 0.13  0.86 0.14  0.74 0.018 
Q5M7T9 Threonine synthase-like 2 6 1.26 0.23  0.94 0.11  0.74 0.037 
P12336 Solute carrier family 2, 
facilitated glucose 
transporter member 2 
5 1.16 0.21  0.86 0.09  0.74 0.038 
P46462 Transitional endoplasmic 
reticulum ATPase 
71 1.14 0.18  0.85 0.11  0.75 0.034 
Q64380 Sarcosine 
dehydrogenase, 
mitochondrial 
41 1.28 0.19  0.96 0.15  0.75 0.047 
Q8CG45 Aflatoxin B1 aldehyde 
reductase member 2 
22 1.11 0.05  0.84 0.07  0.75 0.001 
P97700 Mitochondrial 2-
oxoglutarate/malate 
carrier protein 
7 1.15 0.19  0.87 0.05  0.75 0.016 
Q68FT1 Ubiquinone biosynthesis 
protein COQ9, 
mitochondrial 
9 1.01 0.06  0.77 0.08  0.76 0.004 
Q7TMA5 Apolipoprotein B-100 29 1.09 0.21  0.83 0.08  0.76 0.047 
P97519 Hydroxymethylglutaryl-
CoA lyase, mitochondrial 
14 0.99 0.09  0.77 0.14  0.78 0.036 
Q641Y0 Dolichyl-
diphosphooligosaccharid
e--protein 
glycosyltransferase 48 
kDa subunit 
16 1.18 0.12  0.92 0.13  0.78 0.032 
P80067 Dipeptidyl peptidase 1 12 1.09 0.19  0.86 0.04  0.79 0.039 
Q9JLA3 UDP-
glucose:glycoprotein 
glucosyltransferase 1 
28 0.97 0.06  0.78 0.06  0.8 0.003 
P26453 Basigin 7 1.15 0.14  0.96 0  0.84 0.028 
Q05096 Myosin-Ib 94 1.03 0.04  0.87 0.08  0.84 0.013 
P84903 Stromal interaction 
molecule 1 
5 1.03 0.03  0.91 0.09  0.88 0.047 
Proteins increased at 48h 
         
P42930 Heat shock protein beta-
1 
10 0.12 0.11  2.87 1.41  23.49 <0.001 
Q07439 Heat shock 70 kDa 
protein 1A/1B 
56 0.21 0.2  2.77 1.5  13.39 0.002 
P38918 Aflatoxin B1 aldehyde 42 0.2 0.17  1.55 0.68  7.6 0.003 
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reductase member 3 
P01048 T-kininogen 1 15 0.25 0.21  1.83 0.91  7.21 0.01 
P02764 Alpha-1-acid glycoprotein 6 0.31 0.37  1.83 0.22  5.87 0.017 
P06866 Haptoglobin 21 0.33 0.15  1.74 0.81  5.26 0.003 
P82995 Heat shock protein HSP 
90-alpha 
74 0.47 0.29  2 0.82  4.25 0.006 
P05370 Glucose-6-phosphate 1-
dehydrogenase 
15 0.38 0.22  1.63 0.36  4.24 0.004 
O70199 UDP-glucose 6-
dehydrogenase 
38 0.32 0.1  1.28 0.34  4.04 0.001 
Q66HA8 Heat shock protein 105 
kDa 
23 0.47 0.24  1.72 0.21  3.64 0.004 
P02680 Fibrinogen gamma chain 17 0.54 0.24  1.86 0.65  3.43 0.008 
P20059 Hemopexin 24 0.45 0.12  1.53 0.73  3.37 0.005 
P06762 Heme oxygenase 1 5 0.57 0.28  1.82 0.76  3.21 0.027 
P06399 Fibrinogen alpha chain 39 0.5 0.29  1.58 0.31  3.18 0.019 
P09006 Serine protease inhibitor 
A3N 
19 0.61 0.19  1.82 0.67  3 0.003 
P04961 Proliferating cell nuclear 
antigen 
4 0.41 0.07  1.21 0.37  2.97 0.001 
O89049 Thioredoxin reductase 1, 
cytoplasmic 
17 0.42 0.29  1.19 0.36  2.87 0.031 
P13383 Nucleolin 21 0.47 0.15  1.33 0.13  2.87 <0.001 
P11980 Pyruvate kinase isozymes 
M1/M2 
19 0.44 0.09  1.23 0.38  2.81 0.002 
P17475 Alpha-1-antiproteinase 39 0.47 0.18  1.31 0.57  2.77 0.012 
P62982 Ubiquitin-40S ribosomal 
protein S27a 
23 0.5 0.3  1.38 0.33  2.73 0.018 
P05982 NAD(P)H dehydrogenase 
[quinone] 1 
8 0.5 0.12  1.37 0.37  2.73 0.002 
P07150 Annexin A1 12 0.55 0.23  1.47 0.49  2.7 0.015 
P05371 Clusterin 6 0.56 0.31  1.52 0.52  2.7 0.041 
P04906 Glutathione S-transferase 
P 
12 0.26 0.22  0.7 0.41  2.69 0.045 
O35821 Myb-binding protein 1A 15 0.53 0.17  1.4 0.25  2.63 0.002 
P14480 Fibrinogen beta chain 25 0.52 0.24  1.36 0.55  2.63 0.026 
Q3B8Q1 Nucleolar RNA helicase 2 7 0.48 0.2  1.26 0.26  2.62 0.005 
P13084 Nucleophosmin 14 0.51 0.21  1.29 0.17  2.53 0.011 
P63018 Heat shock cognate 71 
kDa protein 
106 0.6 0.12  1.51 0.35  2.5 0.001 
P06761 78 kDa glucose-regulated 
protein 
112 0.69 0.25  1.7 0.5  2.47 0.008 
P52631 Signal transducer and 
activator of transcription 
3 
10 0.64 0.3  1.57 0.46  2.45 0.011 
P08430 UDP-
glucuronosyltransferase 
1-6 
40 0.58 0.23  1.37 0.48  2.34 0.017 
D4A4T9 Cysteine and histidine-
rich domain-containing 
protein 1 
3 0.86 0.23  2 1.03  2.32 0.046 
Q62812 Myosin-9 161 0.57 0.26  1.31 0.35  2.3 0.018 
P63029 Translationally-controlled 
tumor protein 
9 0.69 0.2  1.52 0.27  2.2 0.004 
P05765 40S ribosomal protein 
S21 
10 0.55 0.32  1.21 0.25  2.2 0.032 
P62961 Nuclease-sensitive 
element-binding protein 
1 
22 0.71 0.33  1.55 0.19  2.17 0.025 
P05197 Elongation factor 2 70 0.71 0.15  1.55 0.27  2.17 0.001 
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O35814 Stress-induced-
phosphoprotein 1 
24 0.72 0.16  1.54 0.71  2.15 0.031 
P34058 Heat shock protein HSP 
90-beta 
80 0.77 0.18  1.65 0.41  2.14 0.005 
B0BNA5 Coactosin-like protein 3 0.6 0.19  1.27 0.44  2.11 0.022 
Q63525 Nuclear migration 
protein nudC 
9 0.51 0.16  1.05 0.42  2.05 0.035 
P31000 Vimentin 32 0.51 0.15  1.03 0.26  2.04 0.012 
Q62651 Delta(3,5)-Delta(2,4)-
dienoyl-CoA isomerase, 
mitochondrial 
17 0.62 0.2  1.26 0.5  2.03 0.026 
O35763 Moesin 19 0.58 0.12  1.18 0.14  2.03 0.001 
Q6AYC2 Immunity-related GTPase 
family M protein 
3 0.71 0.25  1.43 0.29  2.02 0.017 
P50503 Hsc70-interacting protein 14 0.69 0.32  1.39 0.5  2.02 0.047 
P13221 Aspartate 
aminotransferase, 
cytoplasmic 
30 0.51 0.2  1.01 0.37  1.99 0.043 
Q9JJ19 Na(+)/H(+) exchange 
regulatory cofactor NHE-
RF1 
13 0.7 0.17  1.37 0.43  1.95 0.021 
Q6URK4 Heterogeneous nuclear 
ribonucleoprotein A3 
20 0.56 0.07  1.08 0.26  1.91 0.004 
Q1JU68 Eukaryotic translation 
initiation factor 3 subunit 
A 
23 0.66 0.17  1.26 0.26  1.91 0.007 
Q07936 Annexin A2 15 0.61 0.2  1.13 0.38  1.87 0.036 
P26772 10 kDa heat shock 
protein, mitochondrial 
13 0.72 0.29  1.34 0.12  1.87 0.016 
Q9Z2G8 Nucleosome assembly 
protein 1-like 1 
5 0.72 0.14  1.35 0.24  1.87 0.005 
Q5M9G3 Caprin-1 4 0.88 0.24  1.65 0.58  1.87 0.035 
P45592 Cofilin-1 14 0.65 0.06  1.21 0.16  1.86 <0.001 
P70619 Glutathione reductase 
(Fragment) 
8 0.68 0.17  1.25 0.29  1.85 0.014 
O35987 NSFL1 cofactor p47 14 0.71 0.37  1.29 0.21  1.82 0.036 
Q5BJY9 Keratin, type I 
cytoskeletal 18 
82 0.77 0.29  1.35 0.23  1.76 0.04 
P69897 Tubulin beta-5 chain 75 0.53 0.17  0.92 0.2  1.75 0.027 
Q63617 Hypoxia up-regulated 
protein 1 
55 0.66 0.13  1.16 0.17  1.74 0.005 
O88600 Heat shock 70 kDa 
protein 4 
28 0.73 0.13  1.26 0.11  1.72 0.001 
P41777 Nucleolar and coiled-
body phosphoprotein 1 
4 0.65 0.19  1.11 0.13  1.71 0.023 
P13635 Ceruloplasmin 19 0.67 0.2  1.14 0.22  1.7 0.028 
P11442 Clathrin heavy chain 1 103 0.77 0.1  1.28 0.15  1.67 0.001 
P30009 Myristoylated alanine-
rich C-kinase substrate 
12 0.5 0.17  0.84 0.1  1.67 0.032 
Q8K1Q0 Glycylpeptide N-
tetradecanoyltransferase 
1 
5 0.87 0.15  1.45 0.34  1.66 0.016 
P62425 60S ribosomal protein 
L7a 
13 0.7 0.2  1.16 0.15  1.65 0.012 
P48721 Stress-70 protein, 
mitochondrial 
67 0.75 0.14  1.23 0.25  1.64 0.015 
P63102 14-3-3 protein zeta/delta 26 0.63 0.11  1.03 0.17  1.63 0.006 
Q68FR6 Elongation factor 1-
gamma 
21 0.73 0.08  1.19 0.2  1.63 0.002 
P20673 Argininosuccinate lyase 42 0.69 0.14  1.13 0.27  1.62 0.035 
P04276 Vitamin D-binding 15 0.78 0.14  1.24 0.33  1.6 0.031 
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protein 
P63039 60 kDa heat shock 
protein, mitochondrial 
161 0.87 0.3  1.39 0.34  1.6 0.049 
Q9EPH8 Polyadenylate-binding 
protein 1 
24 0.82 0.14  1.3 0.36  1.59 0.038 
P08082 Clathrin light chain B 3 0.67 0.13  1.07 0.1  1.59 0.005 
P11232 Thioredoxin 7 0.69 0.12  1.1 0.3  1.58 0.032 
P19945 60S acidic ribosomal 
protein P0 
24 0.68 0.12  1.08 0.14  1.58 0.007 
P62634 Cellular nucleic acid-
binding protein 
5 0.71 0.18  1.11 0.08  1.56 0.012 
P28064 Proteasome subunit beta 
type-8 
6 0.76 0.16  1.18 0.22  1.56 0.019 
P02401 60S acidic ribosomal 
protein P2 
31 0.71 0.09  1.11 0.16  1.56 0.004 
B5DFC8 Eukaryotic translation 
initiation factor 3 subunit 
C 
14 0.85 0.12  1.31 0.1  1.55 0.002 
Q5RKI1 Eukaryotic initiation 
factor 4A-II 
22 0.84 0.12  1.31 0.11  1.55 0.002 
P81795 Eukaryotic translation 
initiation factor 2 subunit 
3 
11 0.77 0.09  1.19 0.31  1.54 0.021 
O08629 Transcription 
intermediary factor 1-
beta 
8 0.82 0.21  1.24 0.22  1.51 0.036 
Q62667 Major vault protein 19 0.77 0.08  1.13 0.16  1.47 0.007 
P38656 Lupus La protein 
homolog 
7 0.83 0.16  1.21 0.16  1.47 0.017 
Q4V7C6 GMP synthase 
[glutamine-hydrolyzing] 
7 0.78 0.19  1.15 0.13  1.47 0.025 
Q5XIU5 Proteasome inhibitor 
PI31 subunit 
2 0.85 0.2  1.25 0.18  1.46 0.027 
P62250 40S ribosomal protein 
S16 
13 0.83 0.17  1.22 0.18  1.46 0.022 
Q08163 Adenylyl cyclase-
associated protein 1 
9 0.85 0.23  1.23 0.2  1.45 0.044 
P04256 Heterogeneous nuclear 
ribonucleoprotein A1 
18 0.86 0.02  1.24 0.26  1.45 0.012 
A0JPM9 Eukaryotic translation 
initiation factor 3 subunit 
J 
5 0.8 0.22  1.16 0.16  1.45 0.047 
Q6AXS5 Plasminogen activator 
inhibitor 1 RNA-binding 
protein 
12 0.72 0.16  1.05 0.19  1.45 0.036 
Q6P799 Seryl-tRNA synthetase, 
cytoplasmic 
14 0.84 0.15  1.21 0.26  1.45 0.045 
Q07205 Eukaryotic translation 
initiation factor 5 
10 0.8 0.11  1.13 0.18  1.4 0.023 
P62815 V-type proton ATPase 
subunit B, brain isoform 
14 0.82 0.2  1.14 0.15  1.39 0.042 
Q9EQS0 Transaldolase 15 0.73 0.09  0.99 0.13  1.37 0.012 
P63086 Mitogen-activated 
protein kinase 1 
5 0.83 0.08  1.12 0.14  1.36 0.009 
P38650 Cytoplasmic dynein 1 
heavy chain 1 
51 0.76 0.07  1.03 0.14  1.36 0.011 
Q63347 26S protease regulatory 
subunit 7 
15 0.88 0.06  1.19 0.18  1.35 0.013 
P62859 40S ribosomal protein 
S28 
7 0.79 0.14  1.07 0.16  1.35 0.036 
Q6P502 T-complex protein 1 
subunit gamma 
34 0.92 0.14  1.24 0.09  1.34 0.013 
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Q63945 Protein SET 9 0.77 0.15  1.03 0.15  1.34 0.049 
Q4FZY0 EF-hand domain-
containing protein D2 
4 0.84 0.13  1.08 0.15  1.3 0.043 
Q6P7P5 Basic leucine zipper and 
W2 domain-containing 
protein 1 
7 0.79 0.14  1.03 0.09  1.3 0.041 
P68511 14-3-3 protein eta 15 0.85 0.1  1.09 0.12  1.29 0.02 
P12001 60S ribosomal protein 
L18 
9 0.83 0.13  1.07 0.09  1.29 0.025 
P38659 Protein disulfide-
isomerase A4 
45 0.86 0.14  1.09 0.09  1.27 0.039 
Q505J9 ATPase family AAA 
domain-containing 
protein 1 
2 0.93 0.08  1.14 0.16  1.24 0.044 
P29314 40S ribosomal protein S9 13 0.86 0.1  1.06 0.08  1.24 0.022 
P18395 Cold shock domain-
containing protein E1 
3 0.82 0.11  1.01 0.01  1.22 0.026 
Q9ER24 Ataxin-10 4 0.91 0.08  1.1 0.05  1.21 0.009 
Q6RUV5 Ras-related C3 botulinum 
toxin substrate 1 
4 0.88 0.11  1.04 0.03  1.18 0.042 
Q6AXS3 Protein DEK 4 0.93 0.12  1.09 0.05  1.18 0.043 
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Supplementary Table 1C:  iTRAQ-based proteomic comparison of liver proteins in vehicle 
control- and APAP-treated rats (72h timepoint). Proteins with expression that was different 
(raw P < 0.05) between control and APAP-treated rats at 72h are listed.  Mean expression 
values relative to a common pool are given for n=4 animals. Proteins are ordered according 
to the ratio between the 72h and control groups (lowest to highest) such that proteins with 
expression that was most markedly reduced at 72h appear at the top of the list. 
aAverage number of peptides used for quantification across the four individual iTRAQ runs.  
bUncorrected raw p value. 
 
Uniprot 
Accession Name Peptidesa 
Vehicle control 
 
72h 
 
72h/ctrl p 
valueb Mean SD 
 
Mean SD 
 
Ratio 
Proteins reduced at 72h                   
P09606 Glutamine synthetase 17 2.73 0.78  0.06 0.03  0.02 <0.001 
P08683 Cytochrome P450 2C11 51 2.53 0.52  0.16 0.09  0.06 <0.001 
P49890 Estrogen 
sulfotransferase, isoform 
6 
18 3.22 0.91  0.22 0.15  0.07 <0.001 
P14141 Carbonic anhydrase 3 70 1.99 1.3  0.18 0.2  0.09 0.007 
P36365 Dimethylaniline 
monooxygenase [N-
oxide-forming] 1 
13 2.34 0.94  0.22 0.15  0.1 0.002 
P02761 Major urinary protein 22 2.27 0.42  0.3 0.3  0.13 0.006 
Q9ES38 Bile acyl-CoA synthetase 26 2.8 0.86  0.39 0.39  0.14 0.007 
P17988 Sulfotransferase 1A1 30 1.99 0.34  0.28 0.16  0.14 0.001 
P00502 Glutathione S-
transferase alpha-1 
51 1.57 1.21  0.28 0.27  0.18 0.015 
Q03336 Regucalcin 45 1.98 0.18  0.36 0.38  0.18 0.011 
P05183 Cytochrome P450 3A2 15 2.49 0.97  0.46 0.24  0.18 0.009 
P16303 Carboxylesterase 3 33 1.85 0.85  0.36 0.33  0.2 0.012 
Q64565 Alanine--glyoxylate 
aminotransferase 2, 
mitochondrial 
28 1.26 0.46  0.25 0.14  0.2 0.002 
P04182 Ornithine 
aminotransferase, 
mitochondrial 
8 1.44 0.74  0.29 0.13  0.2 0.007 
P50237 Sulfotransferase 1C1 27 1.95 0.15  0.39 0.17  0.2 <0.001 
Q64611 Cysteine sulfinic acid 
decarboxylase 
25 1.81 0.7  0.41 0.61  0.23 0.025 
Q07523 Hydroxyacid oxidase 2 8 1.99 0.34  0.47 0.07  0.24 <0.001 
P12928 Pyruvate kinase isozymes 
R/L 
61 1.64 0.53  0.4 0.17  0.24 0.002 
P14173 Aromatic-L-amino-acid 
decarboxylase 
13 1.74 0.94  0.42 0.39  0.24 0.019 
P10867 L-gulonolactone oxidase 18 2 0.36  0.49 0.28  0.24 0.002 
P10860 Glutamate 
dehydrogenase 1, 
mitochondrial 
118 1.63 0.34  0.4 0.35  0.25 0.019 
Q64638 UDP-
glucuronosyltransferase 
1-5 
25 3.79 1.58  0.97 0.93  0.26 0.022 
P50169 Retinol dehydrogenase 3 30 1.54 0.61  0.4 0.27  0.26 0.008 
P09811 Glycogen phosphorylase, 
liver form 
76 1.4 0.26  0.38 0.15  0.27 0.002 
P25093 Fumarylacetoacetase 48 1.45 0.12  0.41 0.29  0.29 0.012 
Q5U2Q3 Ester hydrolase C11orf54 
homolog 
12 2 0.36  0.58 0.29  0.29 0.011 
P02692 Fatty acid-binding 69 1.94 0.49  0.57 0.18  0.29 0.002 
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protein, liver 
Q4KLP0 Probable 2-oxoglutarate 
dehydrogenase E1 
component DHKTD1, 
mitochondrial 
35 1.59 0.56  0.48 0.26  0.3 0.015 
P55051 Fatty acid-binding 
protein, brain 
9 1.61 0.57  0.49 0.4  0.3 0.024 
Q4KLZ6 Bifunctional ATP-
dependent 
dihydroxyacetone 
kinase/FAD-AMP lyase 
(cyclizing) 
64 1.7 0.39  0.52 0.25  0.31 0.013 
Q497B0 Omega-amidase NIT2 34 1.58 0.09  0.49 0.24  0.31 0.003 
P23680 Serum amyloid P-
component 
4 1.61 0.24  0.5 0.34  0.31 0.014 
P55159 Serum 
paraoxonase/arylesteras
e 1 
17 1.68 0.55  0.53 0.36  0.32 0.025 
P07872 Peroxisomal acyl-
coenzyme A oxidase 1 
42 1.33 0.25  0.43 0.28  0.32 0.017 
P23457 3-alpha-hydroxysteroid 
dehydrogenase 
48 1.51 0.36  0.49 0.41  0.32 0.035 
P30839 Fatty aldehyde 
dehydrogenase 
36 1.74 0.55  0.56 0.37  0.32 0.018 
Q9QYU4 Thiomorpholine-
carboxylate 
dehydrogenase 
9 1.31 0.25  0.44 0.24  0.33 0.01 
P16638 ATP-citrate synthase 65 1.93 0.71  0.65 0.21  0.34 0.006 
P20070 NADH-cytochrome b5 
reductase 3 
26 1.62 0.42  0.57 0.21  0.35 0.005 
Q920P0 L-xylulose reductase 12 1.44 0.45  0.51 0.18  0.35 0.004 
Q07071 Glucokinase regulatory 
protein 
27 1.71 0.64  0.6 0.35  0.35 0.029 
P29147 D-beta-hydroxybutyrate 
dehydrogenase, 
mitochondrial 
42 1.4 0.23  0.5 0.47  0.36 0.047 
Q8CHM7 2-hydroxyacyl-CoA lyase 
1 
28 1.66 0.35  0.61 0.4  0.36 0.021 
P11497 Acetyl-CoA carboxylase 1 44 1.46 0.57  0.53 0.18  0.37 0.01 
P57113 Maleylacetoacetate 
isomerase 
36 1.58 0.34  0.58 0.42  0.37 0.033 
B0BNE5 S-formylglutathione 
hydrolase 
23 1.32 0.33  0.49 0.16  0.37 0.003 
Q6DGG1 Alpha/beta hydrolase 
domain-containing 
protein 14B 
12 1.36 0.25  0.51 0.29  0.37 0.042 
P12785 Fatty acid synthase 155 1.79 1.03  0.67 0.11  0.38 0.03 
P12938 Cytochrome P450 2D3 46 1.52 0.33  0.57 0.11  0.38 0.001 
Q9R063 Peroxiredoxin-5, 
mitochondrial 
21 1.83 0.94  0.7 0.23  0.38 0.032 
A0JPQ8 Alkylglycerol 
monooxygenase 
6 1.64 0.2  0.63 0.19  0.38 0.001 
P70712 Kynureninase 19 1.41 0.32  0.54 0.19  0.38 0.007 
P70473 Alpha-methylacyl-CoA 
racemase 
18 1.07 0.04  0.41 0.3  0.39 0.028 
Q68FU3 Electron transfer 
flavoprotein subunit beta 
29 1.17 0.22  0.46 0.24  0.39 0.01 
P19112 Fructose-1,6-
bisphosphatase 1 
72 1.71 0.38  0.67 0.38  0.39 0.018 
Q66HG4 Aldose 1-epimerase 5 1.37 0.18  0.54 0.12  0.39 <0.001 
P24329 Thiosulfate 
sulfurtransferase 
41 1.33 0.2  0.52 0.41  0.39 0.042 
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Q02253 Methylmalonate-
semialdehyde 
dehydrogenase 
[acylating], 
mitochondrial 
124 1.22 0.24  0.48 0.39  0.39 0.044 
P00884 Fructose-bisphosphate 
aldolase B 
129 1.31 0.33  0.52 0.39  0.4 0.047 
P29411 GTP:AMP 
phosphotransferase, 
mitochondrial 
7 1.41 0.24  0.56 0.11  0.4 0.001 
O35077 Glycerol-3-phosphate 
dehydrogenase [NAD+], 
cytoplasmic 
39 1.45 0.42  0.58 0.32  0.4 0.026 
P97612 Fatty-acid amide 
hydrolase 1 
26 1.67 0.31  0.67 0.5  0.4 0.037 
P52873 Pyruvate carboxylase, 
mitochondrial 
134 1.16 0.13  0.47 0.35  0.4 0.042 
P22791 Hydroxymethylglutaryl-
CoA synthase, 
mitochondrial 
106 1.46 0.4  0.6 0.42  0.41 0.05 
P05544 Serine protease inhibitor 
A3L 
30 1.22 0.12  0.5 0.43  0.41 0.042 
Q02974 Ketohexokinase 25 1.56 0.28  0.64 0.31  0.41 0.01 
P18163 Long-chain-fatty-acid--
CoA ligase 1 
78 1.54 0.13  0.65 0.48  0.42 0.044 
P22734 Catechol O-
methyltransferase 
46 1.49 0.39  0.63 0.37  0.42 0.034 
Q62730 Estradiol 17-beta-
dehydrogenase 2 
17 1.72 0.47  0.74 0.42  0.43 0.029 
P06214 Delta-aminolevulinic acid 
dehydratase 
35 1.5 0.26  0.65 0.13  0.43 0.001 
Q68FP2 Serum 
paraoxonase/lactonase 3 
16 1.43 0.1  0.62 0.19  0.43 0.003 
P08503 Medium-chain specific 
acyl-CoA dehydrogenase, 
mitochondrial 
26 1.49 0.32  0.65 0.32  0.44 0.015 
P05545 Serine protease inhibitor 
A3K 
34 1.5 0.5  0.66 0.38  0.44 0.035 
P13803 Electron transfer 
flavoprotein subunit 
alpha, mitochondrial 
50 1.29 0.23  0.57 0.37  0.44 0.045 
P30713 Glutathione S-
transferase theta-2 
19 1.34 0.31  0.6 0.26  0.45 0.02 
P46720 Solute carrier organic 
anion transporter family 
member 1A1 
4 1.41 0.3  0.63 0.23  0.45 0.008 
P46953 3-hydroxyanthranilate 
3,4-dioxygenase 
25 1.42 0.4  0.64 0.26  0.45 0.03 
P08009 Glutathione S-
transferase Yb-3 
53 1.1 0.29  0.5 0.26  0.45 0.03 
Q64232 Very-long-chain enoyl-
CoA reductase 
35 1.76 0.41  0.8 0.41  0.45 0.045 
O88813 Long-chain-fatty-acid--
CoA ligase 5 
28 1.89 0.67  0.87 0.36  0.46 0.029 
P10760 Adenosylhomocysteinase 54 1.29 0.2  0.61 0.24  0.47 0.01 
P41034 Alpha-tocopherol 
transfer protein 
16 1.28 0.15  0.61 0.19  0.47 0.004 
Q68G31 Phenazine biosynthesis-
like domain-containing 
protein 
16 1.23 0.55  0.59 0.13  0.48 0.023 
P07953 6-phosphofructo-2-
kinase/fructose-2,6-
bisphosphatase 1 
13 1.47 0.11  0.71 0.17  0.48 0.001 
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Q6AYT0 Quinone oxidoreductase 9 1.37 0.36  0.67 0.24  0.49 0.023 
Q561R9 Beta-lactamase-like 
protein 2 
11 1.2 0.24  0.59 0.18  0.49 0.008 
P57093 Phytanoyl-CoA 
dioxygenase, 
peroxisomal 
10 1.36 0.22  0.67 0.18  0.5 0.004 
Q9Z339 Glutathione S-
transferase omega-1 
10 1.42 0.4  0.7 0.22  0.5 0.026 
P62959 Histidine triad 
nucleotide-binding 
protein 1 
8 1.59 0.36  0.8 0.3  0.5 0.031 
P11348 Dihydropteridine 
reductase 
27 1.29 0.44  0.65 0.25  0.51 0.044 
Q99MS0 SEC14-like protein 2 16 1.32 0.14  0.67 0.11  0.51 0.001 
Q63060 Glycerol kinase 20 1.68 0.28  0.86 0.16  0.51 0.002 
P85971 6-
phosphogluconolactonas
e 
12 1.56 0.23  0.8 0.1  0.51 <0.001 
Q63448 Peroxisomal acyl-
coenzyme A oxidase 3 
27 1.27 0.23  0.65 0.26  0.51 0.027 
Q68FS4 Cytosol aminopeptidase 53 1.52 0.14  0.78 0.3  0.51 0.031 
P16970 ATP-binding cassette 
sub-family D member 3 
13 1.69 0.46  0.87 0.35  0.52 0.032 
P45380 Sulfate anion transporter 
1 
3 1.09 0.35  0.57 0.21  0.52 0.029 
Q9Z0V5 Peroxiredoxin-4 16 1.03 0.11  0.55 0.19  0.53 0.016 
P52847 Sulfotransferase family 
cytosolic 1B member 1 
16 1.97 0.42  1.04 0.26  0.53 0.007 
Q66H45 Tetratricopeptide repeat 
protein 36 
5 1.2 0.34  0.65 0.13  0.54 0.014 
P43278 Histone H1.0 4 1.51 0.31  0.82 0.26  0.54 0.021 
Q8CG45 Aflatoxin B1 aldehyde 
reductase member 2 
22 1.11 0.05  0.6 0.27  0.54 0.042 
Q6AXX6 Redox-regulatory protein 
PAMM 
8 1.54 0.33  0.84 0.13  0.55 0.005 
P30904 Macrophage migration 
inhibitory factor 
22 1.31 0.21  0.73 0.3  0.55 0.032 
P10868 Guanidinoacetate N-
methyltransferase 
16 1.58 0.51  0.88 0.23  0.56 0.03 
P29117 Peptidyl-prolyl cis-trans 
isomerase F, 
mitochondrial 
8 1.25 0.26  0.7 0.29  0.56 0.044 
Q03626 Murinoglobulin-1 65 1.26 0.2  0.7 0.22  0.56 0.014 
P51650 Succinate-semialdehyde 
dehydrogenase, 
mitochondrial 
10 1.21 0.32  0.68 0.05  0.56 0.007 
P14604 Enoyl-CoA hydratase, 
mitochondrial 
35 1.08 0.04  0.62 0.23  0.57 0.03 
Q6AYT9 Acyl-coenzyme A 
synthetase ACSM5, 
mitochondrial 
14 1.53 0.3  0.88 0.16  0.58 0.007 
P31044 Phosphatidylethanolami
ne-binding protein 1 
22 1.26 0.27  0.74 0.22  0.58 0.034 
Q8VID1 Dehydrogenase/reductas
e SDR family member 4 
6 1.1 0.23  0.65 0.15  0.59 0.011 
O89000 Dihydropyrimidine 
dehydrogenase [NADP+] 
12 1.36 0.32  0.8 0.21  0.59 0.037 
Q63150 Dihydropyrimidinase 29 1.41 0.17  0.83 0.22  0.59 0.008 
P97852 Peroxisomal 
multifunctional enzyme 
type 2 
47 1.2 0.09  0.71 0.3  0.59 0.04 
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P29266 3-hydroxyisobutyrate 
dehydrogenase, 
mitochondrial 
23 1.21 0.17  0.71 0.12  0.59 0.003 
Q5BK17 Iodotyrosine 
dehalogenase 1 
4 1.75 0.28  1.04 0.24  0.59 0.013 
P35738 2-oxoisovalerate 
dehydrogenase subunit 
beta, mitochondrial 
13 1.23 0.12  0.73 0.24  0.6 0.02 
Q6I7R3 Isochorismatase domain-
containing protein 1 
10 1.44 0.23  0.86 0.15  0.6 0.007 
P27364 3 beta-hydroxysteroid 
dehydrogenase type 5 
19 1.41 0.31  0.84 0.29  0.6 0.037 
Q7TP48 Adipocyte plasma 
membrane-associated 
protein 
10 1.55 0.48  0.94 0.13  0.61 0.035 
O35952 Hydroxyacylglutathione 
hydrolase, mitochondrial 
14 1.36 0.35  0.83 0.06  0.61 0.009 
Q64380 Sarcosine 
dehydrogenase, 
mitochondrial 
41 1.28 0.19  0.81 0.24  0.63 0.037 
Q6AYQ8 Acylpyruvase FAHD1, 
mitochondrial 
10 1.15 0.22  0.74 0.15  0.64 0.023 
P46462 Transitional endoplasmic 
reticulum ATPase 
71 1.14 0.18  0.73 0.23  0.64 0.041 
P07633 Propionyl-CoA 
carboxylase beta chain, 
mitochondrial 
23 1.21 0.18  0.79 0.21  0.65 0.037 
Q9ES21 Phosphatidylinositide 
phosphatase SAC1 
9 1.33 0.25  0.9 0.16  0.67 0.03 
Q923M1 Mitochondrial peptide 
methionine sulfoxide 
reductase 
3 1.19 0.24  0.81 0.15  0.68 0.027 
Q505J8 Phenylalanine--tRNA 
ligase alpha subunit 
31 0.99 0.1  0.67 0.12  0.68 0.007 
B0BNG0 Tetratricopeptide repeat 
protein 35 
11 1.31 0.3  0.89 0.14  0.68 0.028 
P70552 GTP cyclohydrolase 1 
feedback regulatory 
protein 
5 1.09 0.21  0.75 0.09  0.69 0.02 
P16617 Phosphoglycerate kinase 
1 
54 1.09 0.24  0.76 0.17  0.69 0.046 
O88767 Protein DJ-1 16 1.21 0.2  0.84 0.12  0.69 0.021 
P27605 Hypoxanthine-guanine 
phosphoribosyltransferas
e 
12 1.35 0.2  0.96 0.15  0.72 0.025 
Q64591 2,4-dienoyl-CoA 
reductase, mitochondrial 
23 1.02 0.1  0.75 0.14  0.73 0.023 
O35331 Pyridoxal kinase 13 1.22 0.21  0.91 0.13  0.75 0.045 
P35433 Amidophosphoribosyltra
nsferase 
2 1.25 0.17  0.94 0.06  0.75 0.008 
Q9R1Z0 Voltage-dependent 
anion-selective channel 
protein 3 
8 1.17 0.16  0.9 0.11  0.77 0.027 
P17625 Glycogen [starch] 
synthase, liver 
5 1.1 0.11  0.85 0.16  0.77 0.048 
B2RYT9 Translational activator of 
cytochrome c oxidase 1 
3 1.1 0.1  0.88 0.13  0.8 0.042 
Q641Y0 Dolichyl-
diphosphooligosaccharid
e--protein 
glycosyltransferase 48 
kDa subunit 
16 1.18 0.12  0.97 0.07  0.82 0.021 
Q6AY78 Solute carrier family 22 4 1 0.11  0.83 0.05  0.82 0.025 
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member 18 
Q4G064 2-methoxy-6-polyprenyl-
1,4-benzoquinol 
methylase, 
mitochondrial 
6 1.07 0.1  0.89 0.07  0.83 0.027 
Q8VI04 Isoaspartyl peptidase/L-
asparaginase 
7 0.99 0.07  0.83 0.04  0.84 0.006 
Q9Z1N4 3'(2'),5'-bisphosphate 
nucleotidase 1 
4 0.94 0.07  0.83 0.05  0.88 0.044 
Proteins increased at 72h          
P01048 T-kininogen 1 15 0.25 0.21  1.91 0.92  7.52 0.009 
P02764 Alpha-1-acid 
glycoprotein 
6 0.31 0.37  1.91 0.33  6.13 0.017 
P42930 Heat shock protein beta-
1 
10 0.12 0.11  0.67 0.33  5.46 0.006 
P11980 Pyruvate kinase isozymes 
M1/M2 
19 0.44 0.09  2.32 1.65  5.28 0.004 
P31000 Vimentin 32 0.51 0.15  2.4 1.34  4.74 0.004 
P04961 Proliferating cell nuclear 
antigen 
4 0.41 0.07  1.88 1.39  4.62 0.005 
P06866 Haptoglobin 21 0.33 0.15  1.51 0.53  4.57 0.002 
P38918 Aflatoxin B1 aldehyde 
reductase member 3 
42 0.2 0.17  0.87 0.66  4.29 0.042 
Q07439 Heat shock 70 kDa 
protein 1A/1B 
56 0.21 0.2  0.81 0.35  3.93 0.02 
P30009 Myristoylated alanine-
rich C-kinase substrate 
12 0.5 0.17  1.9 1.07  3.76 0.031 
P69897 Tubulin beta-5 chain 75 0.53 0.17  1.83 0.76  3.48 0.004 
P11762 Galectin-1 4 0.73 0.12  2.38 0.75  3.29 0.001 
P20059 Hemopexin 24 0.45 0.12  1.47 0.25  3.26 <0.001 
P04906 Glutathione S-
transferase P 
12 0.26 0.22  0.84 0.56  3.21 0.034 
P05370 Glucose-6-phosphate 1-
dehydrogenase 
15 0.38 0.22  1.16 0.21  3.01 0.011 
P07150 Annexin A1 12 0.55 0.23  1.62 0.67  2.96 0.015 
Q62812 Myosin-9 161 0.57 0.26  1.69 0.72  2.96 0.017 
Q5XFX0 Transgelin-2 13 0.55 0.23  1.61 0.49  2.95 0.01 
Q3B8Q1 Nucleolar RNA helicase 2 7 0.48 0.2  1.4 0.38  2.9 0.004 
P07335 Creatine kinase B-type 11 0.64 0.11  1.83 0.58  2.86 0.001 
P13383 Nucleolin 21 0.47 0.15  1.3 0.42  2.8 0.004 
P17475 Alpha-1-antiproteinase 39 0.47 0.18  1.3 0.36  2.74 0.005 
P06302 Prothymosin alpha 6 0.7 0.47  1.88 0.95  2.7 0.038 
B0BNA5 Coactosin-like protein 3 0.6 0.19  1.63 0.51  2.7 0.007 
Q07936 Annexin A2 15 0.61 0.2  1.62 0.92  2.68 0.032 
P10960 Sulfated glycoprotein 1 14 0.6 0.11  1.62 0.42  2.68 0.001 
P45592 Cofilin-1 14 0.65 0.06  1.73 0.41  2.65 <0.001 
O35763 Moesin 19 0.58 0.12  1.51 0.45  2.61 0.002 
P18437 Non-histone 
chromosomal protein 
HMG-17 
3 0.51 0.22  1.31 0.52  2.58 0.022 
O35821 Myb-binding protein 1A 15 0.53 0.17  1.36 0.37  2.56 0.005 
O70199 UDP-glucose 6-
dehydrogenase 
38 0.32 0.1  0.8 0.29  2.53 0.011 
P14480 Fibrinogen beta chain 25 0.52 0.24  1.24 0.41  2.4 0.033 
Q9Z2G8 Nucleosome assembly 
protein 1-like 1 
5 0.72 0.14  1.72 0.25  2.39 0.001 
P16391 RT1 class I 
histocompatibility 
6 0.6 0.37  1.43 0.26  2.38 0.024 
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antigen, AA alpha chain 
P13084 Nucleophosmin 14 0.51 0.21  1.22 0.39  2.38 0.026 
P13221 Aspartate 
aminotransferase, 
cytoplasmic 
30 0.51 0.2  1.12 0.28  2.22 0.013 
Q6URK4 Heterogeneous nuclear 
ribonucleoprotein A3 
20 0.56 0.07  1.2 0.05  2.14 <0.001 
P63102 14-3-3 protein zeta/delta 26 0.63 0.11  1.34 0.35  2.13 0.004 
P52555 Endoplasmic reticulum 
resident protein 29 
12 0.95 0.19  1.99 0.93  2.09 0.023 
Q62667 Major vault protein 19 0.77 0.08  1.59 0.61  2.06 0.01 
P13635 Ceruloplasmin 19 0.67 0.2  1.36 0.23  2.03 0.008 
P82995 Heat shock protein HSP 
90-alpha 
74 0.47 0.29  0.95 0.23  2.02 0.044 
P05197 Elongation factor 2 70 0.71 0.15  1.42 0.46  2 0.012 
O35814 Stress-induced-
phosphoprotein 1 
24 0.72 0.16  1.44 0.63  2 0.025 
P68255 14-3-3 protein theta 20 0.87 0.3  1.74 0.69  2 0.04 
Q63525 Nuclear migration 
protein nudC 
9 0.51 0.16  1.02 0.36  1.99 0.028 
P24268 Cathepsin D 12 0.86 0.3  1.71 0.28  1.97 0.006 
P34064 Proteasome subunit 
alpha type-5 
15 0.63 0.31  1.22 0.3  1.93 0.042 
P50503 Hsc70-interacting 
protein 
14 0.69 0.32  1.3 0.28  1.89 0.042 
Q66HD0 Endoplasmin 95 0.71 0.27  1.32 0.34  1.86 0.036 
P29457 Serpin H1 11 0.81 0.17  1.51 0.45  1.86 0.019 
Q68FR6 Elongation factor 1-
gamma 
21 0.73 0.08  1.33 0.22  1.83 0.001 
P63018 Heat shock cognate 71 
kDa protein 
106 0.6 0.12  1.1 0.21  1.82 0.006 
O54753 17-beta-hydroxysteroid 
dehydrogenase type 6 
12 0.85 0.33  1.53 0.31  1.8 0.024 
Q63617 Hypoxia up-regulated 
protein 1 
55 0.66 0.13  1.19 0.1  1.8 0.002 
P04639 Apolipoprotein A-I 20 0.82 0.28  1.46 0.27  1.77 0.035 
P19945 60S acidic ribosomal 
protein P0 
24 0.68 0.12  1.18 0.36  1.73 0.026 
Q5BJY9 Keratin, type I 
cytoskeletal 18 
82 0.77 0.29  1.3 0.16  1.7 0.043 
Q5M9G3 Caprin-1 4 0.88 0.24  1.46 0.4  1.65 0.035 
Q1JU68 Eukaryotic translation 
initiation factor 3 subunit 
A 
23 0.66 0.17  1.07 0.24  1.64 0.026 
P38656 Lupus La protein 
homolog 
7 0.83 0.16  1.32 0.25  1.6 0.018 
P62634 Cellular nucleic acid-
binding protein 
5 0.71 0.18  1.14 0.24  1.6 0.024 
P62425 60S ribosomal protein 
L7a 
13 0.7 0.2  1.11 0.13  1.58 0.015 
P62828 GTP-binding nuclear 
protein Ran 
8 0.8 0.17  1.26 0.28  1.57 0.022 
P81795 Eukaryotic translation 
initiation factor 2 subunit 
3 
11 0.77 0.09  1.21 0.12  1.57 0.001 
Q62651 Delta(3,5)-Delta(2,4)-
dienoyl-CoA isomerase, 
mitochondrial 
17 0.62 0.2  0.97 0.15  1.56 0.035 
P62250 40S ribosomal protein 
S16 
13 0.83 0.17  1.29 0.18  1.56 0.011 
P11442 Clathrin heavy chain 1 103 0.77 0.1  1.2 0.25  1.56 0.011 
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P38650 Cytoplasmic dynein 1 
heavy chain 1 
51 0.76 0.07  1.18 0.32  1.56 0.018 
O08557 N(G),N(G)-
dimethylarginine 
dimethylaminohydrolase 
1 
11 0.68 0.19  1.04 0.2  1.54 0.033 
P12346 Serotransferrin 78 0.76 0.13  1.16 0.31  1.54 0.049 
P04644 40S ribosomal protein 
S17 
17 0.8 0.26  1.23 0.19  1.54 0.041 
Q08163 Adenylyl cyclase-
associated protein 1 
9 0.85 0.23  1.31 0.35  1.54 0.049 
O08629 Transcription 
intermediary factor 1-
beta 
8 0.82 0.21  1.27 0.11  1.54 0.016 
Q9JJ22 Endoplasmic reticulum 
aminopeptidase 1 
8 0.93 0.14  1.39 0.37  1.49 0.038 
Q9R0J8 Legumain 3 0.94 0.13  1.39 0.19  1.48 0.008 
P69736 Endothelial 
differentiation-related 
factor 1 
2 0.81 0.2  1.2 0.18  1.48 0.04 
Q9JI85 Nucleobindin-2 17 1.02 0.17  1.5 0.32  1.47 0.029 
P62853 40S ribosomal protein 
S25 
9 0.76 0.12  1.12 0.19  1.47 0.014 
Q63797 Proteasome activator 
complex subunit 1 
26 0.81 0.15  1.19 0.1  1.47 0.009 
Q9R1T1 Barrier-to-
autointegration factor 
3 0.9 0.25  1.32 0.13  1.47 0.026 
Q4AEF8 Coatomer subunit 
gamma-1 
18 0.85 0.23  1.24 0.09  1.46 0.026 
P62752 60S ribosomal protein 
L23a 
8 0.78 0.12  1.14 0.17  1.46 0.014 
P23514 Coatomer subunit beta 30 0.88 0.12  1.27 0.3  1.45 0.04 
P51583 Multifunctional protein 
ADE2 
8 1.12 0.06  1.6 0.34  1.43 0.034 
Q63945 Protein SET 9 0.77 0.15  1.1 0.08  1.43 0.012 
Q8K1Q0 Glycylpeptide N-
tetradecanoyltransferase 
1 
5 0.87 0.15  1.24 0.19  1.42 0.023 
B5DFC8 Eukaryotic translation 
initiation factor 3 subunit 
C 
14 0.85 0.12  1.2 0.19  1.42 0.018 
Q5RJR8 Leucine-rich repeat-
containing protein 59 
21 0.8 0.14  1.14 0.14  1.42 0.021 
P43244 Matrin-3 12 0.91 0.07  1.28 0.09  1.41 0.001 
P25113 Phosphoglycerate 
mutase 1 
20 0.92 0.1  1.3 0.25  1.41 0.024 
P41123 60S ribosomal protein 
L13 
16 0.76 0.1  1.06 0.13  1.4 0.011 
Q3T1J1 Eukaryotic translation 
initiation factor 5A-1 
13 0.84 0.08  1.16 0.22  1.39 0.021 
P68511 14-3-3 protein eta 15 0.85 0.1  1.18 0.25  1.39 0.036 
P21531 60S ribosomal protein L3 23 0.8 0.13  1.11 0.2  1.39 0.037 
Q63584 Transmembrane emp24 
domain-containing 
protein 10 
11 0.9 0.07  1.23 0.26  1.37 0.03 
P63086 Mitogen-activated 
protein kinase 1 
5 0.83 0.08  1.12 0.12  1.36 0.006 
Q641Z6 EH domain-containing 
protein 1 
20 0.87 0.03  1.17 0.06  1.35 <0.001 
P02401 60S acidic ribosomal 
protein P2 
31 0.71 0.09  0.95 0.06  1.34 0.008 
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Q66H80 Coatomer subunit delta 13 0.91 0.15  1.22 0.16  1.34 0.03 
P28023 Dynactin subunit 1 6 0.85 0.11  1.12 0.14  1.31 0.02 
Q6RUV5 Ras-related C3 botulinum 
toxin substrate 1 
4 0.88 0.11  1.14 0.14  1.3 0.025 
Q62871 Cytoplasmic dynein 1 
intermediate chain 2 
6 0.89 0.15  1.14 0.13  1.28 0.048 
Q5M7W5 Microtubule-associated 
protein 4 
8 0.89 0.09  1.14 0.13  1.27 0.02 
P85125 Polymerase I and 
transcript release factor 
5 0.85 0.03  1.07 0.05  1.26 <0.001 
P85972 Vinculin 35 0.85 0.1  1.07 0.15  1.26 0.047 
Q8CFN2 Cell division control 
protein 42 homolog 
8 0.93 0.1  1.14 0.08  1.23 0.014 
P29314 40S ribosomal protein S9 13 0.86 0.1  1.03 0.09  1.2 0.048 
Q5U211 Sorting nexin-3 5 0.93 0.08  1.07 0.08  1.16 0.04 
Q62991 Sec1 family domain-
containing protein 1 
8 0.98 0.05  1.14 0.04  1.16 0.002 
O35142 Coatomer subunit beta' 9 0.93 0.05  1.04 0.04  1.11 0.02 
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Supplementary Table 1D:  iTRAQ-based proteomic comparison of liver proteins in vehicle 
control- and APAP-treated rats (96h timepoint). Proteins with expression that was different 
(raw P < 0.05) between control and APAP-treated rats at 96h are listed.  Mean expression 
values relative to a common pool are given for n=3 animals. Proteins are ordered according 
to the ratio between the 96h and control groups (lowest to highest) such that proteins with 
expression that was most markedly reduced at 96h appear at the top of the list. 
aAverage number of peptides used for quantification across the four individual iTRAQ runs.  
bUncorrected raw p value. 
Uniprot 
Accession Name  
Vehicle control 
 
96h 
 
96h/ctrl p 
valueb Peptidesa Mean SD   Mean SD   Ratio 
Proteins reduced at 96h          
P08683 Cytochrome P450 2C11 51 2.53 0.52  0.09 0.04  0.03 <0.001 
P49890 Estrogen sulfotransferase, 
isoform 6 
18 3.22 0.91  0.11 0.08  0.03 <0.001 
P09606 Glutamine synthetase 17 2.73 0.78  0.1 0.03  0.03 <0.001 
P14141 Carbonic anhydrase 3 70 1.99 1.3  0.1 0.08  0.05 0.004 
Q07523 Hydroxyacid oxidase 2 8 1.99 0.34  0.12 0.08  0.06 <0.001 
P36365 Dimethylaniline 
monooxygenase [N-oxide-
forming] 1 
13 2.34 0.94  0.24 0.05  0.1 <0.001 
P02761 Major urinary protein 22 2.27 0.42  0.25 0.08  0.11 <0.001 
P10867 L-gulonolactone oxidase 18 2 0.36  0.31 0.12  0.15 <0.001 
P50237 Sulfotransferase 1C1 27 1.95 0.15  0.31 0.12  0.16 <0.001 
P17988 Sulfotransferase 1A1 30 1.99 0.34  0.34 0.15  0.17 0.001 
Q9ES38 Bile acyl-CoA synthetase 26 2.8 0.86  0.53 0.32  0.19 0.005 
P05183 Cytochrome P450 3A2 15 2.49 0.97  0.48 0.42  0.19 0.028 
P12785 Fatty acid synthase 155 1.79 1.03  0.36 0.07  0.2 0.009 
P04182 Ornithine 
aminotransferase, 
mitochondrial 
8 1.44 0.74  0.29 0.18  0.2 0.014 
Q62730 Estradiol 17-beta-
dehydrogenase 2 
17 1.72 0.47  0.35 0.11  0.2 0.001 
Q02769 Squalene synthase 8 1.7 0.55  0.36 0.14  0.21 0.005 
P11497 Acetyl-CoA carboxylase 1 44 1.46 0.57  0.33 0.07  0.22 0.003 
P16638 ATP-citrate synthase 65 1.93 0.71  0.45 0.01  0.23 0.001 
Q03336 Regucalcin 45 1.98 0.18  0.49 0.08  0.25 <0.001 
P05369 Farnesyl pyrophosphate 
synthase 
27 1.5 0.39  0.39 0.35  0.26 0.025 
P22734 Catechol O-
methyltransferase 
46 1.49 0.39  0.39 0.13  0.26 0.002 
P52847 Sulfotransferase family 
cytosolic 1B member 1 
16 1.97 0.42  0.53 0.15  0.27 0.001 
P17425 Hydroxymethylglutaryl-
CoA synthase, 
cytoplasmic 
9 1.3 0.44  0.36 0.26  0.28 0.045 
P19225 Cytochrome P450 2C70 19 1.56 0.65  0.45 0.35  0.29 0.041 
P12928 Pyruvate kinase isozymes 
R/L 
61 1.64 0.53  0.49 0.25  0.3 0.009 
Q63060 Glycerol kinase 20 1.68 0.28  0.53 0.1  0.31 <0.001 
Q9EQ76 Dimethylaniline 
monooxygenase [N-oxide-
forming] 3 
21 1.24 0.6  0.4 0.28  0.32 0.031 
Q68FT5 Betaine--homocysteine S-
methyltransferase 2 
82 0.99 0.45  0.32 0.17  0.32 0.026 
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Q5PPL3 Sterol-4-alpha-
carboxylate 3-
dehydrogenase, 
decarboxylating 
20 1.74 0.46  0.56 0.28  0.32 0.008 
P07953 6-phosphofructo-2-
kinase/fructose-2,6-
bisphosphatase 1 
13 1.47 0.11  0.49 0.34  0.33 0.018 
O35760 Isopentenyl-diphosphate 
Delta-isomerase 1 
4 1.38 0.41  0.47 0.11  0.34 0.006 
P02692 Fatty acid-binding 
protein, liver 
69 1.94 0.49  0.67 0.2  0.34 0.004 
P16303 Carboxylesterase 3 33 1.85 0.85  0.64 0.38  0.35 0.05 
P18757 Cystathionine gamma-
lyase 
37 1.4 0.63  0.48 0.19  0.35 0.026 
Q63276 Bile acid-CoA:amino acid 
N-acyltransferase 
57 1.25 0.27  0.45 0.15  0.36 0.004 
P30839 Fatty aldehyde 
dehydrogenase 
36 1.74 0.55  0.64 0.15  0.37 0.011 
Q64611 Cysteine sulfinic acid 
decarboxylase 
25 1.81 0.7  0.67 0.19  0.37 0.012 
Q5FVR2 Thymidine phosphorylase 11 1.8 0.99  0.69 0.08  0.38 0.033 
P11030 Acyl-CoA-binding protein 20 1.87 1.03  0.72 0.23  0.38 0.036 
P20070 NADH-cytochrome b5 
reductase 3 
26 1.62 0.42  0.62 0.09  0.38 0.002 
P06214 Delta-aminolevulinic acid 
dehydratase 
35 1.5 0.26  0.58 0.07  0.39 <0.001 
Q5I0J9 Putative L-aspartate 
dehydrogenase 
17 1.35 0.44  0.53 0.12  0.39 0.017 
P18163 Long-chain-fatty-acid--
CoA ligase 1 
78 1.54 0.13  0.61 0.06  0.4 <0.001 
Q8CHM7 2-hydroxyacyl-CoA lyase 1 28 1.66 0.35  0.67 0.01  0.4 0.001 
P08290 Asialoglycoprotein 
receptor 2 
4 1.04 0.35  0.42 0.21  0.4 0.035 
P57093 Phytanoyl-CoA 
dioxygenase, peroxisomal 
10 1.36 0.22  0.55 0.23  0.41 0.012 
P23680 Serum amyloid P-
component 
4 1.61 0.24  0.68 0.05  0.43 <0.001 
Q5BK17 Iodotyrosine 
dehalogenase 1 
4 1.75 0.28  0.75 0.42  0.43 0.017 
Q64654 Lanosterol 14-alpha 
demethylase 
9 1.45 0.43  0.63 0.09  0.43 0.008 
Q68FS4 Cytosol aminopeptidase 53 1.52 0.14  0.66 0.12  0.43 <0.001 
Q07071 Glucokinase regulatory 
protein 
27 1.71 0.64  0.74 0.35  0.43 0.037 
P08009 Glutathione S-transferase 
Yb-3 
53 1.1 0.29  0.48 0.18  0.44 0.02 
P55051 Fatty acid-binding 
protein, brain 
9 1.61 0.57  0.71 0.31  0.44 0.041 
P85973 Purine nucleoside 
phosphorylase 
41 1.12 0.2  0.49 0.17  0.44 0.009 
P14669 Annexin A3 17 1.09 0.27  0.49 0.12  0.45 0.007 
P25409 Alanine aminotransferase 
1 
19 0.85 0.09  0.38 0.08  0.45 0.001 
P27364 3 beta-hydroxysteroid 
dehydrogenase type 5 
19 1.41 0.31  0.64 0.13  0.45 0.004 
P10860 Glutamate 
dehydrogenase 1, 
mitochondrial 
118 1.63 0.34  0.74 0.34  0.45 0.037 
P97562 Peroxisomal acyl-
coenzyme A oxidase 2 
38 1.45 0.15  0.66 0.34  0.46 0.038 
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O88813 Long-chain-fatty-acid--
CoA ligase 5 
28 1.89 0.67  0.87 0.04  0.46 0.015 
P24329 Thiosulfate 
sulfurtransferase 
41 1.33 0.2  0.62 0.19  0.47 0.006 
O89000 Dihydropyrimidine 
dehydrogenase [NADP+] 
12 1.36 0.32  0.64 0.12  0.47 0.011 
Q920P0 L-xylulose reductase 12 1.44 0.45  0.69 0.1  0.48 0.013 
A0JPQ8 Alkylglycerol 
monooxygenase 
6 1.64 0.2  0.78 0.08  0.48 <0.001 
P00884 Fructose-bisphosphate 
aldolase B 
129 1.31 0.33  0.64 0.1  0.49 0.006 
P13107 Cytochrome P450 2B3 27 1.48 0.55  0.72 0.11  0.49 0.036 
Q6AXX6 Redox-regulatory protein 
PAMM 
8 1.54 0.33  0.75 0.24  0.49 0.015 
Q4KLZ6 Bifunctional ATP-
dependent 
dihydroxyacetone 
kinase/FAD-AMP lyase 
(cyclizing) 
64 1.7 0.39  0.83 0.18  0.49 0.009 
Q66H45 Tetratricopeptide repeat 
protein 36 
5 1.2 0.34  0.59 0.21  0.49 0.036 
P12938 Cytochrome P450 2D3 46 1.52 0.33  0.75 0.12  0.5 0.006 
P10868 Guanidinoacetate N-
methyltransferase 
16 1.58 0.51  0.79 0.18  0.5 0.028 
Q5I0M2 Nicotinate-nucleotide 
pyrophosphorylase 
[carboxylating] 
11 1.28 0.42  0.64 0.13  0.5 0.035 
Q5U2Q3 Ester hydrolase C11orf54 
homolog 
12 2 0.36  1.01 0.3  0.51 0.015 
Q63150 Dihydropyrimidinase 29 1.41 0.17  0.72 0.33  0.51 0.021 
Q9Z339 Glutathione S-transferase 
omega-1 
10 1.42 0.4  0.72 0.28  0.51 0.048 
Q63448 Peroxisomal acyl-
coenzyme A oxidase 3 
27 1.27 0.23  0.65 0.09  0.51 0.003 
Q9WUS0 Adenylate kinase 
isoenzyme 4, 
mitochondrial 
14 1.38 0.19  0.71 0.15  0.52 0.004 
Q9WU49 Calcium-regulated heat 
stable protein 1 
7 1.17 0.2  0.61 0.17  0.52 0.009 
P70712 Kynureninase 19 1.41 0.32  0.74 0.08  0.52 0.008 
P57113 Maleylacetoacetate 
isomerase 
36 1.58 0.34  0.83 0.37  0.53 0.035 
Q7TP48 Adipocyte plasma 
membrane-associated 
protein 
10 1.55 0.48  0.83 0.07  0.53 0.026 
P97612 Fatty-acid amide 
hydrolase 1 
26 1.67 0.31  0.9 0.31  0.54 0.029 
P00173 Cytochrome b5 31 1.37 0.2  0.76 0.14  0.55 0.005 
Q6P7R8 Estradiol 17-beta-
dehydrogenase 12 
6 1.15 0.2  0.64 0.14  0.56 0.014 
P55159 Serum 
paraoxonase/arylesterase 
1 
17 1.68 0.55  0.94 0.06  0.56 0.037 
Q64232 Very-long-chain enoyl-
CoA reductase 
35 1.76 0.41  0.99 0.22  0.56 0.017 
Q02974 Ketohexokinase 25 1.56 0.28  0.89 0.2  0.57 0.015 
Q497B0 Omega-amidase NIT2 34 1.58 0.09  0.9 0.26  0.57 0.008 
Q9QZH8 Arylacetamide 
deacetylase 
6 1.64 0.55  0.93 0.07  0.57 0.038 
Q9QZX8 Solute carrier organic 
anion transporter family 
member 1B2 
3 1.36 0.4  0.78 0.05  0.57 0.021 
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P04937 Fibronectin 27 0.74 0.22  0.43 0.01  0.58 0.041 
Q6AXM8 Serum 
paraoxonase/arylesterase 
2 
8 1.1 0.24  0.65 0.19  0.59 0.046 
P52873 Pyruvate carboxylase, 
mitochondrial 
134 1.16 0.13  0.68 0.14  0.59 0.005 
B0BNG0 Tetratricopeptide repeat 
protein 35 
11 1.31 0.3  0.77 0.15  0.59 0.022 
P29147 D-beta-hydroxybutyrate 
dehydrogenase, 
mitochondrial 
42 1.4 0.23  0.83 0.28  0.59 0.033 
O35331 Pyridoxal kinase 13 1.22 0.21  0.73 0.2  0.6 0.032 
P41034 Alpha-tocopherol transfer 
protein 
16 1.28 0.15  0.77 0.15  0.6 0.008 
P25093 Fumarylacetoacetase 48 1.45 0.12  0.88 0.24  0.61 0.015 
Q498D5 Regulator of microtubule 
dynamics protein 2 
8 1.34 0.14  0.83 0.34  0.62 0.044 
Q9QYU4 Thiomorpholine-
carboxylate 
dehydrogenase 
9 1.31 0.25  0.81 0.25  0.62 0.039 
Q06647 ATP synthase subunit O, 
mitochondrial 
35 1.09 0.27  0.67 0.08  0.62 0.043 
P0C2X9 Delta-1-pyrroline-5-
carboxylate 
dehydrogenase, 
mitochondrial 
43 1.3 0.1  0.81 0.23  0.62 0.016 
P09456 cAMP-dependent protein 
kinase type I-alpha 
regulatory subunit 
7 1.22 0.2  0.76 0.14  0.62 0.018 
Q6DGG1 Alpha/beta hydrolase 
domain-containing 
protein 14B 
12 1.36 0.25  0.85 0.2  0.63 0.031 
P08503 Medium-chain specific 
acyl-CoA dehydrogenase, 
mitochondrial 
26 1.49 0.32  0.94 0.13  0.63 0.024 
P70473 Alpha-methylacyl-CoA 
racemase 
18 1.07 0.04  0.68 0.19  0.64 0.024 
Q5M876 Aspartoacylase-2 5 1.35 0.26  0.88 0.04  0.65 0.013 
Q68FP2 Serum 
paraoxonase/lactonase 3 
16 1.43 0.1  0.95 0.13  0.66 0.003 
Q99MS0 SEC14-like protein 2 16 1.32 0.14  0.88 0.19  0.67 0.02 
Q66HG4 Aldose 1-epimerase 5 1.37 0.18  0.93 0.13  0.68 0.015 
Q6I7R3 Isochorismatase domain-
containing protein 1 
10 1.44 0.23  0.97 0.06  0.68 0.017 
Q63524 Transmembrane emp24 
domain-containing 
protein 2 
8 1.29 0.21  0.89 0.09  0.69 0.018 
P41562 Isocitrate dehydrogenase 
[NADP] cytoplasmic 
59 1.21 0.08  0.88 0.15  0.72 0.014 
P17764 Acetyl-CoA 
acetyltransferase, 
mitochondrial 
60 1.28 0.07  0.93 0.15  0.72 0.009 
Q9Z1W6 Protein LYRIC 7 1.17 0.14  0.87 0.05  0.75 0.011 
P27605 Hypoxanthine-guanine 
phosphoribosyltransferas
e 
12 1.35 0.2  1.01 0.06  0.75 0.035 
Q64057 Alpha-aminoadipic 
semialdehyde 
dehydrogenase 
55 1.17 0.2  0.89 0.07  0.76 0.05 
P60892 Ribose-phosphate 
pyrophosphokinase 1 
6 1.08 0.15  0.84 0.04  0.78 0.035 
P85108 Tubulin beta-2A chain 72 1.11 0.05  0.88 0.12  0.79 0.021 
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O88941 Mannosyl-oligosaccharide 
glucosidase 
12 1.13 0.13  0.89 0.1  0.79 0.044 
P11507 Sarcoplasmic/endoplasmi
c reticulum calcium 
ATPase 2 
30 1.01 0.1  0.81 0.07  0.8 0.028 
Q7TQ16 Cytochrome b-c1 complex 
subunit 8 
4 0.99 0.06  0.8 0.06  0.81 0.01 
P35738 2-oxoisovalerate 
dehydrogenase subunit 
beta, mitochondrial 
13 1.23 0.12  1.03 0.05  0.84 0.039 
B2RYT9 Translational activator of 
cytochrome c oxidase 1 
3 1.1 0.1  0.93 0.05  0.84 0.043 
Q62920 PDZ and LIM domain 
protein 5 
5 1 0.03  0.93 0.03  0.93 0.019 
Proteins increased at 96h          
P04906 Glutathione S-transferase 
P 
12 0.26 0.22  3.37 1.12  12.94 0.002 
P38918 Aflatoxin B1 aldehyde 
reductase member 3 
42 0.2 0.17  2.42 0.14  11.89 0.002 
P05982 NAD(P)H dehydrogenase 
[quinone] 1 
8 0.5 0.12  3.08 2.86  6.14 0.044 
O70199 UDP-glucose 6-
dehydrogenase 
38 0.32 0.1  1.82 0.75  5.76 0.001 
P07687 Epoxide hydrolase 1 54 0.4 0.19  2.11 0.48  5.32 0.004 
P04903 Glutathione S-transferase 
alpha-2 
51 0.54 0.23  2.46 0.87  4.58 0.005 
O89049 Thioredoxin reductase 1, 
cytoplasmic 
17 0.42 0.29  1.57 0.29  3.78 0.026 
P08430 UDP-
glucuronosyltransferase 
1-6 
40 0.58 0.23  2.06 0.36  3.52 0.003 
Q9Z0U5 Aldehyde oxidase 52 0.68 0.2  2.21 0.58  3.23 0.002 
P05370 Glucose-6-phosphate 1-
dehydrogenase 
15 0.38 0.22  1.2 0.33  3.13 0.028 
P13383 Nucleolin 21 0.47 0.15  1.43 0.11  3.07 0.001 
Q62651 Delta(3,5)-Delta(2,4)-
dienoyl-CoA isomerase, 
mitochondrial 
17 0.62 0.2  1.76 0.44  2.83 0.005 
P48508 Glutamate--cysteine 
ligase regulatory subunit 
9 0.68 0.26  1.74 0.31  2.57 0.021 
P23965 Enoyl-CoA delta 
isomerase 1, 
mitochondrial 
18 0.59 0.37  1.46 0.3  2.5 0.046 
P18437 Non-histone 
chromosomal protein 
HMG-17 
3 0.51 0.22  1.26 0.52  2.49 0.037 
Q9Z2Y0 Glycine N-acyltransferase-
like protein Keg1 
6 0.79 0.21  1.94 0.24  2.45 0.003 
O35547 Long-chain-fatty-acid--
CoA ligase 4 
9 0.78 0.11  1.88 0.58  2.4 0.003 
P51647 Retinal dehydrogenase 1 29 0.85 0.45  2 0.05  2.35 0.04 
Q99PS8 Histidine-rich glycoprotein 9 1.03 0.33  2.41 0.76  2.34 0.027 
P13084 Nucleophosmin 14 0.51 0.21  1.17 0.03  2.29 0.036 
P17475 Alpha-1-antiproteinase 39 0.47 0.18  1.08 0.28  2.28 0.022 
P13221 Aspartate 
aminotransferase, 
cytoplasmic 
30 0.51 0.2  1.15 0.05  2.26 0.016 
Q3B8Q1 Nucleolar RNA helicase 2 7 0.48 0.2  1.06 0.16  2.21 0.021 
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Q64633 UDP-
glucuronosyltransferase 
1-7 
23 0.72 0.2  1.58 0.26  2.2 0.009 
Q9EQS0 Transaldolase 15 0.73 0.09  1.58 0.6  2.18 0.011 
O35821 Myb-binding protein 1A 15 0.53 0.17  1.16 0.11  2.17 0.01 
P19468 Glutamate--cysteine 
ligase catalytic subunit 
22 0.87 0.17  1.74 0.13  2.01 0.002 
P06761 78 kDa glucose-regulated 
protein 
112 0.69 0.25  1.37 0.23  1.99 0.029 
Q6P6S9 Ectonucleoside 
triphosphate 
diphosphohydrolase 5 
12 0.79 0.26  1.55 0.4  1.96 0.026 
P70619 Glutathione reductase 
(Fragment) 
8 0.68 0.17  1.31 0.32  1.94 0.019 
Q6P747 Heterochromatin protein 
1-binding protein 3 
4 0.91 0.19  1.75 0.51  1.93 0.019 
P18886 Carnitine O-
palmitoyltransferase 2, 
mitochondrial 
21 0.84 0.19  1.59 0.48  1.89 0.037 
P63102 14-3-3 protein zeta/delta 26 0.63 0.11  1.17 0.07  1.85 0.002 
Q5M827 Pirin 3 0.78 0.33  1.45 0.2  1.85 0.048 
P48721 Stress-70 protein, 
mitochondrial 
67 0.75 0.14  1.39 0.32  1.84 0.013 
P31210 3-oxo-5-beta-steroid 4-
dehydrogenase 
51 1.07 0.22  1.95 0.18  1.83 0.007 
P41777 Nucleolar and coiled-body 
phosphoprotein 1 
4 0.65 0.19  1.18 0.21  1.82 0.044 
Q6URK4 Heterogeneous nuclear 
ribonucleoprotein A3 
20 0.56 0.07  1.02 0.25  1.82 0.009 
P63039 60 kDa heat shock 
protein, mitochondrial 
161 0.87 0.3  1.58 0.22  1.82 0.027 
P97584 Prostaglandin reductase 1 16 0.88 0.1  1.58 0.42  1.8 0.015 
Q68FR9 Elongation factor 1-delta 19 0.75 0.2  1.35 0.43  1.79 0.04 
P11442 Clathrin heavy chain 1 103 0.77 0.1  1.36 0.53  1.78 0.037 
P61980 Heterogeneous nuclear 
ribonucleoprotein K 
27 0.78 0.26  1.38 0.31  1.77 0.038 
P04785 Protein disulfide-
isomerase 
89 0.89 0.3  1.57 0.32  1.76 0.046 
P70580 Membrane-associated 
progesterone receptor 
component 1 
18 0.87 0.2  1.51 0.25  1.74 0.015 
Q9Z2G8 Nucleosome assembly 
protein 1-like 1 
5 0.72 0.14  1.25 0.15  1.73 0.011 
P24368 Peptidyl-prolyl cis-trans 
isomerase B 
14 0.74 0.2  1.27 0.3  1.72 0.045 
O35814 Stress-induced-
phosphoprotein 1 
24 0.72 0.16  1.23 0.31  1.71 0.029 
P05182 Cytochrome P450 2E1 29 0.89 0.14  1.51 0.26  1.7 0.009 
P04961 Proliferating cell nuclear 
antigen 
4 0.41 0.07  0.69 0.16  1.7 0.021 
P24268 Cathepsin D 12 0.86 0.3  1.47 0.32  1.7 0.046 
P10960 Sulfated glycoprotein 1 14 0.6 0.11  1.02 0.19  1.68 0.013 
Q6AXS5 Plasminogen activator 
inhibitor 1 RNA-binding 
protein 
12 0.72 0.16  1.21 0.29  1.66 0.039 
P62752 60S ribosomal protein 
L23a 
8 0.78 0.12  1.26 0.07  1.62 0.004 
P11232 Thioredoxin 7 0.69 0.12  1.11 0.05  1.6 0.009 
P17178 Sterol 26-hydroxylase, 
mitochondrial 
13 1.01 0.13  1.61 0.27  1.6 0.008 
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P19945 60S acidic ribosomal 
protein P0 
24 0.68 0.12  1.08 0.16  1.59 0.017 
Q9ER34 Aconitate hydratase, 
mitochondrial 
46 0.78 0.23  1.23 0.08  1.58 0.029 
Q1JU68 Eukaryotic translation 
initiation factor 3 subunit 
A 
23 0.66 0.17  0.98 0.08  1.5 0.041 
Q641Y8 ATP-dependent RNA 
helicase DDX1 
12 0.73 0.13  1.09 0.15  1.5 0.025 
P08082 Clathrin light chain B 3 0.67 0.13  1.01 0.09  1.5 0.022 
P38656 Lupus La protein homolog 7 0.83 0.16  1.23 0.21  1.49 0.039 
P62919 60S ribosomal protein L8 11 0.79 0.17  1.18 0.19  1.49 0.04 
Q63797 Proteasome activator 
complex subunit 1 
26 0.81 0.15  1.19 0.17  1.48 0.031 
P62161 Calmodulin 20 0.78 0.14  1.15 0.13  1.48 0.024 
O88600 Heat shock 70 kDa protein 
4 
28 0.73 0.13  1.07 0.05  1.47 0.011 
O35244 Peroxiredoxin-6 32 0.87 0.2  1.27 0.11  1.46 0.045 
P07151 Beta-2-microglobulin 3 0.81 0.1  1.17 0.17  1.45 0.012 
Q68FR6 Elongation factor 1-
gamma 
21 0.73 0.08  1.05 0.24  1.44 0.044 
P48679 Prelamin-A/C 35 0.78 0.07  1.12 0.25  1.43 0.043 
Q9EPH8 Polyadenylate-binding 
protein 1 
24 0.82 0.14  1.15 0.05  1.4 0.022 
Q5M875 17-beta-hydroxysteroid 
dehydrogenase 13 
22 1.09 0.17  1.51 0.14  1.39 0.024 
Q05096 Myosin-Ib 94 1.03 0.04  1.42 0.01  1.38 <0.001 
P14942 Glutathione S-transferase 
alpha-4 
12 0.99 0.12  1.37 0.23  1.38 0.035 
P04256 Heterogeneous nuclear 
ribonucleoprotein A1 
18 0.86 0.02  1.15 0.2  1.34 0.019 
P25113 Phosphoglycerate mutase 
1 
20 0.92 0.1  1.23 0.23  1.33 0.048 
P02401 60S acidic ribosomal 
protein P2 
31 0.71 0.09  0.93 0.11  1.31 0.042 
B5DFC8 Eukaryotic translation 
initiation factor 3 subunit 
C 
14 0.85 0.12  1.12 0.08  1.31 0.032 
Q9Z0V6 Thioredoxin-dependent 
peroxide reductase, 
mitochondrial 
10 0.87 0.13  1.13 0.1  1.3 0.045 
P62853 40S ribosomal protein S25 9 0.76 0.12  0.97 0.05  1.27 0.045 
Q3T1J1 Eukaryotic translation 
initiation factor 5A-1 
13 0.84 0.08  1.03 0.04  1.23 0.016 
Q924S5 Lon protease homolog, 
mitochondrial 
27 1.01 0.1  1.23 0.1  1.22 0.033 
Q9ER24 Ataxin-10 4 0.91 0.08  1.1 0.05  1.21 0.022 
Q4G061 Eukaryotic translation 
initiation factor 3 subunit 
B 
15 0.85 0.09  1.03 0.06  1.21 0.04 
P61314 60S ribosomal protein L15 7 0.91 0.11  1.1 0.03  1.21 0.041 
Q63584 Transmembrane emp24 
domain-containing 
protein 10 
11 0.9 0.07  1.08 0.03  1.2 0.014 
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Supplementary Table 2:  Principle Component Analysis PC1 vs PC4 identifies a group of 
proteins which are highly expressed in rat livers after four daily doses of APAP (96 h group) 
and are therefore candidate proteins for further exploration of adaptation 
 
Accession Name 
P04906 Glutathione S-transferase P 
P05982 NAD(P)H dehydrogenase [quinone] 1 
P38918 Aflatoxin B1 aldehyde reductase member 3 
P04903 Glutathione S-transferase alpha-2 
P07687 Epoxide hydrolase 1 
Q9Z0U5 Aldehyde oxidase 
P05179 Cytochrome P450 2C7 
P06757 Alcohol dehydrogenase 1 
Q99PS8 Histidine-rich glycoprotein 
P50137 Transketolase 
P08430 UDP-glucuronosyltransferase 1-6 
O70199 UDP-glucose 6-dehydrogenase 
O35547 Long-chain-fatty-acid--CoA ligase 4 
P48508 Glutamate--cysteine ligase regulatory subunit 
P31210 3-oxo-5-beta-steroid 4-dehydrogenase 
P04905 Glutathione S-transferase Mu 1 
P05182 Cytochrome P450 2E1 
P05545 Serine protease inhibitor A3K 
P51647 Retinal dehydrogenase 1 
Q9Z2Y0 Glycine N-acyltransferase-like protein Keg1 
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Adaptation to acetaminophen 
exposure elicits major changes in 
expression and distribution of the 
hepatic proteome
R. Eakins1,*, J. Walsh1,*, L. Randle2,*, R. E. Jenkins1, I. Schuppe-Koistinen3, C. Rowe1, 
P. Starkey Lewis1, O. Vasieva4, N. Prats5, N. Brillant1, M. Auli5, M. Bayliss1, S. Webb1, 
J. A. Rees1, N. R. Kitteringham1, C. E. Goldring1 & B. K. Park1
Acetaminophen overdose is the leading cause of acute liver failure. One dose of 10–15 g causes 
severe liver damage in humans, whereas repeated exposure to acetaminophen in humans and 
animal models results in autoprotection. Insight of this process is limited to select proteins 
implicated in acetaminophen toxicity and cellular defence. Here we investigate hepatic adaptation to 
acetaminophen toxicity from a whole proteome perspective, using quantitative mass spectrometry. 
In a rat model, we show the response to acetaminophen involves the expression of 30% of all 
proteins detected in the liver. Genetic ablation of a master regulator of cellular defence, NFE2L2, 
has little effect, suggesting redundancy in the regulation of adaptation. We show that adaptation to 
acetaminophen has a spatial component, involving a shift in regionalisation of CYP2E1, which may 
prevent toxicity thresholds being reached. These data reveal unexpected complexity and dynamic 
behaviour in the biological response to drug-induced liver injury.
Acetaminophen (paracetamol, APAP) overdose is the leading cause of acute liver failure in the USA 
and UK, resulting in over 600 deaths a year in these countries1,2. Whilst a single dose of 10–15 g is 
likely to result in severe liver damage3, prolonged exposure to acetaminophen has been shown to result 
in autoprotection in some patients, such that daily doses even in excess of 10 g have apparently little 
adverse effect. In one extreme example, APAP-induced autoprotection was demonstrated in an adult 
male addicted to the analgesic Percocet (APAP formulated with oxycodone), who consumed up to 65 g 
per day of APAP4. In addition, volunteers administered a daily therapeutic dose (4 g) of APAP dis-
played elevations in circulating liver enzymes (clinical markers of liver injury), which then resolved5. 
Autoprotection is therefore likely to be an important human defensive mechanism to prevent progressive 
injury resulting from drug toxicity.
Autoprotection to APAP has also been recapitulated in animal models: in mice, daily escalating doses 
can tolerize against liver damage within a week of treatment4. Our knowledge of the mechanism of 
hepatic adaptation is limited, and focus to date has been on select proteins implicated in APAP tox-
icity. APAP liver damage is caused by a metabolite – N-acetyl-p-benzoquinoneimine (NAPQI) – thus 
enzymes involved in the formation or detoxification of NAPQI are likely to be involved in the adaptive 
response. In particular, cytochrome P450 (CYP) 2E1 which activates APAP to NAPQI and the multidrug 
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resistance-associated proteins ABCC3 and ABCC4 (also known as MRP3 and MRP4), which transport 
APAP and other xenobiotics out of cells, have been implicated in the autoprotection4,6. Alternatively, 
proteins involved in the cell’s natural defence systems, including those regulating glutathione (GSH), may 
underlie the adaptation. A recent microarray study also linked the expression of a number of novel genes 
to the development of tolerance to APAP7. Induction of flavin-containing monooxygenase-3 (FMO3), 
an enzyme identified in this study that has not previously been associated with APAP metabolism, was 
subsequently shown to be protective in an APAP autoprotection model8.
Here, using a rat model, we have investigated this process and show that in fact the expression of as 
many as 30% of all proteins detected in the liver is altered during adaptation to APAP, and see a dramatic 
shift in the localisation of CYP2E1. This indicates that the process of adaptation to APAP-induced liver 
injury is more extensive and dynamic than previously thought.
Results
We examined two separate species, rat and mouse, for adaptation to repeat APAP exposure, in order to 
ensure that this is not a species-selective process and therefore more likely to be relevant to man. The two 
models were selected because of the similar sensitivity of the rat to human APAP hepatotoxicity9–11, and 
because the mouse is more amenable to genetic modification in order to test the role of specific genes 
in the process. Rats were dosed orally with 500, 1000 or 1500 mg/kg APAP, and mice with 250, 500 or 
750 mg/kg APAP. The doses were chosen in order to monitor autoprotection across a range of sub-toxic, 
threshold toxic and overtly toxic doses of APAP, to ensure that the drug exposure is relevant to what may 
occur in humans. Animals were either dosed once at 0 h with sacrifice at 2 h or 24 h, or at 24 h intervals 
for up to 72 h and sacrificed 24 h after the final dose administered. An outline of the dosing protocol 
is shown in Fig.  1a. At the 1500 mg/kg dose, at 48 h, rats exhibited rises in circulating liver enzymes, 
showing a peak serum alanine aminotransferase (ALT) rise 36-fold above vehicle controls, and a 33-fold 
serum aspartate aminotransferase (AST) rise over control (Fig. 1b,c). Both markers returned to normal 
levels by 96 h. Histopathology analyses were performed in order to validate the model of liver injury (rep-
resentative images are shown, Fig. 1d). Although substantial hepatocellular damage was seen at 48 h, this 
injury had largely resolved by 72 h, despite the animals continuing to receive a daily toxic dose of APAP.
At the 750 mg/kg dose of APAP, at 48 h, mice also displayed a peak serum ALT rise, which reached 
200-fold above vehicle controls, and a 67-fold serum AST rise over control (Fig. 1e,f). Both markers also 
returned to normal levels by 96 h. Although substantial hepatocellular damage was seen at 48 h (Fig. 1g), 
this injury had resolved considerably by 72 h, as in the rat model.
In order to reveal the breadth of change occurring in the liver during adaptation, we selected the rat 
model for comprehensive analysis using a global bioanalytical approach. While ALT levels were signif-
icantly elevated at 48 h in the rat (as they were in the mouse), indicative of substantial hepatocellular 
damage, the degree of overt liver tissue degeneration was low (in contrast to the mouse) as assessed 
by histopathology, thus allowing robust proteomic analysis. The technique of isobaric tags for relative 
and absolute quantification (iTRAQ) allows unambiguous identification and quantification of proteins 
expressed in a complex tissue matrix, and presents here a snapshot of the hepatoproteome at each of the 
time-points examined. Analysis of rat liver identified 2181 unique proteins, of which 1169 were common 
to all animals and all time-points, and were therefore amenable for statistical analysis and pathway map-
ping. Lists of significantly altered proteins are shown in Supplementary Tables 1a–d.
Global changes at each time-point were visualised as volcano plots (Fig. 2a–d), in which significance 
(y) is plotted against fold change (x). Although changes can be seen at 24 h (Fig. 2a), at 48 h (Fig. 2b; peak 
toxicity) the volcano plots show the greatest change in protein abundance, as indicated by the number 
of blue points (raw p < 0.05) and red points (FDR ≤ 0.05). Large numbers of protein changes are still 
observed at 72 h (Fig. 2c) and 96 h (Fig. 2d). Principal Component (PC) analysis was performed to iden-
tify the proteins contributing to the clearest differences in the data set as a whole (Fig. 2e). Comparing 
PC1 to PC4 allowed separation into three distinct groups (in Fig.  2e, see control and 24 h to the top 
right, 48 h and 72 h to top left, and 96 h to the bottom of the plot), thereby identifying groups of pro-
teins contributing to the major differences between these groups (Fig.  2e). These proteins are listed in 
Supplementary Table 2. Numerical descriptions of significant changes are shown in Table 1.
The subset of 1169 proteins common to all animals at every time-point is expressed as a heat map 
(Fig. 2f), which demonstrates the similarity in protein expression levels between control and single dose 
livers (24 h). By contrast, the profile of the same proteins in the repeat dose livers (48 h and 72 h) appears 
markedly changed. By 96 h a further shift in the protein expression profile is seen, consistent with the 
clustering shown in Fig. 2e. These observations are consistent with immunoblot data carried out on four 
proteins (Fig.  2g), selected from the mass spectrometric data for their different properties as sentinels 
of metabolic function or regeneration: Glutathione S-transferase P1 (GSTP1), NAD(P)H dehydroge-
nase [quinone] 1 (NQO1), Proliferating cell nuclear antigen (PCNA), and vimentin (VIM). NQO1 and 
GSTP1 are important enzymes in the detoxification of NAPQI, the toxic metabolite of APAP. PCNA is 
a marker of replication12, and indicates a surge in proliferative activity in the rats which peaks at 72 h. 
VIM is a classical marker of progenitor cells and is upregulated in cells that are undergoing epithelial to 
mesenchymal transition, a process implicated in wound healing and organ fibrosis13,14. Overall, the data 
indicate a much wider response in adaptation than has been posited previously, not only implicating 
proteins directly involved in APAP metabolism.
www.nature.com/scientificreports/
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Figure 1. Autoprotection occurs in the rat and the mouse following repeat acetaminophen exposure. 
(a) Dosing protocol used in the study. (b) ALT and (c) AST were determined in rat serum (n = 6). Both 
biomarkers were significantly elevated in the 1500 mg/kg dose group alone (ANOVA with Tukey post-test, 
***p < 0.001; 500 mg/kg circle, 1000 mg/kg square, 1500 mg/kg triangle, vehicle control diamond). (d) H&E 
staining of liver slices for groups of rats at each time-point in 1500 mg/kg group showed progression of 
injury (n = 4, representative images shown). (e) ALT and (f) AST were determined in mouse serum (n = 6). 
Both biomarkers were significantly elevated in the 750 mg/kg dose group alone (ANOVA with Tukey post-
test, ***p < 0.001; 250 mg/kg circle, 500 mg/kg square, 750 mg/kg triangle, vehicle control diamond).  
(g) H&E staining of liver slices for groups of mice at each time-point in 750 mg/kg group showed 
progression of injury (n = 4, representative images shown).
www.nature.com/scientificreports/
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Ingenuity pathway analysis identified the top twenty-five most perturbed canonical pathways during 
the process of adaptation to APAP (Fig. 3, a full list of proteins is shown in Supplementary Table 3). The 
changes highlight alterations in pathways that could be anticipated in our model, e.g. NFE2L2-mediated 
oxidative stress response and the acute phase response and others that were unexpected, e.g. melatonin 
degradation and dopamine degradation. This indicates, on a pathway-scale, that autoprotection to APAP 
involves a range of liver processes that are much more diverse than previously recognised.
Figure 2. Widespread changes in protein abundance occur in rat liver following repeated 
acetaminophen exposure. (a–d) Volcano plots of all common proteins quantified by iTRAQ analysis, at 
each time-point (a) 24 h, (b) 48 h, (c) 72 h, (d) 96 h, relative to vehicle control. A complete list is provided in 
Supplementary Tables 1a–d. Coloured circles represent differential expression (blue - raw P value, p < 0.05; 
red – FDR, p ≤ 0.05). (e) Principal Components Analysis identified the greatest differences between single 
and repeat dose samples. (f ) Heat map representing the 1169 proteins common to all samples and all time-
points identified distinct changes in protein abundance in repeat-dosed animals (red indicates increased 
abundance, blue indicates decreased abundance). (g) Western blots for GSTP1, NQO1, PCNA and VIM, 
performed in order to validate proteomic findings. Representative blots of two rats at each time-point are 
shown. Actin was used as a loading control.
www.nature.com/scientificreports/
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Changes in the proteins responsible for the disposition of most drugs, the so-called Phase I, II and 
III proteins, were explored in more depth (Fig. 4a–d). Thirteen out of the twenty-three quantified CYP 
enzymes, the single most important set of proteins that govern how the liver initially processes a drug, 
were found to be present at lower abundance at 48 h. This included CYP2E1, which is largely expressed 
in the centrilobular region of the liver and CYP2C6, which is expressed across all zones of the liver (36% 
and 30% of control values, respectively), although both of these proteins increased after 96 h (Fig. 4a,b). 
The majority of detected phase I and II proteins decreased during the process of adaptation to APAP. 
Notable exceptions to this were NQO1 and GSTP1. Both of these enzymes were more abundant at 48 h 
(273% and 269% of control values respectively, Fig. 4c), as well as at 96 h (Fig. 4d). The profound changes 
in the phenotype of the liver shown here after two successive doses of APAP are likely to influence the 
fate of subsequent APAP exposure. Importantly, there was no evidence from analysis of intrahepatic 
albumin expression for a global loss of hepatocytes during the process of adaptation to APAP (Fig. 4e). 
Timepoint 
(h)
Doses 
administered
Proteins increased 
abundance (p < 0.05)
Proteins decreased 
abundance (p < 0.05) Total
Percentage of quantifiable 
proteome
24 1 30 43 73 6.24
48 2 116 199 315 26.95
72 3 111 145 256 21.90
96 4 86 125 211 18.05
Table 1.  Relative changes in protein abundance in rat liver in response to repeat acetaminophen 
exposure. The number of proteins that were increased or decreased in abundance in rat liver at each 
timepoint compared to control animals is indicated. The total number of changed proteins is expressed as a 
percentage of the total number of proteins quantified in the analysis (1169).
Figure 3. Analysis of the rat liver proteome reveals widespread pathway changes in response to repeat 
acetaminophen exposure. Ingenuity pathway analysis showing the top twenty-five most perturbed canonical 
pathways during the process of adaptation to APAP exposure. The left panel shows the significance of 
increased abundance proteins and the right panel show significance of reduced abundance proteins. The 
final column denotes the number of unique proteins identified per canonical pathway. Lists are shown in 
Supplementary Table 3. Values in red are significant with colour intensity proportional to significance.
www.nature.com/scientificreports/
6Scientific RepoRts | 5:16423 | DOI: 10.1038/srep16423
C
YP
1A
2
C
YP
2A
1
C
YP
2A
2
C
YP
2B
3
C
YP
2C
6
C
YP
2C
7
C
YP
2C
11
C
YP
2C
13
C
YP
2C
23
C
YP
2C
70
C
YP
2D
1
C
YP
2D
3
C
YP
2D
10
C
YP
2D
26
C
YP
2E
1
C
YP
3A
2
C
YP
3A
18
C
YP
4A
2
C
YP
4A
10
C
YP
4A
14
C
YP
4F
1
C
YP
4F
4
C
YP
4V
2
0
50
100
150
200
P
er
ce
nt
ag
e
of
co
nt
ro
l
*
*
*
* *
*
*
*
*
*
*
*
*
* *
*
*
*
* * *
CYPs - 48 h
C
YP
1A
2
C
YP
2A
1
C
YP
2A
2
C
YP
2B
3
C
YP
2C
6
C
YP
2C
7
C
YP
2C
11
C
YP
2C
13
C
YP
2C
23
C
YP
2C
70
C
YP
2D
1
C
YP
2D
3
C
YP
2D
10
C
YP
2D
26
C
YP
2E
1
C
YP
3A
2
C
YP
3A
18
C
YP
4A
2
C
YP
4A
10
C
YP
4A
14
C
YP
4F
1
C
YP
4F
4
C
YP
4V
2
0
50
100
150
200
200
300
P
er
ce
nt
ag
e
of
co
nt
ro
l
* *
*
*
*
*
*
*
*
*
CYPs - 96 h
Drug metabolism and transport proteins - 48 h
AC
SL
1
B
AA
T
C
ES
1C
C
ES
3
C
O
M
T
EP
H
X1
EP
H
X2
G
AM
T
G
LY
AT
G
ST
M
1
G
ST
P1
N
Q
O
1
SL
C
26
A1
SU
LT
1A
1
SU
LT
1C
1
U
G
T1
A1
U
G
T2
A1
XD
H
SL
C
O
1A
1
SL
C
O
1B
2
0
50
100
150
200
200
300
P
er
ce
nt
ag
e
of
co
nt
ro
l
*
*
*
*
*
*
* *
*
* *
*
*
*
*
*
*
*
*
*
*
*
*
AC
SL
1
B
AA
T
C
ES
1C
C
ES
3
C
O
M
T
EP
H
X1
EP
H
X2
G
AM
T
G
LY
AT
G
ST
M
1
G
ST
P1
N
Q
O
1
SL
C
26
A1
SU
LT
1A
1
SU
LT
1C
1
U
G
T1
A1
U
G
T2
A1
XD
H
SL
C
O
1A
1
SL
C
O
1B
2
0
50
100
150
200
500
1000
1500
P
er
ce
nt
ag
e
of
co
nt
ro
l
*
*
*
*
* * *
*
*
*
*
*
*
*
*
*
*
*
*
*
*
Drug metabolism and transport proteins - 96 h
P
er
ce
nt
ag
e
of
co
nt
ro
l
con
trol 24 h 48
h 72 h 96 h
0
50
100
150
Albumin
Sali
ne-A
PAP
APA
P-A
PAP
Sali
ne-A
PAP
APA
P-A
PAP
0
20
40
60
80
100
P
er
ce
nt
ag
e
su
rv
iv
al
NFE2L2 +/+
NFE2L2 -/-
Nrf2
NFE2L2
a b
c d
e f
Figure 4. Investigation of key liver pathways identified by proteomic analysis in response to repeat 
acetaminophen exposure. In rats, while the abundance of phase I (CYP450) proteins at (a) 48 h and (b) 96 h, 
and phase II and III proteins at (c) 48 h and (d) 96 h was altered compared to control, serum albumin (e) 
remained statistically unchanged throughout the timecourse. Bars represent mean protein abundance (n = 3–4; 
percentage of control + SEM). Dashed lines indicate mean control value. Statistical analysis was performed 
using a linear model in the R programming environment (ANOVA with Dunnett’s post-test, *p < 0.05, 
**p < 0.01, ***p < 0.001). (f) Survival of NFE2L2+/+ and NFE2L2−/− mice in APAP adaptation study. Bar chart 
comparing survival of toxic challenge after APAP or saline (0.9%) pretreatment in NFE2L2+/+ or NFE2L2−/− 
animals. Mice were pretreated with incremental doses of APAP ranging from 150–600 mg/kg i.p. or vehicle 
control for 8 days followed by a final challenge of 1000 mg/kg APAP or vehicle on day 9.
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Together with the ALT and histopathology data (Fig. 1), these observations indicate that although there 
is evidence of significant injury at 48 h, with key protein changes, albumin, a classical marker of liver 
function, remains invariant.
To look at the level of redundancy in the process of autoprotection to APAP, we then investigated 
the role of one of the key processes identified by pathway analysis, as described above, namely the 
‘NFE2L2-mediated Oxidative Stress Response’. Nuclear factor erythroid 2-related factor 2 (NFE2L2; also 
known as NRF2) is a transcription factor that has been shown to play a vital role in the cytoprotective 
response against the type of oxidative and chemical stresses elicited by APAP15–19. We therefore employed 
a genetic strategy to test the hypothesis that interference with such a key pathway would affect the 
outcome of the adaptive response. The effect of pre-treatment with APAP on the ability of NFE2L2+/+ 
and NFE2L2−/− mice to withstand a toxic challenge was investigated. All NFE2L2+/+ mice pre-treated 
with APAP survived a toxic challenge of APAP, whereas only 50% of NFE2L2+/+ mice which were not 
APAP-pre-treated survived (Fig.  4f). Amongst the NFE2L2−/− mice, whilst none of the animals which 
were not APAP-pre-treated survived, 50% of animals which were APAP-pre-treated survived, despite 
NFE2L2 deletion. The effect of APAP pre-treatment on the ability of NFE2L2+/+ and NFE2L2−/− mice 
to withstand a toxic challenge is summarised (Fig. 4f), and shows that in both wild type and NFE2L2−/− 
mice, APAP pre-treatment increases survival upon toxic challenge, i.e. in the absence of a key liver 
defence pathway, adaptation still occurs. This clearly demonstrates for the first time that it is unlikely that 
a single gene or pathway underlies the complexities of the adaptive process to APAP exposure.
In fact, when we looked in greater detail at another of the key changes visualized in our proteomic 
analysis, we determined that the process of autoprotection is yet more complicated than straightforward 
changes in the expression of a specific protein. Our proteomic data for CYP2E1 (Fig. 4a,b) looked to be 
particularly pertinent in the process of adaptation to APAP, as it shows a loss of the pre-eminent metab-
olising enzyme responsible for formation of the toxic metabolite of APAP (NAPQI). We therefore looked 
at the metabolism of both APAP (Fig. 5a) and the CYP2E1 probe substrate chlorzoxazone (Fig. 5b) in our 
rat model. Whilst overall APAP metabolism was significantly increased at 96 h (Fig. 5a), specific CYP2E1 
activity was reduced at 48 h and increased at 96 h (Fig. 5b). Relative CYP2E1 activity was 0.78 at 48 h, and 
1.43 at 96 h, compared to control (arbitrary value of 1). These findings, which mirrored our proteomic 
data for CYP2E1, indicated the potential for an increase in the generation of NAPQI in vivo, which was 
difficult to resolve with the observed process of adaptation to repeated exposure.
We therefore employed immunohistochemical techniques to further probe the expression of CYP2E1. 
In fact, CYP2E1 is shown to undergo a profound change in its distribution within the liver during the 
process of adaptation to APAP (Fig. 5c). Basally, CYP2E1 is mainly expressed in centrilobular regions. 
Upon APAP challenge, CYP2E1 staining becomes diffuse and extends into midzonal regions. Two doses 
produce acute centrilobular necrosis, with markedly reduced CYP2E1 staining in centrilobular regions. 
At later time-points, staining extends diffusely into periportal regions which are CYP2E1-negative in 
control animals. This is clear evidence that the process of adaptation to APAP is yet more complex than 
wide-scale changes in the hepatoproteome, and may also involve a regional reprogramming of gene 
expression in a key step in APAP metabolism. This would not be detected if protein abundance alone 
was measured (Fig.  5d), which shows overall loss and re-establishment of liver CYP2E1, as predicted 
from the proteomic data (Fig. 4a,b). This re-direction of phase I metabolism towards the periportal areas 
of the liver, where the levels of the reducing buffer GSH are highest, is likely to be hepatoprotective. 
Critically, when we looked at expression of another protein which is highly abundant in the centrilobular 
region, glutamine synthetase (GLUL) we did not see the same change (Fig. 5d), showing some degree of 
selectivity in the restoration of adaptive liver function. This is the first time that a regio-spatial control 
of expression of a gene, specifically with respect to hepatic APAP autoprotection, and generally as part 
of a response to a pharmaceutical agent, has been shown. A graphical summary is presented in Fig. 5e 
and shows the evolution of key aspects of the adaptive process in this model.
Discussion
Drug induced liver injury (DILI) is a major problem both in the clinic and for the pharmaceutical 
industry. Our relative lack of understanding of the physiological and toxicological mechanisms involved 
can lead to the loss of potentially effective drugs during development. APAP poisoning is itself also 
a significant clinical problem1,2. Furthermore, APAP is probably the best characterised hepatotoxin in 
pre-clinical models, and therefore provides a means to interrogate the various processes of adaptation 
and regeneration in the liver, which are also relevant to man and may be applicable to other drugs asso-
ciated with DILI.
In our model of APAP autoprotection, significant hepatotoxicity was only observed at a dose of 
1500 mg/kg, confirming that the rat is relatively resistant to APAP toxicity as reported earlier20–22. While 
hepatotoxicity was evident at 48 h (35% cell death, p < 0.001, data not shown), significantly less or no 
necrosis was observed at 72 and 96 h, despite repeated exposure to APAP. Liver function was maintained 
at these points, as assessed by serum transaminases and albumin synthesis. These observations demon-
strate an adaptive response in this model, protecting the liver from further injury, and this adaptation 
involves changes in a very large proportion of the expressed hepatoproteome.
Our data during the early phase of the development of the model, confirms previous studies which 
have shown that hepatic CYP2E1, the predominant enzyme involved in APAP metabolism and CYP1A2, 
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Figure 5. Rat liver CYP2E1 activity and localisation changes in response to repeat acetaminophen 
exposure. Microsomal formation of (a) APAP-GSH and (b) 6′-OH chlorzoxazone in animals which were 
either vehicle control treated, or repeat dosed with or without toxicity. Microsomal CYP2E1 activity is 
reduced in toxic (48 h treated, red squares) group and increased in non-toxic (96h treated, blue triangles) 
group compared to control (black circles). APAP metabolism is significantly higher in non-toxic (96h 
treated) group (**p < 0.01, ***p < 0.001, ****p < 0.0001). Best fit curves for each group (solid lines) were 
modelled using literature values for Km and Vmax. (c) Top panel shows representative IHC staining for 
CYP2E1 across the timecourse; bottom panel shows H&E stain. CV indicates central vein, while PT 
indicates the portal triad. CYP2E1 redistributes markedly as the timecourse progresses. (d) Densitometric 
analysis of total liver GLUL, CYP2E1 and actin detected by western blot, showing preferential restitution 
of CYP2E1 abundance over the similarly centrilobular glutamine synthetase (*p < 0.05, **p < 0.01, 
***p < 0.001). (e) Graphical summary of the model.
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which also plays a minor role in APAP metabolism23,24, are depleted, whilst the rate-limiting enzyme 
involved in the formation of the protective tripeptide GSH, i.e. glutamate-cysteine ligase regulatory 
subunit (GCLC)6,25, is increased, after pre-treatment with APAP. These proteins are likely to contribute 
to protection from toxicity, by reducing the CYP-catalysed bioactivation of APAP to NAPQI, and by 
increasing detoxification of NAPQI through enhanced synthesis of GSH. However, in this study, which 
is the first to formally and quantitatively assess over one thousand liver proteins from an in vivo model 
during adaptation to chemical exposure, we can now see that these changes are only one small part of a 
greatly altered and dynamic phenotype.
The change in the hepatoproteome may enable an adaptation that prevents toxicity from subsequent 
doses of APAP and maintains normal liver function despite repeated exposure to a toxic dose. Although 
Fig. 3, showing the top 25 most perturbed canonical pathways, indicates widespread loss of protein abun-
dance, particularly at the peak of toxicity, a number of pathways showed increased abundance, including 
‘acute phase response signalling’, ‘NFE2L2-mediated oxidative stress response’ and ‘glutathione-mediated 
detoxification’ which are all well-characterised reactions to toxic injury. We therefore employed a con-
ventional reductionist approach to examine in greater detail the role of transcription factor NFE2L2 in 
the process of adaptation. Whilst NFE2L2−/− mice showed a greater susceptibility to APAP toxicity com-
pared to wild types, after pretreatment with APAP an adaptive response was still evident in the absence 
of NFE2L2, albeit to a lesser degree. NFE2L2-mediated transcription is therefore not the only mechanism 
of adaptation to repeated toxic insult in this model, and provides a demonstration that the process of 
adaptation is more wide-ranging than previously thought.
Beyond confirming existing knowledge that several CYPs relevant to APAP metabolism are 
down-regulated upon repeat APAP exposure, we have shown that liver tissue from repeat dosed rats 
shows a significantly reduced abundance of proteins across all phases of drug metabolism (Fig. 4a–d). We 
hypothesise that this reduction in expression represents a key facet of adaptation, and provides an envi-
ronment which facilitates compensatory hyperplastic activity, preserving critical function. At the peak of 
toxicity, the mean of all detected CYPs is reduced to approximately 60% of control values. This change 
in phenotype is likely to be, at least partly, a consequence of the changing cell population in the liver 
over time. The initial toxic insult clearly destroys vulnerable hepatocytes at the centre of the lobule. CYP 
enzymes show predominantly centrilobular expression, and the differential expression of CYPs in intact 
zones may account for the overall change seen at 48 h. Nevertheless, a number of CYPs are pan-zonally 
expressed in rat liver26, and of the ones that are also identified in the present work (1A, 2B, 2C6 and 2C7, 
a close homologue of the pan-zonal CYPEtOH2 enzyme27–30), all are significantly less abundant at 48 h, 
dropping to around 30% of control (with the exception of 2C7 which is not significantly changed). This 
suggests an active change in the phenotype of intact cells, as has been previously postulated, indicating 
a global dedifferentiation resulting in decreased liver-specific protein expression as part of an adaptive 
response to injury31,32, rather than a passive destruction of CYP-rich tissue.
To further elucidate the complex mechanism of adaptation, we focused on CYP2E1 activity and local-
isation in response to repeat APAP exposure. Consistent with proteomic data obtained for CYP2E1 
abundance, microsomal activity assays show a loss of activity at 48h when acute injury is seen. Despite 
continued APAP exposure, however, at 96h a rebound of both expression and activity of CYP2E1 is seen 
(Fig. 5b,d). This is not consistent with the fall in toxicity observed after 48 h (Fig. 1). We therefore exam-
ined the tissue histologically, and identified a diffuse redistribution of CYP2E1 into CYP2E1-negative 
regions (Fig.  5c). Importantly, the loss and restoration of total liver 2E1 was not observed for another 
similarly perivenous enzyme, glutamine synthetase (Fig. 5d), suggesting that this process is selective. We 
hypothesise from these observations that, as a defence mechanism, diffuse expression of CYP2E1 may 
prevent the intracellular threshold of NAPQI toxicity being reached, thereby avoiding the initiation of 
further waves of cell death at later timepoints. Furthermore, in the regions where NAPQI is generated 
after redistribution of CYP2E1 expression, there are known to be higher intracellular concentrations of 
the reducing buffer GSH33. This phenomenon of CYP2E1 redistribution as an adaptive response has only 
been seen after treatment with carbon tetrachloride34 and ethanol35, but has not been detected previously 
after treatment with any pharmaceutical compound.
Proliferating liver demonstrates enhanced resistance to toxicity4,25,36, but the precise mechanism by 
which this occurs is unclear. Consistent with the findings presented here, rats which have been pretreated 
with APAP show signs of a regenerative hepatocyte response, determined through expression of PCNA, 
upon a second toxic challenge25. It has been shown that these new hepatocytes have a greater capacity 
for GSH production, allowing regenerating liver to detoxify NAPQI more efficiently25, but this hypothesis 
needs to be investigated in our model. Furthermore, a single dose of APAP has been shown to induce the 
expression of the transporter protein ABCC4 in proliferating hepatocytes, peaking at 48 h after dosing6. 
A number of transporters were detected in the current work, and of those that were changed, all were 
decreased in abundance at 48 h and onwards. A list of the transporters can be found in Supplementary 
Table 4. This may demonstrate a change in the liver phenotype away from drug metabolism and towards 
self-preservation and regeneration. A single dose control experiment was also performed in our study, 
and this showed a similar profile of toxicity to the repeat dose group (Supplementary Fig. 1). When 
experimental animals were given subsequent exposures, this toxicity was not exacerbated, indicating that 
a single exposure is all that is required to initiate liver adaptive processes.
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How these observations relate to the likely hepatic changes seen during chronic dosing in humans will 
be a key next step in this work. The identification of accessible translational biomarkers that can be used 
in rodents and man37,38 will be necessary to examine whether this process occurs in man at therapeutic 
doses of APAP, as well as with other drugs than can cause DILI.
Materials and Methods
Materials. 8-plex iTRAQ protein labelling kit/reagents were from AB Sciex (Framingham, MA). 
Sequencing grade trypsin was from Promega UK (Southampton, UK). PCNA, GLUL and NQO1 anti-
bodies were from Abcam (Cambridge, UK; cat. no. ab29, ab49873 and ab2346 respectively). VIM anti-
body was from Sigma (St. Louis, MO; cat. no. V6389). GSTP1 antibody was from Enzo Life Sciences 
(Farmingdale, NY; msa-102). CYP2E1 antibody was kindly provided by Magnus Ingelman-Sundberg, 
Karolinska Institute, Sweden. Parent drugs for LC-MS analysis were obtained from Sigma-Aldrich 
(Gillingham, UK), internal standards from Toronto Research Chemicals (Toronto, Canada) and Alsachim 
(Illkirch-Graffenstaden, France). Metabolites were obtained from the same sources. All other reagents 
were of analytical grade and quality and purchased from Sigma (St. Louis, MO).
Animals. Male Crl:WI (Han) rats and Crl:CD1 (ICR) mice (6–8 weeks) from Charles River Laboratories 
(Lyon, France) were acclimatised for 1 week. Six animals were housed per cage, on a 12 h light/dark 
cycle, at constant temperature (22 ± 2 °C). Standard food and tap water were provided ad libitum. Care 
of animals was undertaken in compliance with the European Community Directive 86/609/CEE for the 
use of laboratory animals and with the Autonomous Catalan law (Decret 214/1997). All experimental 
procedures were approved by the Almirall Ethics Committee.
Study design. APAP was dissolved in vehicle (0.5% methylcellulose and 0.1% Tween 80 in distilled 
water, 10 ml/kg) and administered by oral (po) gavage without prior fasting. Formulations were prepared 
daily. Some animals (n = 6) received a single dose of APAP or vehicle at 0 h (for 2 or 24 h). Other animals 
(n = 6) received subsequent administrations every 24 h of APAP or vehicle for 24, 48 or 72 h and were 
sacrificed 24 h after last administration. Mice received 250, 500 or 750 mg/kg of APAP; rats received 500, 
1000 or 1500 mg/kg of APAP. Based on clinical chemistry and histopathology analysis of liver injury, the 
rat 1500 mg/kg group was taken forward for further analysis. Terminal blood samples without previous 
fasting were collected from the retroorbital plexus under isoflurane anaesthesia (4% induction, 1.5–3% 
maintenance). Blood samples were centrifuged for 10 min at 3000 rpm, serum collected and stored at 
− 80 °C. Immediately after blood collection, animals were exsanguinated by cutting the abdominal aorta 
under isoflurane anaesthesia.
Toxicological assessment. A Synchron Clinical System cx7® (Beckman, Brea, CA) was used to 
determine ALT (IU/L) and AST ( IU/L). Samples of liver were frozen in liquid nitrogen before stor-
age at − 80 °C. The hepatic median lobe was formalin-fixed and embedded in paraffin, sectioned and 
stained with haematoxylin and eosin (H&E) for histological blind examination under light microscopy. 
Percentage of live cells was assessed in a complete section from each animal, and data expressed as 
mean ± standard error of mean (SEM).
NFE2L2(−/−) study. All experiments were undertaken in accordance with criteria outlined in a 
licence granted under the Animals (Scientific Procedures) Act 1986, and approved by the Animal Ethics 
Committee of the University of Liverpool. Generation of the NFE2L2 knockout mouse and genotyping 
of progeny have been described elsewhere15,16. Non-fasted male littermate NFE2L2(+/+) and NFE2L2(−/−) 
mice (C57BL6J background, 10–12 weeks of age) were used throughout the study. Mice were housed 
between 19 °C–23 °C, on a 12 h light/dark cycle, and given access to food and water ad libitum. Dosing 
began at 10 am each day and APAP was freshly prepared in warmed saline (0.9%). Pilot dose ranging 
studies confirmed the dose dependent nature of APAP-induced hepatotoxicity. In order to explore both 
the changes occurring during the pre-treatment phase and the effects of pre-treatment on susceptibility 
to a toxic challenge, two independent groups of mice were used:
NFE2L2(+/+) and NFE2L2(−/−) mice received increasing daily doses of APAP (2 × 150 mg/kg, 
2 × 300 mg/kg, 2 × 450 mg/kg, 2 × 600 mg/kg, i.p.) over 8 days, or vehicle control (n = 4). On day 9 mice 
were challenged with 1000 mg/kg APAP (i.p.) or vehicle (n = 4–8). Mice were culled 5 h after the final 
dose by exposure to a rising concentration of CO2 followed by cervical dislocation.
iTRAQ labelling and mass spectrometric analysis of liver homogenates. Rat liver samples 
(n = 4 animals per time-point, 1500 mg/kg group, ~100 mg wet weight) were homogenised in 0.5 M tri-
ethylammonium bicarbonate/0.1% SDS using a Mixer Mill 220 (Retsch, Haan, Germany), and centri-
fuged at 14000 g for 10 min. iTRAQ tagging and analysis was performed as described previously39.
iTRAQ protein identification and statistical analyses. Liver samples from rats treated with APAP 
or vehicle control were analysed across four iTRAQ runs. Data analysis was performed using ProteinPilot 
(Version 3, Life Technologies, Paisley, UK). The SwissProt database was searched with a confidence inter-
val of 95%, and screened in reverse to facilitate false discovery rate analysis. Proteins identified from 
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peptides with > 95% confidence and global false discovery rate of < 1% were included in the statistical 
analysis (1169 proteins).
Mean fold changes were calculated using the limma package within the R programming environment 
(Team, 2005) and analysis conducted on the logged fold-change values. Unadjusted (raw) p values and 
p values following FDR correction for multiple testing were determined.
Ontology and pathway analysis. Pathway analysis was performed using Ingenuity Pathway Analysis 
(Qiagen, Venlo, Netherlands). Ingenuity successfully mapped 1163/1169 proteins to pathways. At each 
timepoint, a ‘Core Analysis’ was performed on all proteins that were differentially expressed compared 
to control animals (raw p < 0.05) using the ‘Ingenuity Knowledge Base (Gene Only) Background’. The 
canonical pathways that were statistically significantly altered at each timepoint were compared using 
the ‘Comparison Analysis’ function.
Western immunoblotting. Buffered homogenates of standardised protein concentration (n = 4) were 
run on polyacrylamide gel, transferred onto nitrocellulose membrane (GE Healthcare, Little Chalfont, 
UK) and visualised using Western Lightning Plus ECL (Perkin Elmer, Waltham, MA). Proteins were 
normalised to actin. For GLUL, equal protein loading was confirmed using a Ponceau S stain.
Enzyme activity. Microsomes were prepared from livers of animals assigned to 2 h vehicle con-
trol, 48 h APAP (repeat exposure with toxicity) or 96 h APAP (repeat exposure, no toxicity) groups by 
homogenisation and ultracentrifugation, quantified using the Lowry method40, snap frozen and stored 
at − 80 °C until required. Microsomes from individual animals were incubated with either APAP (1 mM, 
100 uM or 10 uM for up to 4 h) or the CYP2E1 probe chlorzoxazone (1 uM for up to 90 mins) at 37 °C in 
a shaking water bath. Reactions were stopped with the addition of equal volumes of ice cold acetonitrile 
containing evaporation standard fluconazole and stored at − 80 °C until analysis by HPLC-MS.
Analysis by HPLC-MS/MS. Test samples were treated with acetonitrile, to remove matrix-based inter-
ferences. They were diluted with water prior to analysis by LC-MS/MS on a Sciex API 4000 (Warrington, 
UK) equipped with a Turbo V™ electrospray source (ESI). The gradients were based on mobile phases 
containing 0.1% v/v formic acid in both water (A) and acetonitrile (B).
Measurement of chlorzoxazone and its putative major metabolite, 6-hydroxy chlorzoxaz-
one. The separation was performed on a 2.7 μ M Halo® C18 column (50 × 2.1 mm ID) obtained from 
HiChrom (Reading, UK), and at a temperature of 40 °C and a flow-rate of 0.6 mL min−1. The following 
gradient was used: 0 min 5% B, 0.5 min 5% B, 1.5 min 95% B, 2 min 95% B, 2.1 min 5% B and 2.6 min 
5% B. D4-diclofenac was employed as the internal standard. The MS was operated in negative ion mode.
Measurement of APAP and its major metabolites. Separations were performed on a 2.6 μ m 
Kinetex® XB-C18 column (50 × 2.1 mm ID) obtained from Phenomenex (Macclesfield, UK), at a tem-
perature of 40 °C and a flow-rate of 0.5 mL min−1. The following gradient was used: 0 min 0% B, 0.3 min 
0% B then 2.3 min 50% B. The column was flushed with 100% B, and then returned to 0% B using a 
flow-rate of 0.7 mL min−1, giving a programmed cycle time of 4.2 minutes. A panel of deuterated internal 
standards was employed. The MS was operated in negative ion mode for measuring all but one of the 
putative major metabolites and high concentrations of APAP. It was operated in positive ion mode for 
measuring the remaining metabolite and low concentrations of APAP.
CYP2E1 localisation via immunohistochemistry. Immunohistochemical staining for CYP2E1 
was performed on formalin-fixed, paraffin-embedded liver sections of 3 μ m. Sections were mounted on 
poly-L-lysine coated slides, air-dried, deparaffinized and rehydrated. Slides were incubated with rabbit 
anti CYP2E1 antibody in 20% NGS/TBS-T. Secondary antibody was SignalStain® Boost IHC Detection 
Reagent (HRP, rabbit; Cell Signalling Technology, Beverly, MA, USA). The reaction was developed using 
3′, 3′ -diaminobenzidine tetrahydrochloride. Sections were counterstained with Harris haematoxylin.
Data evaluation and statistical analysis. Clinical chemistry data are expressed as mean ± SEM 
(n = 6). Serum ALT and AST data for vehicle- and APAP-treated animals were compared to time-matched 
controls by one-way ANOVA with Tukey’s post-hoc test using GraphPad PRISM (version 6.03 for 
Windows, GraphPad Software, San Diego, CA). Western immunoblotting data were analysed using 
a one-way ANOVA with Dunnetts post-hoc test. Microsomal data were analysed using an ordinary 
two-way ANOVA with Dunnett’s post-hoc test.
Literature estimates for Km are reported to be 30–300 times larger41,42 than the CZX concentration 
considered (1 uM) so we were able to adopt linear kinetics for CYP2E1 activity (enzyme velocity = α [S], 
where [S] = CZX concentration and α = Vmax/Km) instead of the full nonlinear Michaelis-Menten form. 
Solving the resulting first order ordinary differential equation then yields the following expression for 
6′-OH CZX formation versus time (using notation [P](t) to denote concentration at time t (min)): [P]
(t) = [S](0)(1 − exp(− α t/V)), where [S](0) = initial CZX concentration (1 uM) and V is the sample vol-
ume (0.02 ml). We used a Levenberg Marquardt (non-linear regression) algorithm to then find best 
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fit values for α = Vmax/Km for the control, 48 and 96 hour cases. Note that, in each case, our estimates 
for α = Vmax/Km were found to lie within acceptable literature ranges. Under the assumption that 
enzyme-substrate binding affinity (1/Km) is unaffected by microsomal conditions, ratios of α estimates 
were then used to compare relative enzyme activities.
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